<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Antibiotics for acute pyelonephritis in children - Strohmeier, Y - 2014 | Cochrane Library</title> <meta content="Antibiotics for acute pyelonephritis in children - Strohmeier, Y - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003772.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Antibiotics for acute pyelonephritis in children - Strohmeier, Y - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003772.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD003772.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Antibiotics for acute pyelonephritis in children" name="citation_title"/> <meta content="Yvonne Strohmeier" name="citation_author"/> <meta content="University of Sydney" name="citation_author_institution"/> <meta content="Elisabeth M Hodson" name="citation_author"/> <meta content="elisabeth.hodson@health.nsw.gov.au" name="citation_author_email"/> <meta content="Narelle S Willis" name="citation_author"/> <meta content="Angela C Webster" name="citation_author"/> <meta content="Jonathan C Craig" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="7" name="citation_issue"/> <meta content="10.1002/14651858.CD003772.pub4" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/07/28" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003772.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003772.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003772.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Acute Disease; Administration, Oral; Anti‐Bacterial Agents [administration &amp; dosage, *therapeutic use]; Drug Therapy, Combination; Injections, Intravenous; Pyelonephritis [*drug therapy]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003772.pub4&amp;doi=10.1002/14651858.CD003772.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003772.pub4&amp;doi=10.1002/14651858.CD003772.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003772.pub4&amp;doi=10.1002/14651858.CD003772.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003772.pub4&amp;doi=10.1002/14651858.CD003772.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003772.pub4&amp;doi=10.1002/14651858.CD003772.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003772.pub4&amp;doi=10.1002/14651858.CD003772.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003772.pub4&amp;doi=10.1002/14651858.CD003772.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003772.pub4&amp;doi=10.1002/14651858.CD003772.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003772.pub4&amp;doi=10.1002/14651858.CD003772.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003772.pub4&amp;doi=10.1002/14651858.CD003772.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003772.pub4&amp;doi=10.1002/14651858.CD003772.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003772.pub4&amp;doi=10.1002/14651858.CD003772.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003772.pub4&amp;doi=10.1002/14651858.CD003772.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003772.pub4&amp;doi=10.1002/14651858.CD003772.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003772.pub4&amp;doi=10.1002/14651858.CD003772.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003772.pub4&amp;doi=10.1002/14651858.CD003772.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003772.pub4&amp;doi=10.1002/14651858.CD003772.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003772.pub4&amp;doi=10.1002/14651858.CD003772.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003772.pub4&amp;doi=10.1002/14651858.CD003772.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003772.pub4&amp;doi=10.1002/14651858.CD003772.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003772.pub4&amp;doi=10.1002/14651858.CD003772.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003772.pub4&amp;doi=10.1002/14651858.CD003772.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003772.pub4&amp;doi=10.1002/14651858.CD003772.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="KUoIaN9D";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD003772\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD003772\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003772\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003772\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ms","hr","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD003772.pub4",title:"Antibiotics for acute pyelonephritis in children",firstPublishedDate:"Jul 28, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Kidney and Transplant Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=KUoIaN9D&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003772.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003772.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD003772.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD003772.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003772.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD003772.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD003772.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD003772.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD003772.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD003772.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>12367 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD003772.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003772.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003772.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003772.pub4/full#CD003772-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003772.pub4/full#CD003772-sec-0104"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003772.pub4/full#CD003772-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003772.pub4/full#CD003772-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003772.pub4/full#CD003772-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003772.pub4/full#CD003772-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003772.pub4/full#CD003772-sec-0054"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003772.pub4/full#CD003772-sec-0093"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003772.pub4/appendices#CD003772-sec-0109"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/table_n/CD003772StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/table_n/CD003772StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003772.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003772.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003772.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003772.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003772.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD003772.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2014 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Antibiotics for acute pyelonephritis in children</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003772.pub4/information#CD003772-cr-0002">Yvonne Strohmeier</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003772.pub4/information#CD003772-cr-0003"><i class="icon corresponding-author fa fa-envelope"></i>Elisabeth M Hodson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003772.pub4/information#CD003772-cr-0004">Narelle S Willis</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003772.pub4/information#CD003772-cr-0005">Angela C Webster</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003772.pub4/information#CD003772-cr-0006">Jonathan C Craig</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/information/en#CD003772-sec-0115">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 28 July 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD003772.pub4">https://doi.org/10.1002/14651858.CD003772.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD003772-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003772-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003772-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003772-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD003772-abs-0002">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD003772-abs-0001" lang="en"> <section id="CD003772-sec-0001"> <h3 class="title" id="CD003772-sec-0001">Background</h3> <p>Urinary tract infection (UTI) is one of the most common bacterial infections in infants. The most severe form of UTI is acute pyelonephritis, which results in significant acute morbidity and may cause permanent kidney damage. There remains uncertainty regarding the optimum antibiotic regimen, route of administration and duration of treatment. This is an update of a review that was first published in 2003 and updated in 2005 and 2007. </p> </section> <section id="CD003772-sec-0002"> <h3 class="title" id="CD003772-sec-0002">Objectives</h3> <p>To evaluate the benefits and harms of antibiotics used to treat children with acute pyelonephritis. The aspects of therapy considered were 1) different antibiotics, 2) different dosing regimens of the same antibiotic, 3) different duration of treatment, and 4) different routes of administration. </p> </section> <section id="CD003772-sec-0003"> <h3 class="title" id="CD003772-sec-0003">Search methods</h3> <p>We searched the Cochrane Renal Group's Specialised Register, CENTRAL, MEDLINE, EMBASE, reference lists of articles and conference proceedings without language restriction to 10 April 2014. </p> </section> <section id="CD003772-sec-0004"> <h3 class="title" id="CD003772-sec-0004">Selection criteria</h3> <p>Randomised and quasi‐randomised controlled trials comparing different antibiotic agents, routes, frequencies or durations of therapy in children aged 0 to 18 years with proven UTI and acute pyelonephritis were selected. </p> </section> <section id="CD003772-sec-0005"> <h3 class="title" id="CD003772-sec-0005">Data collection and analysis</h3> <p>Four authors independently assessed study quality and extracted data. Statistical analyses were performed using the random‐effects model and the results expressed as risk ratio (RR) for dichotomous outcomes or mean difference (MD) for continuous data with 95% confidence intervals (CI). </p> </section> <section id="CD003772-sec-0006"> <h3 class="title" id="CD003772-sec-0006">Main results</h3> <p>This updated review included 27 studies (4452 children). This update included evidence from three new studies, and following re‐evaluation, a previously excluded study was included because it now met our inclusion criteria. </p> <p>Risk of bias was assessed as low for sequence generation (12 studies), allocation concealment (six studies), blinding of outcome assessors (17 studies), incomplete outcome reporting (19 studies) and selective outcome reporting (13 studies). No study was blinded for participants or investigators. The 27 included studies evaluated 12 different comparisons. No significant differences were found in duration of fever (2 studies, 808 children: MD 2.05 hours, 95% CI ‐0.84 to 4.94), persistent UTI at 72 hours after commencing therapy (2 studies, 542 children: RR 1.10, 95% CI 0.07 to 17.41) or persistent kidney damage at six to 12 months (4 studies, 943 children: RR 0.82, 95% CI 0.59 to 1.12) between oral antibiotic therapy (10 to 14 days) and intravenous (IV) therapy (3 days) followed by oral therapy (10 days). Similarly, no significant differences in persistent bacteriuria at the end of treatment (4 studies, 305 children: RR 0.78, 95% CI 0.24 to 2.55) or persistent kidney damage (4 studies, 726 children: RR 1.01, 95% CI 0.80 to 1.29) were found between IV therapy (three to four days) followed by oral therapy and IV therapy (seven to 14 days). No significant differences in efficacy were found between daily and thrice daily administration of aminoglycosides (1 study, 179 children, persistent clinical symptoms at three days: RR 1.98, 95% CI 0.37 to 10.53). Adverse events were mild and uncommon and rarely resulted in discontinuation of treatment. </p> </section> <section id="CD003772-sec-0007"> <h3 class="title" id="CD003772-sec-0007">Authors' conclusions</h3> <p>This updated review increases the body of evidence that oral antibiotics alone are as effective as a short course (three to four days) of IV antibiotics followed by oral therapy for a total treatment duration of 10 to 14 days for the treatment of acute pyelonephritis in children. When IV antibiotics are given, a short course (two to four days) of IV therapy followed by oral therapy is as effective as a longer course (seven to 10 days) of IV therapy. If IV therapy with aminoglycosides is chosen, single daily dosing is safe and effective. Insufficient data are available to extrapolate these findings to children aged less than one month of age or to children with dilating vesicoureteric reflux (grades III‐V). Further studies are required to determine the optimal total duration of antibiotic therapy required for acute pyelonephritis. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD003772-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003772-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003772-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003772-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD003772-abs-0007">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD003772-abs-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD003772-abs-0005">Bahasa Malaysia</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD003772-abs-0004" lang="en"> <h3>Are oral antibiotics as effective as a combination of injected and oral antibiotics for kidney infections in children? </h3> <p>Acute pyelonephritis refers to infection of the kidneys and is the most severe form of urinary tract infection (UTI). Acute pyelonephritis causes high fever, vomiting, stomach pain, irritability and poor feeding in infants. </p> <p>We wanted to find out if oral antibiotics were as effective as combined oral and injected antibiotics to treat children for kidney infection. This review updates our previous investigations published in 2003, 2005 and 2007. This review included evidence from 27 studies that involved 4452 children. The last literature search date was April 2014. This update included evidence from three new studies and from one study that was previously excluded. </p> <p>Review results suggested that children aged over one month with acute pyelonephritis can be treated effectively with oral antibiotics (cefixime, ceftibuten or amoxicillin/clavulanic acid) or with short courses (two to four days) of intravenous (IV) therapy followed by oral therapy. If IV therapy with aminoglycosides is needed, single daily dosing is safe and effective. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD003772-sec-0104" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD003772-sec-0104"></div> <h3 class="title" id="CD003772-sec-0105">Implications for practice</h3> <section id="CD003772-sec-0105"> <p>The following implications for practice in the treatment of children with acute pyelonephritis have been identified: </p> <p> <ul id="CD003772-list-0031"> <li> <p>Oral antibiotics (cefixime, ceftibuten or amoxicillin/clavulanic acid) given alone for 10 to 14 days are as effective as sequential IV therapy given for three days followed by oral therapy for a total duration of 10 to 14 days suggesting that children with acute pyelonephritis can be treated effectively with oral antibiotics. </p> </li> <li> <p>If IV antibiotic therapy is given, a short course of IV therapy given for two to four days followed by oral therapy with total therapy duration of 10 to 21 days is as effective as a longer duration of IV antibiotic therapy given for seven to 10 days with total duration of therapy of 10 to 21 days. </p> </li> <li> <p>Studies comparing oral therapy alone with IV then oral antibiotics or IV then oral with IV therapy involved children greater than one month of age and were biased towards children who were less sick and so findings cannot be extrapolated to children less than one month of age or who are severely ill. The studies were also not stratified according to the grade of VUR so it remains unclear whether results differ according to the presence or absence of dilating VUR (grades III‐V). </p> </li> <li> <p>Adequate data from RCTs are not available to determine the optimal total duration of antibiotic therapy required for acute pyelonephritis. </p> </li> </ul> </p> </section> <h3 class="title" id="CD003772-sec-0106">Implications for research</h3> <section id="CD003772-sec-0106"> <p>Further RCTs are required to determine the benefits and harms in children of different ages with acute pyelonephritis of: </p> <p> <ul id="CD003772-list-0032"> <li> <p>Treatment for shorter periods (seven days or less) compared with 10 to 14 days.</p> </li> <li> <p>Initial treatment with oral antibiotics compared with parenteral therapy or IV then oral therapy compared with IV therapy in children with dilating VUR or other major urinary tract malformation. </p> </li> <li> <p>Treatment with aminoglycosides alone or in combination with other antibiotics compared with other antibiotics including third generation cephalosporins in initial parenteral treatment. </p> </li> <li> <p>Treatment with cheaper and more widely available oral antibiotics e.g. cephalexin.</p> </li> </ul> </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD003772-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD003772-sec-0022"></div> <div class="table" id="CD003772-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Oral versus IV followed by oral (11 days) therapy for acute pyelonephritis in children</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Oral versus IV followed by oral (11 days) therapy for acute pyelonephritis in children</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children with acute pyelonephritis<br/> <b>Intervention:</b> oral versus IV followed by oral (11 days) therapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Oral</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> IV followed by oral (11 days) therapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to fever resolution (hours)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean time to fever resolution (hours) in the intervention groups was <b>2.05 higher</b> (0.84 lower to 4.94 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>808 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Renal parenchymal damage at 6 to 12 months: all included children with acute pyelonephritis</b> <br/> DMSA scans<br/> Follow‐up: 6 to 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.82</b> <br/> (0.59 to 1.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>943 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>224 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>184 per 1000</b> <br/> (132 to 251) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>313 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>257 per 1000</b> <br/> (185 to 351) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Renal parenchymal damage at 6 to 12 months: children with renal parenchymal damage on initial DMSA</b> <br/> Follow‐up: 6 to 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.79</b> <br/> (0.61 to 1.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>681 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>320 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>253 per 1000</b> <br/> (195 to 330) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>382 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>302 per 1000</b> <br/> (233 to 393) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Wide confidence intervals due to large standard deviations around the mean durations of fever<br/> <sup>2</sup> Large number of patients excluded because of lack of follow‐up DMSA scans<br/> <sup>3</sup> No explanation was provided </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003772-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Short duration (3 to 4 days) versus long duration (7 to 14 days) IV therapy for acute pyelonephritis in children</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Short duration (3 to 4 days) versus long duration (7 to 14 days) IV therapy for acute pyelonephritis in children</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children with acute pyelonephritis<br/> <b>Intervention:</b> short duration (3 to 4 days) versus long duration (7 to 14 days) IV therapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Short duration (3 to 4 days)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Long duration (7 to 14 days) IV therapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Persistent bacteriuria after treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.78</b> <br/> (0.24 to 2.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>305 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>38 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>30 per 1000</b> <br/> (9 to 98) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Recurrent UTI within 6 months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.97</b> <br/> (0.58 to 1.62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>993 (5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>59 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>57 per 1000</b> <br/> (34 to 95) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>56 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>54 per 1000</b> <br/> (32 to 91) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Persistent renal damage at 3 to 6 months: all included children with acute pyelonephritis</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.01</b> <br/> (0.8 to 1.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>726 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>246 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>249 per 1000</b> <br/> (197 to 318) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>257 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>260 per 1000</b> <br/> (206 to 332) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Persistent renal damage at 3 to 6 months: children with initial renal parenchymal damage on initial DMSA scan</b> <br/> Follow‐up: 6‐12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.1</b> <br/> (0.84 to 1.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>315 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>357 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>393 per 1000</b> <br/> (300 to 518) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>327 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>360 per 1000</b> <br/> (275 to 474) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Unclear or inadequate allocation concealment<br/> <sup>2</sup> Small number of patients and events leading to wide confidence intervals<br/> <sup>3</sup> In several studies, more than 10% patients lost to follow‐up or did not have follow‐up DMSA scans </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003772-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Different dosing regimens of aminoglycosides (daily versus 8 hourly) for acute pyelonephritis in children</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Different dosing regimens of aminoglycosides (daily versus 8 hourly) for acute pyelonephritis in children</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children with acute pyelonephritis<br/> <b>Intervention:</b> different dosing regimens of aminoglycosides (daily versus 8 hourly) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Daily dose</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 hourly dose</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Persistent bacteriuria after 1 to 3 days of treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.05</b> <br/> (0.15 to 7.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>435 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>9 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per 1000</b> <br/> (1 to 67) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Hearing impairment following treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 2.83</b> <br/> (0.33 to 24.56) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>271 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Increase in serum creatinine during treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.75</b> <br/> (0.2 to 2.82) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>419 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>25 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>19 per 1000</b> <br/> (5 to 70) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>25 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>19 per 1000</b> <br/> (5 to 70) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Unclear allocation concealment in two of three studies<br/> <sup>2</sup> Few events resulting in wide confidence intervals </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003772-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Agent: Third generation cephalosporin versus other antibiotic for acute pyelonephritis in children</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Agent: Third generation cephalosporin versus other antibiotic for acute pyelonephritis in children</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children with acute pyelonephritis<br/> <b>Intervention:</b> third generation cephalosporin versus other antibiotic </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Antibiotic</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Third generation cephalosporin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Persistent bacteriuria</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 2.41</b> <br/> (0.98 to 5.93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>439 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>34 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>81 per 1000</b> <br/> (33 to 199) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Recurrent UTI after end of therapy</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.23</b> <br/> (0.32 to 4.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>491 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>22 per 1000</b> <br/> (6 to 87) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per 1000</b> <br/> (3 to 38) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Persistent symptoms after end of treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.28</b> <br/> (0.13 to 0.62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>471 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>104 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>29 per 1000</b> <br/> (14 to 64) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Unclear allocation in several studies<br/> <sup>2</sup> Few events leading to imprecision<br/> <sup>3</sup> Meta‐analysis dominated by single trial and results inconsistent with bacteriologic results </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD003772-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD003772-sec-0023"></div> <section id="CD003772-sec-0024"> <h3 class="title" id="CD003772-sec-0024">Description of the condition</h3> <p>The urinary tract is a common site of bacterial infection in infants and young children. Pooled prevalence data demonstrate that approximately 7% of girls and boys are diagnosed with at least one urinary tract infection (UTI) by the age of 19 years (<a href="./references#CD003772-bbs2-0088" title="ShaikhN , MoroneNE , BostJE , FarrellMH . Prevalence of urinary tract infection in childhood: a meta‐analysis. Pediatric Infectious Disease Journal2008;27(4):302‐8. [MEDLINE: 18316994] ">Shaikh 2008</a>). Girls are more susceptible to UTIs than boys after the first six months of life with a prevalence of 11% in girls and 4% in boys (<a href="./references#CD003772-bbs2-0075" title="BrkicS , MustaficS , NuhbegovicS , LjucaF , GavranL . Clinical and epidemiology characteristics of urinary tract infections in childhood. Medicinski Arhiv2010;64(3):135‐8. [MEDLINE: 20645503] ">Brkic 2010</a>). UTI is defined by the presence of bacteria in urine (bacteriuria), which when cultured is measured in colony forming units/mL (CFU/mL) of uncentrifuged urine. The diagnosis of UTI in children is generally confirmed by the pure growth of a bacteria of greater than 10³ CFU/mL from a suprapubic aspirate, 10⁴ CFU/mL from a bladder catheter specimen and 10⁵ CFU/mL from non‐invasive collection methods (clean catch and urinary bag specimens) (<a href="./references#CD003772-bbs2-0074" title="BhatRG , KatyTA , PlaceFC . Pediatric urinary tract infections. Emergency Medicine Clinics of North America2011;29(3):637‐53. [MEDLINE: 21782079] ">Bhat 2011</a>). </p> <p>UTIs can be clinically grouped into asymptomatic bacteriuria, cystitis and acute pyelonephritis.</p> <p> <ul id="CD003772-list-0001"> <li> <p>Asymptomatic bacteriuria is the presence of bacteriuria without clinical signs and symptoms. </p> </li> <li> <p>Cystitis is a UTI limited to the urethra and bladder and is seen most commonly in girls over two years of age. It presents with localising symptoms of dysuria (pain when passing urine), frequency, urgency, cloudy urine and lower abdominal discomfort. Pyuria (white cells in the urine) and haematuria (blood in the urine) may also be found. </p> </li> <li> <p>Acute pyelonephritis refers to infection of the kidneys, and is the most severe form of UTI in children. Clinically, this is associated with systemic features such as high fever, malaise, vomiting, abdominal and loin pain and tenderness, poor feeding and irritability in infants. Together with urine culture, diagnosis may be assisted by imaging using technetium 99m labelled dimercaptosuccinic acid (DMSA) renal scan and markers of inflammation in the blood such as erythrocyte sedimentation rate (ESR) and C‐reactive protein (CRP). </p> </li> <li> <p>Acute pyelonephritis is associated with significant short‐term morbidity, including shock and septicaemia, especially in infants. Acute kidney parenchymal injury has been demonstrated on DMSA scan in about 60% of children shortly after UTI diagnosis (<a href="./references#CD003772-bbs2-0089" title="ShaikhN , EwingAL , BhatnagarS , HobermanA . Risk of renal scarring in children with a first urinary tract infection: a systematic review. Pediatrics2010;126(6):1084‐91. [MEDLINE: 21059720] ">Shaikh 2010</a>). Permanent kidney damage may occur following acute pyelonephritis and is more frequent in children who have multiple episodes or who have vesicoureteric reflux (VUR) (<a href="./references#CD003772-bbs2-0089" title="ShaikhN , EwingAL , BhatnagarS , HobermanA . Risk of renal scarring in children with a first urinary tract infection: a systematic review. Pediatrics2010;126(6):1084‐91. [MEDLINE: 21059720] ">Shaikh 2010</a>; <a href="./references#CD003772-bbs2-0090" title="SmellieJM , RansleyPG , NormandICS , PrescodN , EdwardsD . Development of renal scars: a collaborative study. BMJ1985;290(6486):1957‐60. [MEDLINE: 3924325] ">Smellie 1985</a>). Serial DMSA scans of children after a first episode of acute pyelonephritis show that 15% of children with acute changes on DMSA scans have permanent kidney scarring at follow up (<a href="./references#CD003772-bbs2-0089" title="ShaikhN , EwingAL , BhatnagarS , HobermanA . Risk of renal scarring in children with a first urinary tract infection: a systematic review. Pediatrics2010;126(6):1084‐91. [MEDLINE: 21059720] ">Shaikh 2010</a>). However, the long term significance of kidney damage following acute pyelonephritis is debatable. In children with previously normal kidneys, the amount of damage is small and unlikely to cause disease (<a href="./references#CD003772-bbs2-0086" title="SaloJ , IkäheimoR , TapiainenT , UhariM . Childhood urinary tract infections as a cause of chronic kidney disease. Pediatrics2011;128(5):840‐7. [MEDLINE: 21987701] ">Salo 2011</a>; <a href="./references#CD003772-bbs2-0091" title="ToffoloA , AmmentiA , MontiniG . Long‐term clinical consequences of urinary tract infections during childhood: a review. Acta Paediatrica2012;101(10):1018‐31. [MEDLINE: 22784016] ">Toffolo 2012</a>). </p> </li> </ul> </p> </section> <section id="CD003772-sec-0025"> <h3 class="title" id="CD003772-sec-0025">Description of the intervention</h3> <p>A wide variety of antibiotic agents have been used to treat acute pyelonephritis in children. Antibiotics that have been used include aminoglycosides, cephalosporins, penicillins and trimethoprim/sulphamethoxazole (TMP/SMX). Historically, children who are judged by clinicians to be in poor general condition are given parenteral antibiotics and those who appear less sick have been given oral antibiotics, without clarity whether one route of administration is superior. An antibiotic course of seven to 14 days is generally recommended although the optimal duration of therapy is not known. Shorter courses may be associated with treatment failure while longer courses may unnecessarily expose children to the adverse effects of treatment. This review evaluated antibiotic therapies used to treat acute pyelonephritis, with consideration of different antibiotic agents, different dosing regimens of the same antibiotic, different durations of treatment and different routes of administration. </p> </section> <section id="CD003772-sec-0026"> <h3 class="title" id="CD003772-sec-0026">How the intervention might work</h3> <p>Antibiotics work in the treatment of acute pyelonephritis by eliminating bacterial infection in the urinary tract. The purpose of antibiotic therapy is to eradicate and prevent progressive infection and its consequences, including shock and septicaemia, reduce acute kidney injury and resolve the acute clinical symptoms of infection. The efficacy of treatment depends on using the antibiotic(s) to which the bacteria is sensitive. While the results of antibiotic sensitivity testing are pending, initial treatment is chosen on an empiric basis to cover the most likely cause of infection. </p> </section> <section id="CD003772-sec-0027"> <h3 class="title" id="CD003772-sec-0027">Why it is important to do this review</h3> <p>Acute pyelonephritis is a common serious infection in children. Nonetheless, there remains no consensus on the most effective antibiotic regimen for the treatment of acute pyelonephritis. There is also uncertainty regarding the optimal route of administration of antibiotic therapy. Previously, most authorities recommended commencing antibiotic therapy by the parenteral route. The most recent guidelines however recommend initial treatment with oral antibiotics for children older than two months (<a href="./references#CD003772-bbs2-0072" title="American Academy of Pediatrics. Subcommittee On Urinary Tract Infection, Steering Committee On Quality Improvement and Management. Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months. Pediatrics2011;128(3):595‐610. [MEDLINE: 21873693] ">AAP 2011</a>) or three months of age (<a href="./references#CD003772-bbs2-0085" title="National Institute for Health and Clinical Excellence. Urinary tract infection in children: diagnosis, treatment and long‐term management CG54. 2007. http://www.nice.org.uk/guidance/CG54. London: RCOG Press, (accessed 4 July 2014). ">NICE 2007</a>) unless children are considered to be too unwell or unable to take oral antibiotics. This is advantageous because oral therapy is more convenient and does not require hospital admission, thereby reducing costs. There is further uncertainty about the optimal duration of antibiotic therapy. Currently, the recommended duration of therapy varies from seven to 14 days. </p> <p>This review update was necessary to provide additional information about the optimum antibiotic regimens, route of administration and duration of treatment for acute pyelonephritis in children and about adverse effects of treatment. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD003772-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD003772-sec-0028"></div> <p>To evaluate the benefits and harms of antibiotics used to treat children with acute pyelonephritis. The aspects of therapy considered were: </p> <p> <ol id="CD003772-list-0002"> <li> <p>different antibiotics</p> </li> <li> <p>different dosing regimens of the same antibiotic</p> </li> <li> <p>different duration of treatment</p> </li> <li> <p>different routes of administration.</p> </li> </ol> </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD003772-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD003772-sec-0029"></div> <section id="CD003772-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD003772-sec-0031"> <h4 class="title">Types of studies</h4> <p>All randomised controlled trials (RCTs) and quasi‐RCTs (RCTs in which allocation to treatment was obtained by alternation, use of alternate medical records, date of birth or other predictable methods) in which antibiotics were used in the treatment of children (birth to 18 years) with acute pyelonephritis were included. Where studies included both children with acute pyelonephritis and those with cystitis, these were included if data for participants with acute pyelonephritis could be extracted separately; otherwise, these studies were excluded. </p> </section> <section id="CD003772-sec-0032"> <h4 class="title">Types of participants</h4> <section id="CD003772-sec-0033"> <h5 class="title">Inclusion criteria</h5> <p>Children from birth to 18 years with acute pyelonephritis treated either in hospital or as outpatients with antibiotics were included. For this review, the diagnosis of acute pyelonephritis required UTI (as specified in the included studies but generally requiring a bacterial growth on urine culture of more than 10⁵ CFU/mL or 10⁸ CFU/L) with at least one symptom or sign of systemic illness such as fever, loin pain or toxicity and additional diagnostic criteria as defined by the authors of the included studies. Children with previously diagnosed urinary tract abnormalities including VUR or previous UTI could be included. </p> </section> <section id="CD003772-sec-0034"> <h5 class="title">Exclusion criteria</h5> <p>Patients considered to have asymptomatic bacteriuria or cystitis (UTI as defined in Inclusions with no symptom or sign of systemic illness) were excluded. </p> </section> </section> <section id="CD003772-sec-0035"> <h4 class="title">Types of interventions</h4> <p> <ul id="CD003772-list-0003"> <li> <p>Different antibiotic agents</p> </li> <li> <p>IV antibiotic versus oral antibiotic</p> </li> <li> <p>Different doses or duration or both of the same antibiotic</p> </li> <li> <p>Antibiotic versus placebo, no therapy or alternative non‐antibiotic therapy.</p> </li> </ul> </p> </section> <section id="CD003772-sec-0036"> <h4 class="title">Types of outcome measures</h4> <section id="CD003772-sec-0037"> <h5 class="title">Primary outcomes</h5> <p>Short‐term outcome measures.</p> <p> <ul id="CD003772-list-0004"> <li> <p>Duration of fever</p> </li> <li> <p>Persistent symptoms (e.g. UTI at 72 hours; inflammatory markers at 72 hours (ESR, WCC, CRP) </p> </li> <li> <p>Acute kidney parenchymal damage on DMSA scan</p> </li> <li> <p>Length of hospital stay for inpatients</p> </li> <li> <p>Persistent bacteriuria after completion of antibiotics</p> </li> <li> <p>Recurrent UTI</p> </li> <li> <p>Adverse effects of treatment including minor (e.g. vomiting, discomfort from IV cannula) and major (e.g. anaphylaxis, hearing impairment) </p> </li> <li> <p>Economic costs of treatment (if data available).</p> </li> </ul> </p> </section> <section id="CD003772-sec-0038"> <h5 class="title">Secondary outcomes</h5> <p>Long‐term outcome measures.</p> <p> <ul id="CD003772-list-0005"> <li> <p>Persistent kidney damage (as defined by authors of included studies)</p> </li> <li> <p>Hypertension</p> </li> <li> <p>Chronic kidney disease.</p> </li> </ul> </p> </section> </section> </section> <section id="CD003772-sec-0039"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD003772-sec-0040"> <h4 class="title">Electronic searches</h4> <p>For the 2014 update, we searched the Cochrane Renal Group's Specialised Register through contact with the Trials' Search Co‐ordinator using search terms relevant to this review. The Cochrane Renal Group’s Specialised Register contains studies identified from the following sources. </p> <p> <ol id="CD003772-list-0006"> <li> <p>Monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL)</p> </li> <li> <p>Weekly searches of MEDLINE OVID SP</p> </li> <li> <p>Handsearching of renal‐related journals and the proceedings of major renal conferences</p> </li> <li> <p>Searching of the current year of EMBASE OVID SP</p> </li> <li> <p>Weekly current awareness alerts for selected renal journals</p> </li> <li> <p>Searches of the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.</p> </li> </ol> </p> <p>Studies contained in the Specialised Register are identified through search strategies for CENTRAL, MEDLINE, and EMBASE based on the scope of the Cochrane Renal Group. Details of these strategies, as well as a list of handsearched journals, conference proceedings and current awareness alerts, are available in the Specialised Register section of information about the <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/RENAL/frame.html" target="_blank">Cochrane Renal Group</a>. </p> <p>See <a href="./appendices#CD003772-sec-0110">Appendix 1</a> for search terms used in strategies for this review update. </p> <p>For previous search strategies please refer to our earlier reviews (<a href="./references#CD003772-bbs2-0094" title="BloomfieldP , HodsonEM , CraigJC . Antibiotics for acute pyelonephritis in children. Cochrane Database of Systematic Reviews2003, Issue 2. [DOI: 10.1002/14651858.CD003772] ">Bloomfield 2003</a>; <a href="./references#CD003772-bbs2-0095" title="BloomfieldP , HodsonEM , CraigJC . Antibiotics for acute pyelonephritis in children. Cochrane Database of Systematic Reviews2005, Issue 1. [DOI: 10.1002/14651858.CD003772.pub2] ">Bloomfield 2005</a>; <a href="./references#CD003772-bbs2-0096" title="HodsonEM , WillisNS , CraigJC . Antibiotics for acute pyelonephritis in children. Cochrane Database of Systematic Reviews2007, Issue 4. [DOI: 10.1002/14651858.CD003772.pub3] ">Hodson 2007</a>). </p> </section> <section id="CD003772-sec-0041"> <h4 class="title">Searching other resources</h4> <p> <ol id="CD003772-list-0007"> <li> <p>Reference lists of review articles, relevant studies and clinical practice guidelines.</p> </li> <li> <p>Letters seeking information about unpublished or incomplete studies to investigators known to be involved in previous studies. </p> </li> </ol> </p> </section> </section> <section id="CD003772-sec-0042"> <h3 class="title" id="CD003772-sec-0042">Data collection and analysis</h3> <section id="CD003772-sec-0043"> <h4 class="title">Selection of studies</h4> <p>The search strategy described was used to obtain titles and abstracts of studies relevant to the review. Titles and abstracts were screened independently by four authors, who discarded studies that were not applicable. However, studies and reviews that included relevant data or information on studies were retained initially. Four authors independently assessed retrieved abstracts, and if necessary the full text, to determine which studies satisfied the inclusion criteria. </p> </section> <section id="CD003772-sec-0044"> <h4 class="title">Data extraction and management</h4> <p>Data extraction was carried out independently by four authors using standard data extraction forms. Studies reported in non‐English language journals were translated before assessment. Where more than one publication of one study existed, reports were grouped together and the publication with the most complete data was used in the analyses. Where relevant outcomes were only published in earlier versions those data were used. Any discrepancy between published versions was highlighted. </p> </section> <section id="CD003772-sec-0045"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The following items were independently assessed by four authors using the risk of bias assessment tool (<a href="./references#CD003772-bbs2-0078" title="HigginsJ , AltmanD , GotzscheP , JuniP , MoherD , OxmanA , et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ2011; Vol. 343:d5928. [MEDLINE: 22008217] ">Higgins 2011</a>) (see <a href="./appendices#CD003772-sec-0111">Appendix 2</a>). </p> <p> <ul id="CD003772-list-0008"> <li> <p>Was there adequate sequence generation (selection bias)?</p> </li> <li> <p>Was allocation adequately concealed (selection bias)?</p> </li> <li> <p>Was knowledge of the allocated interventions adequately prevented during the study (detection bias)? </p> <ul id="CD003772-list-0009"> <li> <p>Participants and personnel</p> </li> <li> <p>Outcome assessors</p> </li> </ul> </li> <li> <p>Were incomplete outcome data adequately addressed (attrition bias)?</p> </li> <li> <p>Are reports of the study free of suggestion of selective outcome reporting (reporting bias)? </p> </li> <li> <p>Was the study apparently free of other problems that could put it at a risk of bias?</p> </li> </ul> </p> </section> <section id="CD003772-sec-0046"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes (persistent bacteriuria, recurrent UTI, persistent clinical symptoms, presence of kidney parenchymal damage, adverse effects) results were expressed as risk ratio (RR) with 95% confidence intervals (CI). Where continuous scales of measurement were used to assess the effects of treatment (duration of fever, inflammatory markers, extent of kidney parenchymal damage), the mean difference (MD) was used. </p> </section> <section id="CD003772-sec-0047"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the study participant and not events, that is, the number of children with acute pyelonephritis rather than the number of episodes of acute pyelonephritis per child. </p> </section> <section id="CD003772-sec-0048"> <h4 class="title">Dealing with missing data</h4> <p>Where data were missing or unclear, we contacted the original authors of studies to request additional data. An attempt to obtain the preliminary results of the terminated study (<a href="./references#CD003772-bbs2-0071" title="NCT00724256 . Randomised controlled trial on efficacy and safety of short term versus long term antibiotic therapy for pyelonephritis in childhood. ClinicalTrials.gov http://www.clinicaltrials.gov/ct2/results?term=NCT00724256; Vol. (accessed 4 July 2014). ">NCT00724256</a>) was made by contacting the lead investigator. We did not impute missing data. </p> </section> <section id="CD003772-sec-0049"> <h4 class="title">Assessment of heterogeneity</h4> <p>Heterogeneity was analysed using a Chi squared test on N‐1 degrees of freedom with an alpha of 0.1 used for statistical significance and the I² statistic (<a href="./references#CD003772-bbs2-0077" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. [MEDLINE: 12958120] ">Higgins 2003</a>). I² values of 25%, 50% and 75% correspond to low, medium and high levels of heterogeneity. </p> </section> <section id="CD003772-sec-0050"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to assess publication bias by constructing funnel plots; however, there were insufficient data in each meta‐analysis to enable this analysis to be conducted. </p> </section> <section id="CD003772-sec-0051"> <h4 class="title">Data synthesis</h4> <p>Data were pooled using the random‐effects model but the fixed‐effect model was also used to ensure robustness of the model chosen and susceptibility to outliers. </p> </section> <section id="CD003772-sec-0052"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Subgroup analysis was planned to explore possible sources of heterogeneity (participants, treatments and study quality) but could not be undertaken because of the small number of studies for each comparison. Heterogeneity among participants could be related to age (infants versus adolescents) and pre‐existing renal tract pathology. Heterogeneity in treatment could be related to inpatient versus outpatient management, prior antibiotics used and the antibiotic, dose, duration and route of administration of therapy. </p> </section> <section id="CD003772-sec-0053"> <h4 class="title">Sensitivity analysis</h4> <p>Sensitivity analysis was planned to identify individual studies that were contributing to significant heterogeneity (I² value greater than 75%) but the I² values of all meta‐analyses were less than 50% so sensitivity analysis was not undertaken. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD003772-sec-0054" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD003772-sec-0054"></div> <section id="CD003772-sec-0055"> <h3 class="title">Description of studies</h3> <section id="CD003772-sec-0056"> <h4 class="title">Results of the search</h4> <section id="CD003772-sec-0057"> <h5 class="title">First version published 2003</h5> <p>The initial search in September 2002 identified 1520 titles and abstracts of which 51 were screened. We found that 16 parallel RCTs (16 reports) involving 1872 children fulfilled the eligibility criteria and were included in the review. We excluded 11 studies (11 reports) (<a href="./references#CD003772-bbs2-0094" title="BloomfieldP , HodsonEM , CraigJC . Antibiotics for acute pyelonephritis in children. Cochrane Database of Systematic Reviews2003, Issue 2. [DOI: 10.1002/14651858.CD003772] ">Bloomfield 2003</a>). </p> </section> <section id="CD003772-sec-0058"> <h5 class="title">Review updates published 2005 and 2007</h5> <p>A search in June 2004 identified two additional studies (three reports) (<a href="./references#CD003772-bbs2-0009" title="ChaoSM , ChongCY , Tan‐HendrickA , TanAS , NgWY . Efficacy and safety of once‐a‐day gentamicin in the treatment of childhood acute pyelonephritis [abstract]. Pediatric Nephrology2001;16(8):C105. [CENTRAL: CN‐00444755] ChongCY , TanAS , NgW , Tan‐KendrickA , BalakrishnanA , ChaoSM . Treatment of urinary tract infection with gentamicin once or three times daily. Acta Paediatrica2003;92(3):291‐6. [MEDLINE: 12725542] ">Chong 2003</a>; <a href="./references#CD003772-bbs2-0019" title="HewittIK , TomasiL , PavanelloL , MaschioF , MolinariPP , ToffoloA , et al. Early treatment of acute pyelonephritis in children fails to reduce renal scarring [abstract no: SA‐PO1100]. Journal of the American Society of Nephrology2006;17(Abstracts):804A. [CENTRAL: CN‐00653791] HewittIK , ZucchettaP , RigonL , MaschioF , MolinariPP , TomasiL , et al. Early treatment of acute pyelonephritis in children fails to reduce renal scarring: data from the Italian Renal Infection Study Trials. Pediatrics2008;122(3):486‐90. [MEDLINE: 18762516] LaScolaC , DeMutiisC , HewittIK , PuccioG , ToffoloA , ZucchettaP , et al. Different guidelines for imaging after first UTI in febrile infants: yield, cost, and radiation. Pediatrics2013;131(3):e665‐71. [MEDLINE: 23439905] MontiniG , MurerL , GobberD , CommacchioS , ToffoloA , Dall'AmicoR , et al. Oral vs initial intravenous antibiotic treatment of urinary tract infections in children: a multicentre study [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):816. [CENTRAL: CN‐00446817] MontiniG , ToffoloA , ZucchettaP , Dall'AmicoR , GobberD , CalderonA , et al. Antibiotic treatment for pyelonephritis in children: multicentre randomised controlled non‐inferiority trial. BMJ2007;335(7616):386‐92. [MEDLINE: 17611232] MontiniG , ZucchettaP , GobberD , MurerL , RigonL , ToffoloA , et al. Usefulness of renal radiology and scintigraphy in children with a first episode of upper urinary tract infection [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):813. [CENTRAL: CN‐00446818] MontiniG , ZucchettaP , TomasiL , TalentiE , RigamontiW , PiccoG , et al. Value of imaging studies after a first febrile urinary tract infection in young children: data from Italian renal infection study 1. Pediatrics2009;123(2):e239‐46. [MEDLINE: 19139086] ">Montini 2007</a>). A total of 18 studies (19 reports) involving 2612 children were included in our 2005 review update (<a href="./references#CD003772-bbs2-0095" title="BloomfieldP , HodsonEM , CraigJC . Antibiotics for acute pyelonephritis in children. Cochrane Database of Systematic Reviews2005, Issue 1. [DOI: 10.1002/14651858.CD003772.pub2] ">Bloomfield 2005</a>). </p> <p>A search from 2004 to July 2007 identified 26 reports of which 16 were excluded (not randomised, mixed populations or wrong interventions). We included five new studies (nine reports) (<a href="./references#CD003772-bbs2-0003" title="BanfiAG , Hill‐JuarezJM , KaufmanA , MoensE . Multinational comparative trial of ceftibuten and trimethoprim‐sulfamethoxazole in the treatment of children with complicated or recurrent urinary tract infections. Members of the ceftibuten urinary tract infection international study group. Pediatric Infectious Disease Journal1993;12(6 Suppl):S84‐S91. [CENTRAL: CN‐00334829] ">Banfi 1993</a>; <a href="./references#CD003772-bbs2-0008" title="ChengCH , TsauYK , ChangCJ , ChangYC , KuoCY , TsaiIJ , et al. Acute lobar nephronia is associated with a high incidence of renal scarring in childhood urinary tract infections. Pediatric Infectious Disease Journal2010;29(7):624‐8. [MEDLINE: 20234330] ChengCH , TsauYK , LinTY . Effective duration of antimicrobial therapy for the treatment of acute lobar nephronia. Pediatrics2006;117(1):e84‐9. [MEDLINE: 16326693] ">Cheng 2006</a>; <a href="./references#CD003772-bbs2-0012" title="FujiiR , ShinozakiT , MeguroH , ArimasuO , IzumiK , OsanoM , et al. Comparative, controlled study on an ampicillin suppository (KS‐R 1) with an oral form of ampicillin in urinary tract infections. Japanese Journal of Antibiotics1987;40(3):476‐92. [MEDLINE: 3302342] ">Fujii 1987</a>; <a href="./references#CD003772-bbs2-0020" title="BuechnerK , GirardinF , BergerC , WilliU , NadafD , Neuhaus T for the Swiss Pyelonephritis Study Group. Randomised controlled trial of oral versus sequential intravenous/oral cephalosporins in DMSA scintigraphy‐documented acute pyelonephritis [abstract no: COD. OP 18]. Pediatric Nephrology2006;21(10):1511. [CENTRAL: CN‐00601934] NeuhausTJ , BergerC , BuechnerK , ParvexP , BischoffG , GoetschelP , et al. Randomised trial of oral versus sequential intravenous/oral cephalosporins in children with pyelonephritis. European Journal of Pediatrics2008;167(9):1037‐47. [MEDLINE: 18074149] NeuhausTJ , BüchnerK , GirardinE , WilliU , BergerC , NadalD . Oral versus sequential intravenous/oral cephalosporin‐therapy in DMSA‐scintigraphy documented acute pyelonephritis: randomized Swiss pyelonephritis‐study [abstract] [Orale versus sequentiell intravenös/orale Cephalosporin‐Therapie bei DMSA‐Szintigraphie dokumentierter akuter Pyelonephritis: Randomisierte Schweizer Pyelonephritis‐Studie]. Nieren‐ und Hochdruckkrankheiten2007;36(2):43. [CENTRAL: CN‐00615897] ">Neuhaus 2008</a>; <a href="./references#CD003772-bbs2-0021" title="NoorbakhshS , LariAR , MasjedianF , MostafaviH , AlaghehbandanR . Comparison of intravenous aminoglycoside therapy with switch therapy to cefixime in urinary tract infections. Saudi Medical Journal2004;25(10):1513‐5. [MEDLINE: 15494842] ">Noorbakhsh 2004</a>). The final results of the multicentre study by <a href="./references#CD003772-bbs2-0019" title="HewittIK , TomasiL , PavanelloL , MaschioF , MolinariPP , ToffoloA , et al. Early treatment of acute pyelonephritis in children fails to reduce renal scarring [abstract no: SA‐PO1100]. Journal of the American Society of Nephrology2006;17(Abstracts):804A. [CENTRAL: CN‐00653791] HewittIK , ZucchettaP , RigonL , MaschioF , MolinariPP , TomasiL , et al. Early treatment of acute pyelonephritis in children fails to reduce renal scarring: data from the Italian Renal Infection Study Trials. Pediatrics2008;122(3):486‐90. [MEDLINE: 18762516] LaScolaC , DeMutiisC , HewittIK , PuccioG , ToffoloA , ZucchettaP , et al. Different guidelines for imaging after first UTI in febrile infants: yield, cost, and radiation. Pediatrics2013;131(3):e665‐71. [MEDLINE: 23439905] MontiniG , MurerL , GobberD , CommacchioS , ToffoloA , Dall'AmicoR , et al. Oral vs initial intravenous antibiotic treatment of urinary tract infections in children: a multicentre study [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):816. [CENTRAL: CN‐00446817] MontiniG , ToffoloA , ZucchettaP , Dall'AmicoR , GobberD , CalderonA , et al. Antibiotic treatment for pyelonephritis in children: multicentre randomised controlled non‐inferiority trial. BMJ2007;335(7616):386‐92. [MEDLINE: 17611232] MontiniG , ZucchettaP , GobberD , MurerL , RigonL , ToffoloA , et al. Usefulness of renal radiology and scintigraphy in children with a first episode of upper urinary tract infection [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):813. [CENTRAL: CN‐00446818] MontiniG , ZucchettaP , TomasiL , TalentiE , RigamontiW , PiccoG , et al. Value of imaging studies after a first febrile urinary tract infection in young children: data from Italian renal infection study 1. Pediatrics2009;123(2):e239‐46. [MEDLINE: 19139086] ">Montini 2007</a> were published and included in this update. We included 23 studies (29 reports) that involved 3407 children in the 2007 update (<a href="./references#CD003772-bbs2-0096" title="HodsonEM , WillisNS , CraigJC . Antibiotics for acute pyelonephritis in children. Cochrane Database of Systematic Reviews2007, Issue 4. [DOI: 10.1002/14651858.CD003772.pub3] ">Hodson 2007</a>). </p> </section> <section id="CD003772-sec-0059"> <h5 class="title">Review update 2014</h5> <p>A search in 10 April 2014 identified 32 reports. In addition, a previously excluded study was re‐evaluated and included because it had been excluded incorrectly based on how outcomes were reported. <a href="./references#CD003772-bbs2-0016" title="KahnAJ , KumarK , EvansHE . Three‐day antimicrobial therapy of urinary tract infection. Journal of Pediatrics1981;99(6):992‐4. [MEDLINE: 7031217] ">Khan 1981</a> had been previously excluded because results were reported as episodes of acute pyelonephritis rather than number of patients with an episode of acute pyelonephritis. We excluded 17 studies (17 reports) and identified one eligible study that was terminated (see <a href="./references#CD003772-sec-0121" title="">Characteristics of ongoing studies</a>); contact with the triallists confirmed that no results were available (<a href="./references#CD003772-bbs2-0071" title="NCT00724256 . Randomised controlled trial on efficacy and safety of short term versus long term antibiotic therapy for pyelonephritis in childhood. ClinicalTrials.gov http://www.clinicaltrials.gov/ct2/results?term=NCT00724256; Vol. (accessed 4 July 2014). ">NCT00724256</a>). We found that nine new records were further reports of four previously included studies (<a href="./references#CD003772-bbs2-0004" title="BenadorD , NeuhausTJ , PapazyanJ‐P , WilliUV , Engel‐BicikI , NadalD , et al. Randomised controlled trial of three day versus 10 day intravenous antibiotics in acute pyelonephritis: effect on renal scarring. Archives of Disease in Childhood2001;84(3):241‐6. [MEDLINE: 11207174] GirardinE , NeuhausT , PapazyanJ , WilliUV , BicikI , NadalD , et al. Acute pyelonephritis: comparison of 3 vs 10 days IV antibiotic treatment [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):592A. [CENTRAL: CN‐00583905] ">Benador 2001</a>; <a href="./references#CD003772-bbs2-0008" title="ChengCH , TsauYK , ChangCJ , ChangYC , KuoCY , TsaiIJ , et al. Acute lobar nephronia is associated with a high incidence of renal scarring in childhood urinary tract infections. Pediatric Infectious Disease Journal2010;29(7):624‐8. [MEDLINE: 20234330] ChengCH , TsauYK , LinTY . Effective duration of antimicrobial therapy for the treatment of acute lobar nephronia. Pediatrics2006;117(1):e84‐9. [MEDLINE: 16326693] ">Cheng 2006</a>; <a href="./references#CD003772-bbs2-0019" title="HewittIK , TomasiL , PavanelloL , MaschioF , MolinariPP , ToffoloA , et al. Early treatment of acute pyelonephritis in children fails to reduce renal scarring [abstract no: SA‐PO1100]. Journal of the American Society of Nephrology2006;17(Abstracts):804A. [CENTRAL: CN‐00653791] HewittIK , ZucchettaP , RigonL , MaschioF , MolinariPP , TomasiL , et al. Early treatment of acute pyelonephritis in children fails to reduce renal scarring: data from the Italian Renal Infection Study Trials. Pediatrics2008;122(3):486‐90. [MEDLINE: 18762516] LaScolaC , DeMutiisC , HewittIK , PuccioG , ToffoloA , ZucchettaP , et al. Different guidelines for imaging after first UTI in febrile infants: yield, cost, and radiation. Pediatrics2013;131(3):e665‐71. [MEDLINE: 23439905] MontiniG , MurerL , GobberD , CommacchioS , ToffoloA , Dall'AmicoR , et al. Oral vs initial intravenous antibiotic treatment of urinary tract infections in children: a multicentre study [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):816. [CENTRAL: CN‐00446817] MontiniG , ToffoloA , ZucchettaP , Dall'AmicoR , GobberD , CalderonA , et al. Antibiotic treatment for pyelonephritis in children: multicentre randomised controlled non‐inferiority trial. BMJ2007;335(7616):386‐92. [MEDLINE: 17611232] MontiniG , ZucchettaP , GobberD , MurerL , RigonL , ToffoloA , et al. Usefulness of renal radiology and scintigraphy in children with a first episode of upper urinary tract infection [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):813. [CENTRAL: CN‐00446818] MontiniG , ZucchettaP , TomasiL , TalentiE , RigamontiW , PiccoG , et al. Value of imaging studies after a first febrile urinary tract infection in young children: data from Italian renal infection study 1. Pediatrics2009;123(2):e239‐46. [MEDLINE: 19139086] ">Montini 2007</a>; <a href="./references#CD003772-bbs2-0020" title="BuechnerK , GirardinF , BergerC , WilliU , NadafD , Neuhaus T for the Swiss Pyelonephritis Study Group. Randomised controlled trial of oral versus sequential intravenous/oral cephalosporins in DMSA scintigraphy‐documented acute pyelonephritis [abstract no: COD. OP 18]. Pediatric Nephrology2006;21(10):1511. [CENTRAL: CN‐00601934] NeuhausTJ , BergerC , BuechnerK , ParvexP , BischoffG , GoetschelP , et al. Randomised trial of oral versus sequential intravenous/oral cephalosporins in children with pyelonephritis. European Journal of Pediatrics2008;167(9):1037‐47. [MEDLINE: 18074149] NeuhausTJ , BüchnerK , GirardinE , WilliU , BergerC , NadalD . Oral versus sequential intravenous/oral cephalosporin‐therapy in DMSA‐scintigraphy documented acute pyelonephritis: randomized Swiss pyelonephritis‐study [abstract] [Orale versus sequentiell intravenös/orale Cephalosporin‐Therapie bei DMSA‐Szintigraphie dokumentierter akuter Pyelonephritis: Randomisierte Schweizer Pyelonephritis‐Studie]. Nieren‐ und Hochdruckkrankheiten2007;36(2):43. [CENTRAL: CN‐00615897] ">Neuhaus 2008</a>). Reports relating to <a href="./references#CD003772-bbs2-0004" title="BenadorD , NeuhausTJ , PapazyanJ‐P , WilliUV , Engel‐BicikI , NadalD , et al. Randomised controlled trial of three day versus 10 day intravenous antibiotics in acute pyelonephritis: effect on renal scarring. Archives of Disease in Childhood2001;84(3):241‐6. [MEDLINE: 11207174] GirardinE , NeuhausT , PapazyanJ , WilliUV , BicikI , NadalD , et al. Acute pyelonephritis: comparison of 3 vs 10 days IV antibiotic treatment [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):592A. [CENTRAL: CN‐00583905] ">Benador 2001</a>, <a href="./references#CD003772-bbs2-0008" title="ChengCH , TsauYK , ChangCJ , ChangYC , KuoCY , TsaiIJ , et al. Acute lobar nephronia is associated with a high incidence of renal scarring in childhood urinary tract infections. Pediatric Infectious Disease Journal2010;29(7):624‐8. [MEDLINE: 20234330] ChengCH , TsauYK , LinTY . Effective duration of antimicrobial therapy for the treatment of acute lobar nephronia. Pediatrics2006;117(1):e84‐9. [MEDLINE: 16326693] ">Cheng 2006</a> and <a href="./references#CD003772-bbs2-0019" title="HewittIK , TomasiL , PavanelloL , MaschioF , MolinariPP , ToffoloA , et al. Early treatment of acute pyelonephritis in children fails to reduce renal scarring [abstract no: SA‐PO1100]. Journal of the American Society of Nephrology2006;17(Abstracts):804A. [CENTRAL: CN‐00653791] HewittIK , ZucchettaP , RigonL , MaschioF , MolinariPP , TomasiL , et al. Early treatment of acute pyelonephritis in children fails to reduce renal scarring: data from the Italian Renal Infection Study Trials. Pediatrics2008;122(3):486‐90. [MEDLINE: 18762516] LaScolaC , DeMutiisC , HewittIK , PuccioG , ToffoloA , ZucchettaP , et al. Different guidelines for imaging after first UTI in febrile infants: yield, cost, and radiation. Pediatrics2013;131(3):e665‐71. [MEDLINE: 23439905] MontiniG , MurerL , GobberD , CommacchioS , ToffoloA , Dall'AmicoR , et al. Oral vs initial intravenous antibiotic treatment of urinary tract infections in children: a multicentre study [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):816. [CENTRAL: CN‐00446817] MontiniG , ToffoloA , ZucchettaP , Dall'AmicoR , GobberD , CalderonA , et al. Antibiotic treatment for pyelonephritis in children: multicentre randomised controlled non‐inferiority trial. BMJ2007;335(7616):386‐92. [MEDLINE: 17611232] MontiniG , ZucchettaP , GobberD , MurerL , RigonL , ToffoloA , et al. Usefulness of renal radiology and scintigraphy in children with a first episode of upper urinary tract infection [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):813. [CENTRAL: CN‐00446818] MontiniG , ZucchettaP , TomasiL , TalentiE , RigamontiW , PiccoG , et al. Value of imaging studies after a first febrile urinary tract infection in young children: data from Italian renal infection study 1. Pediatrics2009;123(2):e239‐46. [MEDLINE: 19139086] ">Montini 2007</a> did not provide any new data; however, the final results of <a href="./references#CD003772-bbs2-0020" title="BuechnerK , GirardinF , BergerC , WilliU , NadafD , Neuhaus T for the Swiss Pyelonephritis Study Group. Randomised controlled trial of oral versus sequential intravenous/oral cephalosporins in DMSA scintigraphy‐documented acute pyelonephritis [abstract no: COD. OP 18]. Pediatric Nephrology2006;21(10):1511. [CENTRAL: CN‐00601934] NeuhausTJ , BergerC , BuechnerK , ParvexP , BischoffG , GoetschelP , et al. Randomised trial of oral versus sequential intravenous/oral cephalosporins in children with pyelonephritis. European Journal of Pediatrics2008;167(9):1037‐47. [MEDLINE: 18074149] NeuhausTJ , BüchnerK , GirardinE , WilliU , BergerC , NadalD . Oral versus sequential intravenous/oral cephalosporin‐therapy in DMSA‐scintigraphy documented acute pyelonephritis: randomized Swiss pyelonephritis‐study [abstract] [Orale versus sequentiell intravenös/orale Cephalosporin‐Therapie bei DMSA‐Szintigraphie dokumentierter akuter Pyelonephritis: Randomisierte Schweizer Pyelonephritis‐Studie]. Nieren‐ und Hochdruckkrankheiten2007;36(2):43. [CENTRAL: CN‐00615897] ">Neuhaus 2008</a> (two new reports) were published in September 2008 and results were included in this review update. Four reports were of three newly identified studies (<a href="./references#CD003772-bbs2-0005" title="BocquetN , Sergent AlaouiA , JaisJP , GajdosV , GuigonisV , LacourB , et al. Randomized trial of oral versus sequential IV/oral antibiotic for acute pyelonephritis in children. Pediatrics2012;129(2):e269‐75. [MEDLINE: 22291112] ">Bocquet 2012</a>; <a href="./references#CD003772-bbs2-0006" title="BouissouF , MunzerC , DecramerS , RousselB , NovoR , MorinD , et al. Prospective, randomized trial comparing short and long intravenous antibiotic treatment of acute pyelonephritis in children: dimercaptosuccinic acid scintigraphic evaluation at 9 months. Pediatrics2008;121(3):e553‐60. [MEDLINE: 18267977] ">Bouissou 2008</a>; <a href="./references#CD003772-bbs2-0018" title="MarildS , EsbjornerE , JakobssonB , LinneT , LubeckP , SjogrenI , et al. Randomised study of ceftibuten vs trimethoprim‐sulfamethoxazole in pyelonephritis in children [abstract no: P466]. Pediatric Nephrology2004;19(9):C208. MarildS , JodalU , SandbergT . Ceftibuten versus trimethoprim‐sulfamethoxazole for oral treatment of febrile urinary tract infection in children. Pediatric Nephrology2009;24(3):521‐6. [MEDLINE: 18818954] ">Marild 2009</a>). This update included 27 studies (42 reports) that involved 4452 children. </p> <p>See <a href="#CD003772-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD003772-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD003772-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> </section> <section id="CD003772-sec-0060"> <h4 class="title">Included studies</h4> <p>The characteristics of the 27 included studies are summarised in <a href="./references#CD003772-sec-0119" title="">Characteristics of included studies</a>. </p> <section id="CD003772-sec-0061"> <h5 class="title">Participants</h5> <p>Studies recruited participants from the ages of two weeks to 16 years. Three studies did not specify age range (<a href="./references#CD003772-bbs2-0002" title="BakkalogluA , SaatciU , SoylemezogluO , OzenS , TopalogluR , BesbasN , et al. Comparison of ceftriaxone versus cefotaxime for childhood upper urinary tract infections. Journal of Chemotherapy1996;8(1):59‐62. [MEDLINE: 8835111] ">Bakkaloglu 1996</a>; <a href="./references#CD003772-bbs2-0017" title="LevtchenkoE , LahyC , LevyJ , HamH , PiepszA . Treatment of children with acute pyelonephritis: a prospective randomized study. Pediatric Nephrology2001;16(11):878‐84. [MEDLINE: 11685593] ">Levtchenko 2001</a>; <a href="./references#CD003772-bbs2-0022" title="PylkkänenJ , VilskaJ , KoskimiesO . The length of antimicrobial therapy in upper vs. lower urinary tract infection of childhood. Acta Paediatrica Scandinavica1981;70(6):885‐8. [MEDLINE: 7324942] PylkkänenJ , VilskaJ , KoskimiesO . The value of level diagnosis of childhood urinary tract infection in predicting renal injury. Acta Paediatrica Scandinavica1981;70(6):879‐83. [MEDLINE: 7324941] ">Pylkkänen 1981</a>). </p> </section> <section id="CD003772-sec-0062"> <h5 class="title">Healthcare settings</h5> <p> <ul id="CD003772-list-0010"> <li> <p>Children received treatment while inpatients in seven studies (<a href="./references#CD003772-bbs2-0002" title="BakkalogluA , SaatciU , SoylemezogluO , OzenS , TopalogluR , BesbasN , et al. Comparison of ceftriaxone versus cefotaxime for childhood upper urinary tract infections. Journal of Chemotherapy1996;8(1):59‐62. [MEDLINE: 8835111] ">Bakkaloglu 1996</a>; <a href="./references#CD003772-bbs2-0007" title="CarapetisJ , JaquieryA , ButteryJ , StarrM . A randomised controlled trial of once‐daily gentamicin in children with urinary tract infections [abstract]. Australian &amp; New Zealand Journal of Medicine1999;29:608. [CENTRAL: CN‐00583423] CarapetisJ , JaquieryA , ButteryJ , StarrM , CranswickN , KohnS , et al. Randomized, controlled trial comparing once daily and three times daily gentamicin in children with urinary tract infections. Pediatric Infectious Disease Journal2001;20(3):240‐6. [MEDLINE: 11303823] ">Carapetis 2001</a>; <a href="./references#CD003772-bbs2-0009" title="ChaoSM , ChongCY , Tan‐HendrickA , TanAS , NgWY . Efficacy and safety of once‐a‐day gentamicin in the treatment of childhood acute pyelonephritis [abstract]. Pediatric Nephrology2001;16(8):C105. [CENTRAL: CN‐00444755] ChongCY , TanAS , NgW , Tan‐KendrickA , BalakrishnanA , ChaoSM . Treatment of urinary tract infection with gentamicin once or three times daily. Acta Paediatrica2003;92(3):291‐6. [MEDLINE: 12725542] ">Chong 2003</a>; <a href="./references#CD003772-bbs2-0012" title="FujiiR , ShinozakiT , MeguroH , ArimasuO , IzumiK , OsanoM , et al. Comparative, controlled study on an ampicillin suppository (KS‐R 1) with an oral form of ampicillin in urinary tract infections. Japanese Journal of Antibiotics1987;40(3):476‐92. [MEDLINE: 3302342] ">Fujii 1987</a>; <a href="./references#CD003772-bbs2-0015" title="KafetzisDA , MaltezouHC , MavrikouM , SiafasC , ParaskakisI , DelisD , et al. Isepamicin versus amikacin for the treatment of acute pyelonephritis in children. International Journal of Antimicrobial Agents2000;14(1):51‐5. [MEDLINE: 10717501] ">Kafetzis 2000</a>; <a href="./references#CD003772-bbs2-0019" title="HewittIK , TomasiL , PavanelloL , MaschioF , MolinariPP , ToffoloA , et al. Early treatment of acute pyelonephritis in children fails to reduce renal scarring [abstract no: SA‐PO1100]. Journal of the American Society of Nephrology2006;17(Abstracts):804A. [CENTRAL: CN‐00653791] HewittIK , ZucchettaP , RigonL , MaschioF , MolinariPP , TomasiL , et al. Early treatment of acute pyelonephritis in children fails to reduce renal scarring: data from the Italian Renal Infection Study Trials. Pediatrics2008;122(3):486‐90. [MEDLINE: 18762516] LaScolaC , DeMutiisC , HewittIK , PuccioG , ToffoloA , ZucchettaP , et al. Different guidelines for imaging after first UTI in febrile infants: yield, cost, and radiation. Pediatrics2013;131(3):e665‐71. [MEDLINE: 23439905] MontiniG , MurerL , GobberD , CommacchioS , ToffoloA , Dall'AmicoR , et al. Oral vs initial intravenous antibiotic treatment of urinary tract infections in children: a multicentre study [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):816. [CENTRAL: CN‐00446817] MontiniG , ToffoloA , ZucchettaP , Dall'AmicoR , GobberD , CalderonA , et al. Antibiotic treatment for pyelonephritis in children: multicentre randomised controlled non‐inferiority trial. BMJ2007;335(7616):386‐92. [MEDLINE: 17611232] MontiniG , ZucchettaP , GobberD , MurerL , RigonL , ToffoloA , et al. Usefulness of renal radiology and scintigraphy in children with a first episode of upper urinary tract infection [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):813. [CENTRAL: CN‐00446818] MontiniG , ZucchettaP , TomasiL , TalentiE , RigamontiW , PiccoG , et al. Value of imaging studies after a first febrile urinary tract infection in young children: data from Italian renal infection study 1. Pediatrics2009;123(2):e239‐46. [MEDLINE: 19139086] ">Montini 2007</a>; <a href="./references#CD003772-bbs2-0026" title="ViganoA , PrincipiN , BrivioL , TommasiP , StasiP , VillaAD . Comparison of 5 milligrams of netilmicin per kilogram of body weight once daily versus 2 milligrams per kilogram thrice daily for treatment of gram‐negative pyelonephritis in children. Antimicrobial Agents &amp; Chemotherapy1992;36(7):1499‐503. [MEDLINE: 92378248] ">Vigano 1992</a>). </p> </li> <li> <p>Children were treated as outpatients only in four studies (<a href="./references#CD003772-bbs2-0001" title="BakerPC , NelsonDS , SchunkJE . The addition of ceftriaxone to oral therapy does not improve outcome in febrile children with urinary tract infections. Archives of Pediatrics &amp; Adolescent Medicine2001;155(2):135‐9. [MEDLINE: 11177086] ">Baker 2001</a>; <a href="./references#CD003772-bbs2-0016" title="KahnAJ , KumarK , EvansHE . Three‐day antimicrobial therapy of urinary tract infection. Journal of Pediatrics1981;99(6):992‐4. [MEDLINE: 7031217] ">Khan 1981</a>; <a href="./references#CD003772-bbs2-0022" title="PylkkänenJ , VilskaJ , KoskimiesO . The length of antimicrobial therapy in upper vs. lower urinary tract infection of childhood. Acta Paediatrica Scandinavica1981;70(6):885‐8. [MEDLINE: 7324942] PylkkänenJ , VilskaJ , KoskimiesO . The value of level diagnosis of childhood urinary tract infection in predicting renal injury. Acta Paediatrica Scandinavica1981;70(6):879‐83. [MEDLINE: 7324941] ">Pylkkänen 1981</a>; <a href="./references#CD003772-bbs2-0023" title="RepettoHA , MacLoughlinGJ . Single‐dose cefotaxime in the treatment of urinary tract infections in children: a randomized clinical trial. Journal of Antimicrobial Chemotherapy1984;14(Suppl B):307‐10. [MEDLINE: 6094457] ">Repetto 1984</a>). </p> </li> <li> <p>Children received treatment in both in‐ and outpatient settings in 16 studies (<a href="./references#CD003772-bbs2-0003" title="BanfiAG , Hill‐JuarezJM , KaufmanA , MoensE . Multinational comparative trial of ceftibuten and trimethoprim‐sulfamethoxazole in the treatment of children with complicated or recurrent urinary tract infections. Members of the ceftibuten urinary tract infection international study group. Pediatric Infectious Disease Journal1993;12(6 Suppl):S84‐S91. [CENTRAL: CN‐00334829] ">Banfi 1993</a>; <a href="./references#CD003772-bbs2-0004" title="BenadorD , NeuhausTJ , PapazyanJ‐P , WilliUV , Engel‐BicikI , NadalD , et al. Randomised controlled trial of three day versus 10 day intravenous antibiotics in acute pyelonephritis: effect on renal scarring. Archives of Disease in Childhood2001;84(3):241‐6. [MEDLINE: 11207174] GirardinE , NeuhausT , PapazyanJ , WilliUV , BicikI , NadalD , et al. Acute pyelonephritis: comparison of 3 vs 10 days IV antibiotic treatment [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):592A. [CENTRAL: CN‐00583905] ">Benador 2001</a>; <a href="./references#CD003772-bbs2-0005" title="BocquetN , Sergent AlaouiA , JaisJP , GajdosV , GuigonisV , LacourB , et al. Randomized trial of oral versus sequential IV/oral antibiotic for acute pyelonephritis in children. Pediatrics2012;129(2):e269‐75. [MEDLINE: 22291112] ">Bocquet 2012</a>; <a href="./references#CD003772-bbs2-0006" title="BouissouF , MunzerC , DecramerS , RousselB , NovoR , MorinD , et al. Prospective, randomized trial comparing short and long intravenous antibiotic treatment of acute pyelonephritis in children: dimercaptosuccinic acid scintigraphic evaluation at 9 months. Pediatrics2008;121(3):e553‐60. [MEDLINE: 18267977] ">Bouissou 2008</a>; <a href="./references#CD003772-bbs2-0008" title="ChengCH , TsauYK , ChangCJ , ChangYC , KuoCY , TsaiIJ , et al. Acute lobar nephronia is associated with a high incidence of renal scarring in childhood urinary tract infections. Pediatric Infectious Disease Journal2010;29(7):624‐8. [MEDLINE: 20234330] ChengCH , TsauYK , LinTY . Effective duration of antimicrobial therapy for the treatment of acute lobar nephronia. Pediatrics2006;117(1):e84‐9. [MEDLINE: 16326693] ">Cheng 2006</a>; <a href="./references#CD003772-bbs2-0010" title="FischbachM , SimeoniU , MengusL , JehlF , MonteilH , GeisertJ , et al. Urinary tract infections with tissue penetration in children: cefotaxime compared with amoxycillin/clavulanate. Journal of Antimicrobial Chemotherapy1989;24(Suppl B):177‐83. [MEDLINE: 2691478] ">Fischbach 1989</a>; <a href="./references#CD003772-bbs2-0011" title="FrancoisP , BensmanA , BegueP , ArtazM‐A , CoudevilleL , LebrunT , et al. Assessment of the efficacy and cost efficiency of two strategies in the treatment of acute pyelonephritis in children: oral cefixime or parenteral ceftriaxone after an initial IV combination therapy [Evaluation de l'efficacité et du coût de deux stratégies thérapeutiques dans les pyélonéphrites de l'enfant: céfixime per os versus ceftriaxone parentérale en relais d'une bithérapie intraveineuse]. Medecine et Maladies Infectieuses1997;27(Spec Iss June):667‐73. [EMBASE: 1997230388] ">Francois 1997</a>; <a href="./references#CD003772-bbs2-0014" title="HobermanA , WaldER . Intravenous versus oral antibiotics for urinary tract infections. Pediatrics2000;106(4):865. [MEDLINE: 11183178] HobermanA , WaldER , HickeyRW , BaskinM , CharronM , MajdM , et al. Oral versus initial intravenous therapy for urinary tract infections in young febrile children. Pediatrics1999;104(1 Pt 1):79‐86. [MEDLINE: 10390264] ">Hoberman 1999</a>; <a href="./references#CD003772-bbs2-0013" title="GrimwoodK , AbbottGD , FergussonDM . Single dose gentamicin treatment of urinary infections in children. New Zealand Medical Journal1988;101(852):539‐41. [MEDLINE: 3045718] ">Grimwood 1988</a>; <a href="./references#CD003772-bbs2-0017" title="LevtchenkoE , LahyC , LevyJ , HamH , PiepszA . Treatment of children with acute pyelonephritis: a prospective randomized study. Pediatric Nephrology2001;16(11):878‐84. [MEDLINE: 11685593] ">Levtchenko 2001</a>; <a href="./references#CD003772-bbs2-0018" title="MarildS , EsbjornerE , JakobssonB , LinneT , LubeckP , SjogrenI , et al. Randomised study of ceftibuten vs trimethoprim‐sulfamethoxazole in pyelonephritis in children [abstract no: P466]. Pediatric Nephrology2004;19(9):C208. MarildS , JodalU , SandbergT . Ceftibuten versus trimethoprim‐sulfamethoxazole for oral treatment of febrile urinary tract infection in children. Pediatric Nephrology2009;24(3):521‐6. [MEDLINE: 18818954] ">Marild 2009</a>; <a href="./references#CD003772-bbs2-0020" title="BuechnerK , GirardinF , BergerC , WilliU , NadafD , Neuhaus T for the Swiss Pyelonephritis Study Group. Randomised controlled trial of oral versus sequential intravenous/oral cephalosporins in DMSA scintigraphy‐documented acute pyelonephritis [abstract no: COD. OP 18]. Pediatric Nephrology2006;21(10):1511. [CENTRAL: CN‐00601934] NeuhausTJ , BergerC , BuechnerK , ParvexP , BischoffG , GoetschelP , et al. Randomised trial of oral versus sequential intravenous/oral cephalosporins in children with pyelonephritis. European Journal of Pediatrics2008;167(9):1037‐47. [MEDLINE: 18074149] NeuhausTJ , BüchnerK , GirardinE , WilliU , BergerC , NadalD . Oral versus sequential intravenous/oral cephalosporin‐therapy in DMSA‐scintigraphy documented acute pyelonephritis: randomized Swiss pyelonephritis‐study [abstract] [Orale versus sequentiell intravenös/orale Cephalosporin‐Therapie bei DMSA‐Szintigraphie dokumentierter akuter Pyelonephritis: Randomisierte Schweizer Pyelonephritis‐Studie]. Nieren‐ und Hochdruckkrankheiten2007;36(2):43. [CENTRAL: CN‐00615897] ">Neuhaus 2008</a>; <a href="./references#CD003772-bbs2-0021" title="NoorbakhshS , LariAR , MasjedianF , MostafaviH , AlaghehbandanR . Comparison of intravenous aminoglycoside therapy with switch therapy to cefixime in urinary tract infections. Saudi Medical Journal2004;25(10):1513‐5. [MEDLINE: 15494842] ">Noorbakhsh 2004</a>; <a href="./references#CD003772-bbs2-0024" title="SchaadUB , EskolaJ , KafetzisD , FischbachM , AshekenaziS , SyriopoulouV , et al. Cefepine vs. ceftazidime treatment of pyelonephritis: a European, randomized, controlled study of 300 pediatric cases. European Society for Paediatric Infectious Diseases (ESPID) Pyelonephritis Study Group. Pediatric Infectious Disease Journal1998;17(7):639‐44. [MEDLINE: 9686732] ">Schaad 1998</a>; <a href="./references#CD003772-bbs2-0025" title="ToporovskiJ , SteffensL , NoackM , KranzA , BurdeskaA , KisslingM . Effectiveness of cefetamet pivoxil in the treatment of pyelonephritis in children. Journal of International Medical Research1992;20(1):87‐93. [MEDLINE: 1568523] ">Toporovski 1992</a>; <a href="./references#CD003772-bbs2-0027" title="VilaichoneA , WatanaD , ChaiwatanaratT . Oral ceftibuten switch therapy for acute pyelonephritis in children. Journal of the Medical Association of Thailand2001;84 Suppl(1):61‐7. [MEDLINE: 11529382] ">Vilaichone 2001</a>). </p> </li> </ul> </p> </section> <section id="CD003772-sec-0063"> <h5 class="title">Urine collection</h5> <p> <ul id="CD003772-list-0011"> <li> <p>All urine specimens were collected by suprapubic aspiration, catheter or midstream specimens in 14 studies (<a href="./references#CD003772-bbs2-0003" title="BanfiAG , Hill‐JuarezJM , KaufmanA , MoensE . Multinational comparative trial of ceftibuten and trimethoprim‐sulfamethoxazole in the treatment of children with complicated or recurrent urinary tract infections. Members of the ceftibuten urinary tract infection international study group. Pediatric Infectious Disease Journal1993;12(6 Suppl):S84‐S91. [CENTRAL: CN‐00334829] ">Banfi 1993</a>; <a href="./references#CD003772-bbs2-0001" title="BakerPC , NelsonDS , SchunkJE . The addition of ceftriaxone to oral therapy does not improve outcome in febrile children with urinary tract infections. Archives of Pediatrics &amp; Adolescent Medicine2001;155(2):135‐9. [MEDLINE: 11177086] ">Baker 2001</a>; <a href="./references#CD003772-bbs2-0006" title="BouissouF , MunzerC , DecramerS , RousselB , NovoR , MorinD , et al. Prospective, randomized trial comparing short and long intravenous antibiotic treatment of acute pyelonephritis in children: dimercaptosuccinic acid scintigraphic evaluation at 9 months. Pediatrics2008;121(3):e553‐60. [MEDLINE: 18267977] ">Bouissou 2008</a>; <a href="./references#CD003772-bbs2-0007" title="CarapetisJ , JaquieryA , ButteryJ , StarrM . A randomised controlled trial of once‐daily gentamicin in children with urinary tract infections [abstract]. Australian &amp; New Zealand Journal of Medicine1999;29:608. [CENTRAL: CN‐00583423] CarapetisJ , JaquieryA , ButteryJ , StarrM , CranswickN , KohnS , et al. Randomized, controlled trial comparing once daily and three times daily gentamicin in children with urinary tract infections. Pediatric Infectious Disease Journal2001;20(3):240‐6. [MEDLINE: 11303823] ">Carapetis 2001</a>;<a href="./references#CD003772-bbs2-0009" title="ChaoSM , ChongCY , Tan‐HendrickA , TanAS , NgWY . Efficacy and safety of once‐a‐day gentamicin in the treatment of childhood acute pyelonephritis [abstract]. Pediatric Nephrology2001;16(8):C105. [CENTRAL: CN‐00444755] ChongCY , TanAS , NgW , Tan‐KendrickA , BalakrishnanA , ChaoSM . Treatment of urinary tract infection with gentamicin once or three times daily. Acta Paediatrica2003;92(3):291‐6. [MEDLINE: 12725542] ">Chong 2003</a>; <a href="./references#CD003772-bbs2-0013" title="GrimwoodK , AbbottGD , FergussonDM . Single dose gentamicin treatment of urinary infections in children. New Zealand Medical Journal1988;101(852):539‐41. [MEDLINE: 3045718] ">Grimwood 1988</a>; <a href="./references#CD003772-bbs2-0014" title="HobermanA , WaldER . Intravenous versus oral antibiotics for urinary tract infections. Pediatrics2000;106(4):865. [MEDLINE: 11183178] HobermanA , WaldER , HickeyRW , BaskinM , CharronM , MajdM , et al. Oral versus initial intravenous therapy for urinary tract infections in young febrile children. Pediatrics1999;104(1 Pt 1):79‐86. [MEDLINE: 10390264] ">Hoberman 1999</a>; <a href="./references#CD003772-bbs2-0015" title="KafetzisDA , MaltezouHC , MavrikouM , SiafasC , ParaskakisI , DelisD , et al. Isepamicin versus amikacin for the treatment of acute pyelonephritis in children. International Journal of Antimicrobial Agents2000;14(1):51‐5. [MEDLINE: 10717501] ">Kafetzis 2000</a>; <a href="./references#CD003772-bbs2-0016" title="KahnAJ , KumarK , EvansHE . Three‐day antimicrobial therapy of urinary tract infection. Journal of Pediatrics1981;99(6):992‐4. [MEDLINE: 7031217] ">Khan 1981</a>; <a href="./references#CD003772-bbs2-0020" title="BuechnerK , GirardinF , BergerC , WilliU , NadafD , Neuhaus T for the Swiss Pyelonephritis Study Group. Randomised controlled trial of oral versus sequential intravenous/oral cephalosporins in DMSA scintigraphy‐documented acute pyelonephritis [abstract no: COD. OP 18]. Pediatric Nephrology2006;21(10):1511. [CENTRAL: CN‐00601934] NeuhausTJ , BergerC , BuechnerK , ParvexP , BischoffG , GoetschelP , et al. Randomised trial of oral versus sequential intravenous/oral cephalosporins in children with pyelonephritis. European Journal of Pediatrics2008;167(9):1037‐47. [MEDLINE: 18074149] NeuhausTJ , BüchnerK , GirardinE , WilliU , BergerC , NadalD . Oral versus sequential intravenous/oral cephalosporin‐therapy in DMSA‐scintigraphy documented acute pyelonephritis: randomized Swiss pyelonephritis‐study [abstract] [Orale versus sequentiell intravenös/orale Cephalosporin‐Therapie bei DMSA‐Szintigraphie dokumentierter akuter Pyelonephritis: Randomisierte Schweizer Pyelonephritis‐Studie]. Nieren‐ und Hochdruckkrankheiten2007;36(2):43. [CENTRAL: CN‐00615897] ">Neuhaus 2008</a>; <a href="./references#CD003772-bbs2-0022" title="PylkkänenJ , VilskaJ , KoskimiesO . The length of antimicrobial therapy in upper vs. lower urinary tract infection of childhood. Acta Paediatrica Scandinavica1981;70(6):885‐8. [MEDLINE: 7324942] PylkkänenJ , VilskaJ , KoskimiesO . The value of level diagnosis of childhood urinary tract infection in predicting renal injury. Acta Paediatrica Scandinavica1981;70(6):879‐83. [MEDLINE: 7324941] ">Pylkkänen 1981</a>; <a href="./references#CD003772-bbs2-0023" title="RepettoHA , MacLoughlinGJ . Single‐dose cefotaxime in the treatment of urinary tract infections in children: a randomized clinical trial. Journal of Antimicrobial Chemotherapy1984;14(Suppl B):307‐10. [MEDLINE: 6094457] ">Repetto 1984</a>; <a href="./references#CD003772-bbs2-0025" title="ToporovskiJ , SteffensL , NoackM , KranzA , BurdeskaA , KisslingM . Effectiveness of cefetamet pivoxil in the treatment of pyelonephritis in children. Journal of International Medical Research1992;20(1):87‐93. [MEDLINE: 1568523] ">Toporovski 1992</a>; <a href="./references#CD003772-bbs2-0026" title="ViganoA , PrincipiN , BrivioL , TommasiP , StasiP , VillaAD . Comparison of 5 milligrams of netilmicin per kilogram of body weight once daily versus 2 milligrams per kilogram thrice daily for treatment of gram‐negative pyelonephritis in children. Antimicrobial Agents &amp; Chemotherapy1992;36(7):1499‐503. [MEDLINE: 92378248] ">Vigano 1992</a>). </p> </li> <li> <p>Specimens were obtained by strap‐on bag collection in nine studies (<a href="./references#CD003772-bbs2-0004" title="BenadorD , NeuhausTJ , PapazyanJ‐P , WilliUV , Engel‐BicikI , NadalD , et al. Randomised controlled trial of three day versus 10 day intravenous antibiotics in acute pyelonephritis: effect on renal scarring. Archives of Disease in Childhood2001;84(3):241‐6. [MEDLINE: 11207174] GirardinE , NeuhausT , PapazyanJ , WilliUV , BicikI , NadalD , et al. Acute pyelonephritis: comparison of 3 vs 10 days IV antibiotic treatment [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):592A. [CENTRAL: CN‐00583905] ">Benador 2001</a>; <a href="./references#CD003772-bbs2-0005" title="BocquetN , Sergent AlaouiA , JaisJP , GajdosV , GuigonisV , LacourB , et al. Randomized trial of oral versus sequential IV/oral antibiotic for acute pyelonephritis in children. Pediatrics2012;129(2):e269‐75. [MEDLINE: 22291112] ">Bocquet 2012</a>; <a href="./references#CD003772-bbs2-0008" title="ChengCH , TsauYK , ChangCJ , ChangYC , KuoCY , TsaiIJ , et al. Acute lobar nephronia is associated with a high incidence of renal scarring in childhood urinary tract infections. Pediatric Infectious Disease Journal2010;29(7):624‐8. [MEDLINE: 20234330] ChengCH , TsauYK , LinTY . Effective duration of antimicrobial therapy for the treatment of acute lobar nephronia. Pediatrics2006;117(1):e84‐9. [MEDLINE: 16326693] ">Cheng 2006</a>; <a href="./references#CD003772-bbs2-0017" title="LevtchenkoE , LahyC , LevyJ , HamH , PiepszA . Treatment of children with acute pyelonephritis: a prospective randomized study. Pediatric Nephrology2001;16(11):878‐84. [MEDLINE: 11685593] ">Levtchenko 2001</a>; <a href="./references#CD003772-bbs2-0018" title="MarildS , EsbjornerE , JakobssonB , LinneT , LubeckP , SjogrenI , et al. Randomised study of ceftibuten vs trimethoprim‐sulfamethoxazole in pyelonephritis in children [abstract no: P466]. Pediatric Nephrology2004;19(9):C208. MarildS , JodalU , SandbergT . Ceftibuten versus trimethoprim‐sulfamethoxazole for oral treatment of febrile urinary tract infection in children. Pediatric Nephrology2009;24(3):521‐6. [MEDLINE: 18818954] ">Marild 2009</a>; <a href="./references#CD003772-bbs2-0019" title="HewittIK , TomasiL , PavanelloL , MaschioF , MolinariPP , ToffoloA , et al. Early treatment of acute pyelonephritis in children fails to reduce renal scarring [abstract no: SA‐PO1100]. Journal of the American Society of Nephrology2006;17(Abstracts):804A. [CENTRAL: CN‐00653791] HewittIK , ZucchettaP , RigonL , MaschioF , MolinariPP , TomasiL , et al. Early treatment of acute pyelonephritis in children fails to reduce renal scarring: data from the Italian Renal Infection Study Trials. Pediatrics2008;122(3):486‐90. [MEDLINE: 18762516] LaScolaC , DeMutiisC , HewittIK , PuccioG , ToffoloA , ZucchettaP , et al. Different guidelines for imaging after first UTI in febrile infants: yield, cost, and radiation. Pediatrics2013;131(3):e665‐71. [MEDLINE: 23439905] MontiniG , MurerL , GobberD , CommacchioS , ToffoloA , Dall'AmicoR , et al. Oral vs initial intravenous antibiotic treatment of urinary tract infections in children: a multicentre study [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):816. [CENTRAL: CN‐00446817] MontiniG , ToffoloA , ZucchettaP , Dall'AmicoR , GobberD , CalderonA , et al. Antibiotic treatment for pyelonephritis in children: multicentre randomised controlled non‐inferiority trial. BMJ2007;335(7616):386‐92. [MEDLINE: 17611232] MontiniG , ZucchettaP , GobberD , MurerL , RigonL , ToffoloA , et al. Usefulness of renal radiology and scintigraphy in children with a first episode of upper urinary tract infection [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):813. [CENTRAL: CN‐00446818] MontiniG , ZucchettaP , TomasiL , TalentiE , RigamontiW , PiccoG , et al. Value of imaging studies after a first febrile urinary tract infection in young children: data from Italian renal infection study 1. Pediatrics2009;123(2):e239‐46. [MEDLINE: 19139086] ">Montini 2007</a>; <a href="./references#CD003772-bbs2-0021" title="NoorbakhshS , LariAR , MasjedianF , MostafaviH , AlaghehbandanR . Comparison of intravenous aminoglycoside therapy with switch therapy to cefixime in urinary tract infections. Saudi Medical Journal2004;25(10):1513‐5. [MEDLINE: 15494842] ">Noorbakhsh 2004</a>; <a href="./references#CD003772-bbs2-0024" title="SchaadUB , EskolaJ , KafetzisD , FischbachM , AshekenaziS , SyriopoulouV , et al. Cefepine vs. ceftazidime treatment of pyelonephritis: a European, randomized, controlled study of 300 pediatric cases. European Society for Paediatric Infectious Diseases (ESPID) Pyelonephritis Study Group. Pediatric Infectious Disease Journal1998;17(7):639‐44. [MEDLINE: 9686732] ">Schaad 1998</a>; <a href="./references#CD003772-bbs2-0027" title="VilaichoneA , WatanaD , ChaiwatanaratT . Oral ceftibuten switch therapy for acute pyelonephritis in children. Journal of the Medical Association of Thailand2001;84 Suppl(1):61‐7. [MEDLINE: 11529382] ">Vilaichone 2001</a>). </p> </li> <li> <p>The method of urine collection was not specified in four studies (<a href="./references#CD003772-bbs2-0002" title="BakkalogluA , SaatciU , SoylemezogluO , OzenS , TopalogluR , BesbasN , et al. Comparison of ceftriaxone versus cefotaxime for childhood upper urinary tract infections. Journal of Chemotherapy1996;8(1):59‐62. [MEDLINE: 8835111] ">Bakkaloglu 1996</a>; <a href="./references#CD003772-bbs2-0010" title="FischbachM , SimeoniU , MengusL , JehlF , MonteilH , GeisertJ , et al. Urinary tract infections with tissue penetration in children: cefotaxime compared with amoxycillin/clavulanate. Journal of Antimicrobial Chemotherapy1989;24(Suppl B):177‐83. [MEDLINE: 2691478] ">Fischbach 1989</a>; <a href="./references#CD003772-bbs2-0011" title="FrancoisP , BensmanA , BegueP , ArtazM‐A , CoudevilleL , LebrunT , et al. Assessment of the efficacy and cost efficiency of two strategies in the treatment of acute pyelonephritis in children: oral cefixime or parenteral ceftriaxone after an initial IV combination therapy [Evaluation de l'efficacité et du coût de deux stratégies thérapeutiques dans les pyélonéphrites de l'enfant: céfixime per os versus ceftriaxone parentérale en relais d'une bithérapie intraveineuse]. Medecine et Maladies Infectieuses1997;27(Spec Iss June):667‐73. [EMBASE: 1997230388] ">Francois 1997</a>; <a href="./references#CD003772-bbs2-0012" title="FujiiR , ShinozakiT , MeguroH , ArimasuO , IzumiK , OsanoM , et al. Comparative, controlled study on an ampicillin suppository (KS‐R 1) with an oral form of ampicillin in urinary tract infections. Japanese Journal of Antibiotics1987;40(3):476‐92. [MEDLINE: 3302342] ">Fujii 1987</a>). </p> </li> </ul> </p> </section> <section id="CD003772-sec-0064"> <h5 class="title">Diagnosis</h5> <p> <ul id="CD003772-list-0012"> <li> <p>All participants had acute pyelonephritis in 22 studies (<a href="./references#CD003772-bbs2-0001" title="BakerPC , NelsonDS , SchunkJE . The addition of ceftriaxone to oral therapy does not improve outcome in febrile children with urinary tract infections. Archives of Pediatrics &amp; Adolescent Medicine2001;155(2):135‐9. [MEDLINE: 11177086] ">Baker 2001</a>; <a href="./references#CD003772-bbs2-0002" title="BakkalogluA , SaatciU , SoylemezogluO , OzenS , TopalogluR , BesbasN , et al. Comparison of ceftriaxone versus cefotaxime for childhood upper urinary tract infections. Journal of Chemotherapy1996;8(1):59‐62. [MEDLINE: 8835111] ">Bakkaloglu 1996</a>; <a href="./references#CD003772-bbs2-0004" title="BenadorD , NeuhausTJ , PapazyanJ‐P , WilliUV , Engel‐BicikI , NadalD , et al. Randomised controlled trial of three day versus 10 day intravenous antibiotics in acute pyelonephritis: effect on renal scarring. Archives of Disease in Childhood2001;84(3):241‐6. [MEDLINE: 11207174] GirardinE , NeuhausT , PapazyanJ , WilliUV , BicikI , NadalD , et al. Acute pyelonephritis: comparison of 3 vs 10 days IV antibiotic treatment [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):592A. [CENTRAL: CN‐00583905] ">Benador 2001</a>; <a href="./references#CD003772-bbs2-0005" title="BocquetN , Sergent AlaouiA , JaisJP , GajdosV , GuigonisV , LacourB , et al. Randomized trial of oral versus sequential IV/oral antibiotic for acute pyelonephritis in children. Pediatrics2012;129(2):e269‐75. [MEDLINE: 22291112] ">Bocquet 2012</a>; <a href="./references#CD003772-bbs2-0006" title="BouissouF , MunzerC , DecramerS , RousselB , NovoR , MorinD , et al. Prospective, randomized trial comparing short and long intravenous antibiotic treatment of acute pyelonephritis in children: dimercaptosuccinic acid scintigraphic evaluation at 9 months. Pediatrics2008;121(3):e553‐60. [MEDLINE: 18267977] ">Bouissou 2008</a>; <a href="./references#CD003772-bbs2-0007" title="CarapetisJ , JaquieryA , ButteryJ , StarrM . A randomised controlled trial of once‐daily gentamicin in children with urinary tract infections [abstract]. Australian &amp; New Zealand Journal of Medicine1999;29:608. [CENTRAL: CN‐00583423] CarapetisJ , JaquieryA , ButteryJ , StarrM , CranswickN , KohnS , et al. Randomized, controlled trial comparing once daily and three times daily gentamicin in children with urinary tract infections. Pediatric Infectious Disease Journal2001;20(3):240‐6. [MEDLINE: 11303823] ">Carapetis 2001</a>; <a href="./references#CD003772-bbs2-0008" title="ChengCH , TsauYK , ChangCJ , ChangYC , KuoCY , TsaiIJ , et al. Acute lobar nephronia is associated with a high incidence of renal scarring in childhood urinary tract infections. Pediatric Infectious Disease Journal2010;29(7):624‐8. [MEDLINE: 20234330] ChengCH , TsauYK , LinTY . Effective duration of antimicrobial therapy for the treatment of acute lobar nephronia. Pediatrics2006;117(1):e84‐9. [MEDLINE: 16326693] ">Cheng 2006</a>; <a href="./references#CD003772-bbs2-0009" title="ChaoSM , ChongCY , Tan‐HendrickA , TanAS , NgWY . Efficacy and safety of once‐a‐day gentamicin in the treatment of childhood acute pyelonephritis [abstract]. Pediatric Nephrology2001;16(8):C105. [CENTRAL: CN‐00444755] ChongCY , TanAS , NgW , Tan‐KendrickA , BalakrishnanA , ChaoSM . Treatment of urinary tract infection with gentamicin once or three times daily. Acta Paediatrica2003;92(3):291‐6. [MEDLINE: 12725542] ">Chong 2003</a>; <a href="./references#CD003772-bbs2-0010" title="FischbachM , SimeoniU , MengusL , JehlF , MonteilH , GeisertJ , et al. Urinary tract infections with tissue penetration in children: cefotaxime compared with amoxycillin/clavulanate. Journal of Antimicrobial Chemotherapy1989;24(Suppl B):177‐83. [MEDLINE: 2691478] ">Fischbach 1989</a>; <a href="./references#CD003772-bbs2-0011" title="FrancoisP , BensmanA , BegueP , ArtazM‐A , CoudevilleL , LebrunT , et al. Assessment of the efficacy and cost efficiency of two strategies in the treatment of acute pyelonephritis in children: oral cefixime or parenteral ceftriaxone after an initial IV combination therapy [Evaluation de l'efficacité et du coût de deux stratégies thérapeutiques dans les pyélonéphrites de l'enfant: céfixime per os versus ceftriaxone parentérale en relais d'une bithérapie intraveineuse]. Medecine et Maladies Infectieuses1997;27(Spec Iss June):667‐73. [EMBASE: 1997230388] ">Francois 1997</a>; <a href="./references#CD003772-bbs2-0012" title="FujiiR , ShinozakiT , MeguroH , ArimasuO , IzumiK , OsanoM , et al. Comparative, controlled study on an ampicillin suppository (KS‐R 1) with an oral form of ampicillin in urinary tract infections. Japanese Journal of Antibiotics1987;40(3):476‐92. [MEDLINE: 3302342] ">Fujii 1987</a>; <a href="./references#CD003772-bbs2-0014" title="HobermanA , WaldER . Intravenous versus oral antibiotics for urinary tract infections. Pediatrics2000;106(4):865. [MEDLINE: 11183178] HobermanA , WaldER , HickeyRW , BaskinM , CharronM , MajdM , et al. Oral versus initial intravenous therapy for urinary tract infections in young febrile children. Pediatrics1999;104(1 Pt 1):79‐86. [MEDLINE: 10390264] ">Hoberman 1999</a>; <a href="./references#CD003772-bbs2-0015" title="KafetzisDA , MaltezouHC , MavrikouM , SiafasC , ParaskakisI , DelisD , et al. Isepamicin versus amikacin for the treatment of acute pyelonephritis in children. International Journal of Antimicrobial Agents2000;14(1):51‐5. [MEDLINE: 10717501] ">Kafetzis 2000</a>; <a href="./references#CD003772-bbs2-0017" title="LevtchenkoE , LahyC , LevyJ , HamH , PiepszA . Treatment of children with acute pyelonephritis: a prospective randomized study. Pediatric Nephrology2001;16(11):878‐84. [MEDLINE: 11685593] ">Levtchenko 2001</a>; <a href="./references#CD003772-bbs2-0018" title="MarildS , EsbjornerE , JakobssonB , LinneT , LubeckP , SjogrenI , et al. Randomised study of ceftibuten vs trimethoprim‐sulfamethoxazole in pyelonephritis in children [abstract no: P466]. Pediatric Nephrology2004;19(9):C208. MarildS , JodalU , SandbergT . Ceftibuten versus trimethoprim‐sulfamethoxazole for oral treatment of febrile urinary tract infection in children. Pediatric Nephrology2009;24(3):521‐6. [MEDLINE: 18818954] ">Marild 2009</a>; <a href="./references#CD003772-bbs2-0019" title="HewittIK , TomasiL , PavanelloL , MaschioF , MolinariPP , ToffoloA , et al. Early treatment of acute pyelonephritis in children fails to reduce renal scarring [abstract no: SA‐PO1100]. Journal of the American Society of Nephrology2006;17(Abstracts):804A. [CENTRAL: CN‐00653791] HewittIK , ZucchettaP , RigonL , MaschioF , MolinariPP , TomasiL , et al. Early treatment of acute pyelonephritis in children fails to reduce renal scarring: data from the Italian Renal Infection Study Trials. Pediatrics2008;122(3):486‐90. [MEDLINE: 18762516] LaScolaC , DeMutiisC , HewittIK , PuccioG , ToffoloA , ZucchettaP , et al. Different guidelines for imaging after first UTI in febrile infants: yield, cost, and radiation. Pediatrics2013;131(3):e665‐71. [MEDLINE: 23439905] MontiniG , MurerL , GobberD , CommacchioS , ToffoloA , Dall'AmicoR , et al. Oral vs initial intravenous antibiotic treatment of urinary tract infections in children: a multicentre study [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):816. [CENTRAL: CN‐00446817] MontiniG , ToffoloA , ZucchettaP , Dall'AmicoR , GobberD , CalderonA , et al. Antibiotic treatment for pyelonephritis in children: multicentre randomised controlled non‐inferiority trial. BMJ2007;335(7616):386‐92. [MEDLINE: 17611232] MontiniG , ZucchettaP , GobberD , MurerL , RigonL , ToffoloA , et al. Usefulness of renal radiology and scintigraphy in children with a first episode of upper urinary tract infection [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):813. [CENTRAL: CN‐00446818] MontiniG , ZucchettaP , TomasiL , TalentiE , RigamontiW , PiccoG , et al. Value of imaging studies after a first febrile urinary tract infection in young children: data from Italian renal infection study 1. Pediatrics2009;123(2):e239‐46. [MEDLINE: 19139086] ">Montini 2007</a>; <a href="./references#CD003772-bbs2-0020" title="BuechnerK , GirardinF , BergerC , WilliU , NadafD , Neuhaus T for the Swiss Pyelonephritis Study Group. Randomised controlled trial of oral versus sequential intravenous/oral cephalosporins in DMSA scintigraphy‐documented acute pyelonephritis [abstract no: COD. OP 18]. Pediatric Nephrology2006;21(10):1511. [CENTRAL: CN‐00601934] NeuhausTJ , BergerC , BuechnerK , ParvexP , BischoffG , GoetschelP , et al. Randomised trial of oral versus sequential intravenous/oral cephalosporins in children with pyelonephritis. European Journal of Pediatrics2008;167(9):1037‐47. [MEDLINE: 18074149] NeuhausTJ , BüchnerK , GirardinE , WilliU , BergerC , NadalD . Oral versus sequential intravenous/oral cephalosporin‐therapy in DMSA‐scintigraphy documented acute pyelonephritis: randomized Swiss pyelonephritis‐study [abstract] [Orale versus sequentiell intravenös/orale Cephalosporin‐Therapie bei DMSA‐Szintigraphie dokumentierter akuter Pyelonephritis: Randomisierte Schweizer Pyelonephritis‐Studie]. Nieren‐ und Hochdruckkrankheiten2007;36(2):43. [CENTRAL: CN‐00615897] ">Neuhaus 2008</a>; <a href="./references#CD003772-bbs2-0021" title="NoorbakhshS , LariAR , MasjedianF , MostafaviH , AlaghehbandanR . Comparison of intravenous aminoglycoside therapy with switch therapy to cefixime in urinary tract infections. Saudi Medical Journal2004;25(10):1513‐5. [MEDLINE: 15494842] ">Noorbakhsh 2004</a>; <a href="./references#CD003772-bbs2-0024" title="SchaadUB , EskolaJ , KafetzisD , FischbachM , AshekenaziS , SyriopoulouV , et al. Cefepine vs. ceftazidime treatment of pyelonephritis: a European, randomized, controlled study of 300 pediatric cases. European Society for Paediatric Infectious Diseases (ESPID) Pyelonephritis Study Group. Pediatric Infectious Disease Journal1998;17(7):639‐44. [MEDLINE: 9686732] ">Schaad 1998</a>; <a href="./references#CD003772-bbs2-0025" title="ToporovskiJ , SteffensL , NoackM , KranzA , BurdeskaA , KisslingM . Effectiveness of cefetamet pivoxil in the treatment of pyelonephritis in children. Journal of International Medical Research1992;20(1):87‐93. [MEDLINE: 1568523] ">Toporovski 1992</a>; <a href="./references#CD003772-bbs2-0026" title="ViganoA , PrincipiN , BrivioL , TommasiP , StasiP , VillaAD . Comparison of 5 milligrams of netilmicin per kilogram of body weight once daily versus 2 milligrams per kilogram thrice daily for treatment of gram‐negative pyelonephritis in children. Antimicrobial Agents &amp; Chemotherapy1992;36(7):1499‐503. [MEDLINE: 92378248] ">Vigano 1992</a>; <a href="./references#CD003772-bbs2-0027" title="VilaichoneA , WatanaD , ChaiwatanaratT . Oral ceftibuten switch therapy for acute pyelonephritis in children. Journal of the Medical Association of Thailand2001;84 Suppl(1):61‐7. [MEDLINE: 11529382] ">Vilaichone 2001</a>). </p> </li> <li> <p>Five studies enrolled children with both acute pyelonephritis and lower UTI (<a href="./references#CD003772-bbs2-0003" title="BanfiAG , Hill‐JuarezJM , KaufmanA , MoensE . Multinational comparative trial of ceftibuten and trimethoprim‐sulfamethoxazole in the treatment of children with complicated or recurrent urinary tract infections. Members of the ceftibuten urinary tract infection international study group. Pediatric Infectious Disease Journal1993;12(6 Suppl):S84‐S91. [CENTRAL: CN‐00334829] ">Banfi 1993</a>; <a href="./references#CD003772-bbs2-0013" title="GrimwoodK , AbbottGD , FergussonDM . Single dose gentamicin treatment of urinary infections in children. New Zealand Medical Journal1988;101(852):539‐41. [MEDLINE: 3045718] ">Grimwood 1988</a>; <a href="./references#CD003772-bbs2-0016" title="KahnAJ , KumarK , EvansHE . Three‐day antimicrobial therapy of urinary tract infection. Journal of Pediatrics1981;99(6):992‐4. [MEDLINE: 7031217] ">Khan 1981</a>; <a href="./references#CD003772-bbs2-0022" title="PylkkänenJ , VilskaJ , KoskimiesO . The length of antimicrobial therapy in upper vs. lower urinary tract infection of childhood. Acta Paediatrica Scandinavica1981;70(6):885‐8. [MEDLINE: 7324942] PylkkänenJ , VilskaJ , KoskimiesO . The value of level diagnosis of childhood urinary tract infection in predicting renal injury. Acta Paediatrica Scandinavica1981;70(6):879‐83. [MEDLINE: 7324941] ">Pylkkänen 1981</a>; <a href="./references#CD003772-bbs2-0023" title="RepettoHA , MacLoughlinGJ . Single‐dose cefotaxime in the treatment of urinary tract infections in children: a randomized clinical trial. Journal of Antimicrobial Chemotherapy1984;14(Suppl B):307‐10. [MEDLINE: 6094457] ">Repetto 1984</a>); data from children with acute pyelonephritis, which could be separated, were included in this review. </p> </li> </ul> </p> </section> <section id="CD003772-sec-0065"> <h5 class="title">Definition of acute pyelonephritis</h5> <p>All studies required positive urine culture. Additional criteria required for diagnosis of acute pyelonephritis in children with UTI varied among studies: </p> <p> <ul id="CD003772-list-0013"> <li> <p>Four studies required fever &gt; 38°C (<a href="./references#CD003772-bbs2-0001" title="BakerPC , NelsonDS , SchunkJE . The addition of ceftriaxone to oral therapy does not improve outcome in febrile children with urinary tract infections. Archives of Pediatrics &amp; Adolescent Medicine2001;155(2):135‐9. [MEDLINE: 11177086] ">Baker 2001</a>; <a href="./references#CD003772-bbs2-0005" title="BocquetN , Sergent AlaouiA , JaisJP , GajdosV , GuigonisV , LacourB , et al. Randomized trial of oral versus sequential IV/oral antibiotic for acute pyelonephritis in children. Pediatrics2012;129(2):e269‐75. [MEDLINE: 22291112] ">Bocquet 2012</a>; <a href="./references#CD003772-bbs2-0014" title="HobermanA , WaldER . Intravenous versus oral antibiotics for urinary tract infections. Pediatrics2000;106(4):865. [MEDLINE: 11183178] HobermanA , WaldER , HickeyRW , BaskinM , CharronM , MajdM , et al. Oral versus initial intravenous therapy for urinary tract infections in young febrile children. Pediatrics1999;104(1 Pt 1):79‐86. [MEDLINE: 10390264] ">Hoberman 1999</a>; <a href="./references#CD003772-bbs2-0016" title="KahnAJ , KumarK , EvansHE . Three‐day antimicrobial therapy of urinary tract infection. Journal of Pediatrics1981;99(6):992‐4. [MEDLINE: 7031217] ">Khan 1981</a>). </p> </li> <li> <p>Eight required fever and at least one additional clinical feature (<a href="./references#CD003772-bbs2-0002" title="BakkalogluA , SaatciU , SoylemezogluO , OzenS , TopalogluR , BesbasN , et al. Comparison of ceftriaxone versus cefotaxime for childhood upper urinary tract infections. Journal of Chemotherapy1996;8(1):59‐62. [MEDLINE: 8835111] ">Bakkaloglu 1996</a>; <a href="./references#CD003772-bbs2-0007" title="CarapetisJ , JaquieryA , ButteryJ , StarrM . A randomised controlled trial of once‐daily gentamicin in children with urinary tract infections [abstract]. Australian &amp; New Zealand Journal of Medicine1999;29:608. [CENTRAL: CN‐00583423] CarapetisJ , JaquieryA , ButteryJ , StarrM , CranswickN , KohnS , et al. Randomized, controlled trial comparing once daily and three times daily gentamicin in children with urinary tract infections. Pediatric Infectious Disease Journal2001;20(3):240‐6. [MEDLINE: 11303823] ">Carapetis 2001</a>; <a href="./references#CD003772-bbs2-0009" title="ChaoSM , ChongCY , Tan‐HendrickA , TanAS , NgWY . Efficacy and safety of once‐a‐day gentamicin in the treatment of childhood acute pyelonephritis [abstract]. Pediatric Nephrology2001;16(8):C105. [CENTRAL: CN‐00444755] ChongCY , TanAS , NgW , Tan‐KendrickA , BalakrishnanA , ChaoSM . Treatment of urinary tract infection with gentamicin once or three times daily. Acta Paediatrica2003;92(3):291‐6. [MEDLINE: 12725542] ">Chong 2003</a>; <a href="./references#CD003772-bbs2-0013" title="GrimwoodK , AbbottGD , FergussonDM . Single dose gentamicin treatment of urinary infections in children. New Zealand Medical Journal1988;101(852):539‐41. [MEDLINE: 3045718] ">Grimwood 1988</a>; <a href="./references#CD003772-bbs2-0021" title="NoorbakhshS , LariAR , MasjedianF , MostafaviH , AlaghehbandanR . Comparison of intravenous aminoglycoside therapy with switch therapy to cefixime in urinary tract infections. Saudi Medical Journal2004;25(10):1513‐5. [MEDLINE: 15494842] ">Noorbakhsh 2004</a>; <a href="./references#CD003772-bbs2-0023" title="RepettoHA , MacLoughlinGJ . Single‐dose cefotaxime in the treatment of urinary tract infections in children: a randomized clinical trial. Journal of Antimicrobial Chemotherapy1984;14(Suppl B):307‐10. [MEDLINE: 6094457] ">Repetto 1984</a>; <a href="./references#CD003772-bbs2-0024" title="SchaadUB , EskolaJ , KafetzisD , FischbachM , AshekenaziS , SyriopoulouV , et al. Cefepine vs. ceftazidime treatment of pyelonephritis: a European, randomized, controlled study of 300 pediatric cases. European Society for Paediatric Infectious Diseases (ESPID) Pyelonephritis Study Group. Pediatric Infectious Disease Journal1998;17(7):639‐44. [MEDLINE: 9686732] ">Schaad 1998</a>; <a href="./references#CD003772-bbs2-0025" title="ToporovskiJ , SteffensL , NoackM , KranzA , BurdeskaA , KisslingM . Effectiveness of cefetamet pivoxil in the treatment of pyelonephritis in children. Journal of International Medical Research1992;20(1):87‐93. [MEDLINE: 1568523] ">Toporovski 1992</a>). </p> </li> <li> <p>Nine required fever, clinical features and/or laboratory abnormalities (CRP, ESR, white blood count) (<a href="./references#CD003772-bbs2-0006" title="BouissouF , MunzerC , DecramerS , RousselB , NovoR , MorinD , et al. Prospective, randomized trial comparing short and long intravenous antibiotic treatment of acute pyelonephritis in children: dimercaptosuccinic acid scintigraphic evaluation at 9 months. Pediatrics2008;121(3):e553‐60. [MEDLINE: 18267977] ">Bouissou 2008</a>; <a href="./references#CD003772-bbs2-0010" title="FischbachM , SimeoniU , MengusL , JehlF , MonteilH , GeisertJ , et al. Urinary tract infections with tissue penetration in children: cefotaxime compared with amoxycillin/clavulanate. Journal of Antimicrobial Chemotherapy1989;24(Suppl B):177‐83. [MEDLINE: 2691478] ">Fischbach 1989</a>; <a href="./references#CD003772-bbs2-0011" title="FrancoisP , BensmanA , BegueP , ArtazM‐A , CoudevilleL , LebrunT , et al. Assessment of the efficacy and cost efficiency of two strategies in the treatment of acute pyelonephritis in children: oral cefixime or parenteral ceftriaxone after an initial IV combination therapy [Evaluation de l'efficacité et du coût de deux stratégies thérapeutiques dans les pyélonéphrites de l'enfant: céfixime per os versus ceftriaxone parentérale en relais d'une bithérapie intraveineuse]. Medecine et Maladies Infectieuses1997;27(Spec Iss June):667‐73. [EMBASE: 1997230388] ">Francois 1997</a>; <a href="./references#CD003772-bbs2-0015" title="KafetzisDA , MaltezouHC , MavrikouM , SiafasC , ParaskakisI , DelisD , et al. Isepamicin versus amikacin for the treatment of acute pyelonephritis in children. International Journal of Antimicrobial Agents2000;14(1):51‐5. [MEDLINE: 10717501] ">Kafetzis 2000</a>; <a href="./references#CD003772-bbs2-0017" title="LevtchenkoE , LahyC , LevyJ , HamH , PiepszA . Treatment of children with acute pyelonephritis: a prospective randomized study. Pediatric Nephrology2001;16(11):878‐84. [MEDLINE: 11685593] ">Levtchenko 2001</a>; <a href="./references#CD003772-bbs2-0018" title="MarildS , EsbjornerE , JakobssonB , LinneT , LubeckP , SjogrenI , et al. Randomised study of ceftibuten vs trimethoprim‐sulfamethoxazole in pyelonephritis in children [abstract no: P466]. Pediatric Nephrology2004;19(9):C208. MarildS , JodalU , SandbergT . Ceftibuten versus trimethoprim‐sulfamethoxazole for oral treatment of febrile urinary tract infection in children. Pediatric Nephrology2009;24(3):521‐6. [MEDLINE: 18818954] ">Marild 2009</a>; <a href="./references#CD003772-bbs2-0019" title="HewittIK , TomasiL , PavanelloL , MaschioF , MolinariPP , ToffoloA , et al. Early treatment of acute pyelonephritis in children fails to reduce renal scarring [abstract no: SA‐PO1100]. Journal of the American Society of Nephrology2006;17(Abstracts):804A. [CENTRAL: CN‐00653791] HewittIK , ZucchettaP , RigonL , MaschioF , MolinariPP , TomasiL , et al. Early treatment of acute pyelonephritis in children fails to reduce renal scarring: data from the Italian Renal Infection Study Trials. Pediatrics2008;122(3):486‐90. [MEDLINE: 18762516] LaScolaC , DeMutiisC , HewittIK , PuccioG , ToffoloA , ZucchettaP , et al. Different guidelines for imaging after first UTI in febrile infants: yield, cost, and radiation. Pediatrics2013;131(3):e665‐71. [MEDLINE: 23439905] MontiniG , MurerL , GobberD , CommacchioS , ToffoloA , Dall'AmicoR , et al. Oral vs initial intravenous antibiotic treatment of urinary tract infections in children: a multicentre study [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):816. [CENTRAL: CN‐00446817] MontiniG , ToffoloA , ZucchettaP , Dall'AmicoR , GobberD , CalderonA , et al. Antibiotic treatment for pyelonephritis in children: multicentre randomised controlled non‐inferiority trial. BMJ2007;335(7616):386‐92. [MEDLINE: 17611232] MontiniG , ZucchettaP , GobberD , MurerL , RigonL , ToffoloA , et al. Usefulness of renal radiology and scintigraphy in children with a first episode of upper urinary tract infection [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):813. [CENTRAL: CN‐00446818] MontiniG , ZucchettaP , TomasiL , TalentiE , RigamontiW , PiccoG , et al. Value of imaging studies after a first febrile urinary tract infection in young children: data from Italian renal infection study 1. Pediatrics2009;123(2):e239‐46. [MEDLINE: 19139086] ">Montini 2007</a>; <a href="./references#CD003772-bbs2-0022" title="PylkkänenJ , VilskaJ , KoskimiesO . The length of antimicrobial therapy in upper vs. lower urinary tract infection of childhood. Acta Paediatrica Scandinavica1981;70(6):885‐8. [MEDLINE: 7324942] PylkkänenJ , VilskaJ , KoskimiesO . The value of level diagnosis of childhood urinary tract infection in predicting renal injury. Acta Paediatrica Scandinavica1981;70(6):879‐83. [MEDLINE: 7324941] ">Pylkkänen 1981</a>; <a href="./references#CD003772-bbs2-0026" title="ViganoA , PrincipiN , BrivioL , TommasiP , StasiP , VillaAD . Comparison of 5 milligrams of netilmicin per kilogram of body weight once daily versus 2 milligrams per kilogram thrice daily for treatment of gram‐negative pyelonephritis in children. Antimicrobial Agents &amp; Chemotherapy1992;36(7):1499‐503. [MEDLINE: 92378248] ">Vigano 1992</a>). </p> </li> <li> <p>Three required fever, clinical features and acute kidney parenchymal injury on DMSA scan (<a href="./references#CD003772-bbs2-0004" title="BenadorD , NeuhausTJ , PapazyanJ‐P , WilliUV , Engel‐BicikI , NadalD , et al. Randomised controlled trial of three day versus 10 day intravenous antibiotics in acute pyelonephritis: effect on renal scarring. Archives of Disease in Childhood2001;84(3):241‐6. [MEDLINE: 11207174] GirardinE , NeuhausT , PapazyanJ , WilliUV , BicikI , NadalD , et al. Acute pyelonephritis: comparison of 3 vs 10 days IV antibiotic treatment [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):592A. [CENTRAL: CN‐00583905] ">Benador 2001</a>; <a href="./references#CD003772-bbs2-0020" title="BuechnerK , GirardinF , BergerC , WilliU , NadafD , Neuhaus T for the Swiss Pyelonephritis Study Group. Randomised controlled trial of oral versus sequential intravenous/oral cephalosporins in DMSA scintigraphy‐documented acute pyelonephritis [abstract no: COD. OP 18]. Pediatric Nephrology2006;21(10):1511. [CENTRAL: CN‐00601934] NeuhausTJ , BergerC , BuechnerK , ParvexP , BischoffG , GoetschelP , et al. Randomised trial of oral versus sequential intravenous/oral cephalosporins in children with pyelonephritis. European Journal of Pediatrics2008;167(9):1037‐47. [MEDLINE: 18074149] NeuhausTJ , BüchnerK , GirardinE , WilliU , BergerC , NadalD . Oral versus sequential intravenous/oral cephalosporin‐therapy in DMSA‐scintigraphy documented acute pyelonephritis: randomized Swiss pyelonephritis‐study [abstract] [Orale versus sequentiell intravenös/orale Cephalosporin‐Therapie bei DMSA‐Szintigraphie dokumentierter akuter Pyelonephritis: Randomisierte Schweizer Pyelonephritis‐Studie]. Nieren‐ und Hochdruckkrankheiten2007;36(2):43. [CENTRAL: CN‐00615897] ">Neuhaus 2008</a>; <a href="./references#CD003772-bbs2-0027" title="VilaichoneA , WatanaD , ChaiwatanaratT . Oral ceftibuten switch therapy for acute pyelonephritis in children. Journal of the Medical Association of Thailand2001;84 Suppl(1):61‐7. [MEDLINE: 11529382] ">Vilaichone 2001</a>). </p> </li> <li> <p>Five other studies (<a href="./references#CD003772-bbs2-0005" title="BocquetN , Sergent AlaouiA , JaisJP , GajdosV , GuigonisV , LacourB , et al. Randomized trial of oral versus sequential IV/oral antibiotic for acute pyelonephritis in children. Pediatrics2012;129(2):e269‐75. [MEDLINE: 22291112] ">Bocquet 2012</a>; <a href="./references#CD003772-bbs2-0009" title="ChaoSM , ChongCY , Tan‐HendrickA , TanAS , NgWY . Efficacy and safety of once‐a‐day gentamicin in the treatment of childhood acute pyelonephritis [abstract]. Pediatric Nephrology2001;16(8):C105. [CENTRAL: CN‐00444755] ChongCY , TanAS , NgW , Tan‐KendrickA , BalakrishnanA , ChaoSM . Treatment of urinary tract infection with gentamicin once or three times daily. Acta Paediatrica2003;92(3):291‐6. [MEDLINE: 12725542] ">Chong 2003</a>; <a href="./references#CD003772-bbs2-0014" title="HobermanA , WaldER . Intravenous versus oral antibiotics for urinary tract infections. Pediatrics2000;106(4):865. [MEDLINE: 11183178] HobermanA , WaldER , HickeyRW , BaskinM , CharronM , MajdM , et al. Oral versus initial intravenous therapy for urinary tract infections in young febrile children. Pediatrics1999;104(1 Pt 1):79‐86. [MEDLINE: 10390264] ">Hoberman 1999</a>; <a href="./references#CD003772-bbs2-0017" title="LevtchenkoE , LahyC , LevyJ , HamH , PiepszA . Treatment of children with acute pyelonephritis: a prospective randomized study. Pediatric Nephrology2001;16(11):878‐84. [MEDLINE: 11685593] ">Levtchenko 2001</a>; <a href="./references#CD003772-bbs2-0019" title="HewittIK , TomasiL , PavanelloL , MaschioF , MolinariPP , ToffoloA , et al. Early treatment of acute pyelonephritis in children fails to reduce renal scarring [abstract no: SA‐PO1100]. Journal of the American Society of Nephrology2006;17(Abstracts):804A. [CENTRAL: CN‐00653791] HewittIK , ZucchettaP , RigonL , MaschioF , MolinariPP , TomasiL , et al. Early treatment of acute pyelonephritis in children fails to reduce renal scarring: data from the Italian Renal Infection Study Trials. Pediatrics2008;122(3):486‐90. [MEDLINE: 18762516] LaScolaC , DeMutiisC , HewittIK , PuccioG , ToffoloA , ZucchettaP , et al. Different guidelines for imaging after first UTI in febrile infants: yield, cost, and radiation. Pediatrics2013;131(3):e665‐71. [MEDLINE: 23439905] MontiniG , MurerL , GobberD , CommacchioS , ToffoloA , Dall'AmicoR , et al. Oral vs initial intravenous antibiotic treatment of urinary tract infections in children: a multicentre study [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):816. [CENTRAL: CN‐00446817] MontiniG , ToffoloA , ZucchettaP , Dall'AmicoR , GobberD , CalderonA , et al. Antibiotic treatment for pyelonephritis in children: multicentre randomised controlled non‐inferiority trial. BMJ2007;335(7616):386‐92. [MEDLINE: 17611232] MontiniG , ZucchettaP , GobberD , MurerL , RigonL , ToffoloA , et al. Usefulness of renal radiology and scintigraphy in children with a first episode of upper urinary tract infection [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):813. [CENTRAL: CN‐00446818] MontiniG , ZucchettaP , TomasiL , TalentiE , RigamontiW , PiccoG , et al. Value of imaging studies after a first febrile urinary tract infection in young children: data from Italian renal infection study 1. Pediatrics2009;123(2):e239‐46. [MEDLINE: 19139086] ">Montini 2007</a>) provided information on the number of children with acute pyelonephritis based on clinical characteristics, who had DMSA abnormalities at study entry. </p> </li> <li> <p>One study required fever with computer tomography scan evidence of acute lobular nephronia (<a href="./references#CD003772-bbs2-0008" title="ChengCH , TsauYK , ChangCJ , ChangYC , KuoCY , TsaiIJ , et al. Acute lobar nephronia is associated with a high incidence of renal scarring in childhood urinary tract infections. Pediatric Infectious Disease Journal2010;29(7):624‐8. [MEDLINE: 20234330] ChengCH , TsauYK , LinTY . Effective duration of antimicrobial therapy for the treatment of acute lobar nephronia. Pediatrics2006;117(1):e84‐9. [MEDLINE: 16326693] ">Cheng 2006</a>). </p> </li> </ul> </p> <p>Two studies did not report the definition used for acute pyelonephritis (<a href="./references#CD003772-bbs2-0003" title="BanfiAG , Hill‐JuarezJM , KaufmanA , MoensE . Multinational comparative trial of ceftibuten and trimethoprim‐sulfamethoxazole in the treatment of children with complicated or recurrent urinary tract infections. Members of the ceftibuten urinary tract infection international study group. Pediatric Infectious Disease Journal1993;12(6 Suppl):S84‐S91. [CENTRAL: CN‐00334829] ">Banfi 1993</a>; <a href="./references#CD003772-bbs2-0012" title="FujiiR , ShinozakiT , MeguroH , ArimasuO , IzumiK , OsanoM , et al. Comparative, controlled study on an ampicillin suppository (KS‐R 1) with an oral form of ampicillin in urinary tract infections. Japanese Journal of Antibiotics1987;40(3):476‐92. [MEDLINE: 3302342] ">Fujii 1987</a>). </p> </section> <section id="CD003772-sec-0066"> <h5 class="title">Commonly reported exclusion criteria</h5> <p> <ul id="CD003772-list-0014"> <li> <p>Impaired kidney function (12 studies: <a href="./references#CD003772-bbs2-0007" title="CarapetisJ , JaquieryA , ButteryJ , StarrM . A randomised controlled trial of once‐daily gentamicin in children with urinary tract infections [abstract]. Australian &amp; New Zealand Journal of Medicine1999;29:608. [CENTRAL: CN‐00583423] CarapetisJ , JaquieryA , ButteryJ , StarrM , CranswickN , KohnS , et al. Randomized, controlled trial comparing once daily and three times daily gentamicin in children with urinary tract infections. Pediatric Infectious Disease Journal2001;20(3):240‐6. [MEDLINE: 11303823] ">Carapetis 2001</a>; <a href="./references#CD003772-bbs2-0009" title="ChaoSM , ChongCY , Tan‐HendrickA , TanAS , NgWY . Efficacy and safety of once‐a‐day gentamicin in the treatment of childhood acute pyelonephritis [abstract]. Pediatric Nephrology2001;16(8):C105. [CENTRAL: CN‐00444755] ChongCY , TanAS , NgW , Tan‐KendrickA , BalakrishnanA , ChaoSM . Treatment of urinary tract infection with gentamicin once or three times daily. Acta Paediatrica2003;92(3):291‐6. [MEDLINE: 12725542] ">Chong 2003</a>; <a href="./references#CD003772-bbs2-0010" title="FischbachM , SimeoniU , MengusL , JehlF , MonteilH , GeisertJ , et al. Urinary tract infections with tissue penetration in children: cefotaxime compared with amoxycillin/clavulanate. Journal of Antimicrobial Chemotherapy1989;24(Suppl B):177‐83. [MEDLINE: 2691478] ">Fischbach 1989</a>; <a href="./references#CD003772-bbs2-0011" title="FrancoisP , BensmanA , BegueP , ArtazM‐A , CoudevilleL , LebrunT , et al. Assessment of the efficacy and cost efficiency of two strategies in the treatment of acute pyelonephritis in children: oral cefixime or parenteral ceftriaxone after an initial IV combination therapy [Evaluation de l'efficacité et du coût de deux stratégies thérapeutiques dans les pyélonéphrites de l'enfant: céfixime per os versus ceftriaxone parentérale en relais d'une bithérapie intraveineuse]. Medecine et Maladies Infectieuses1997;27(Spec Iss June):667‐73. [EMBASE: 1997230388] ">Francois 1997</a>; <a href="./references#CD003772-bbs2-0015" title="KafetzisDA , MaltezouHC , MavrikouM , SiafasC , ParaskakisI , DelisD , et al. Isepamicin versus amikacin for the treatment of acute pyelonephritis in children. International Journal of Antimicrobial Agents2000;14(1):51‐5. [MEDLINE: 10717501] ">Kafetzis 2000</a>; <a href="./references#CD003772-bbs2-0016" title="KahnAJ , KumarK , EvansHE . Three‐day antimicrobial therapy of urinary tract infection. Journal of Pediatrics1981;99(6):992‐4. [MEDLINE: 7031217] ">Khan 1981</a>; <a href="./references#CD003772-bbs2-0021" title="NoorbakhshS , LariAR , MasjedianF , MostafaviH , AlaghehbandanR . Comparison of intravenous aminoglycoside therapy with switch therapy to cefixime in urinary tract infections. Saudi Medical Journal2004;25(10):1513‐5. [MEDLINE: 15494842] ">Noorbakhsh 2004</a>; <a href="./references#CD003772-bbs2-0023" title="RepettoHA , MacLoughlinGJ . Single‐dose cefotaxime in the treatment of urinary tract infections in children: a randomized clinical trial. Journal of Antimicrobial Chemotherapy1984;14(Suppl B):307‐10. [MEDLINE: 6094457] ">Repetto 1984</a>; <a href="./references#CD003772-bbs2-0024" title="SchaadUB , EskolaJ , KafetzisD , FischbachM , AshekenaziS , SyriopoulouV , et al. Cefepine vs. ceftazidime treatment of pyelonephritis: a European, randomized, controlled study of 300 pediatric cases. European Society for Paediatric Infectious Diseases (ESPID) Pyelonephritis Study Group. Pediatric Infectious Disease Journal1998;17(7):639‐44. [MEDLINE: 9686732] ">Schaad 1998</a>; <a href="./references#CD003772-bbs2-0025" title="ToporovskiJ , SteffensL , NoackM , KranzA , BurdeskaA , KisslingM . Effectiveness of cefetamet pivoxil in the treatment of pyelonephritis in children. Journal of International Medical Research1992;20(1):87‐93. [MEDLINE: 1568523] ">Toporovski 1992</a>; <a href="./references#CD003772-bbs2-0026" title="ViganoA , PrincipiN , BrivioL , TommasiP , StasiP , VillaAD . Comparison of 5 milligrams of netilmicin per kilogram of body weight once daily versus 2 milligrams per kilogram thrice daily for treatment of gram‐negative pyelonephritis in children. Antimicrobial Agents &amp; Chemotherapy1992;36(7):1499‐503. [MEDLINE: 92378248] ">Vigano 1992</a>; <a href="./references#CD003772-bbs2-0027" title="VilaichoneA , WatanaD , ChaiwatanaratT . Oral ceftibuten switch therapy for acute pyelonephritis in children. Journal of the Medical Association of Thailand2001;84 Suppl(1):61‐7. [MEDLINE: 11529382] ">Vilaichone 2001</a>). </p> </li> <li> <p>Known severe urinary tract abnormality (14 studies: <a href="./references#CD003772-bbs2-0001" title="BakerPC , NelsonDS , SchunkJE . The addition of ceftriaxone to oral therapy does not improve outcome in febrile children with urinary tract infections. Archives of Pediatrics &amp; Adolescent Medicine2001;155(2):135‐9. [MEDLINE: 11177086] ">Baker 2001</a>; <a href="./references#CD003772-bbs2-0004" title="BenadorD , NeuhausTJ , PapazyanJ‐P , WilliUV , Engel‐BicikI , NadalD , et al. Randomised controlled trial of three day versus 10 day intravenous antibiotics in acute pyelonephritis: effect on renal scarring. Archives of Disease in Childhood2001;84(3):241‐6. [MEDLINE: 11207174] GirardinE , NeuhausT , PapazyanJ , WilliUV , BicikI , NadalD , et al. Acute pyelonephritis: comparison of 3 vs 10 days IV antibiotic treatment [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):592A. [CENTRAL: CN‐00583905] ">Benador 2001</a>; <a href="./references#CD003772-bbs2-0005" title="BocquetN , Sergent AlaouiA , JaisJP , GajdosV , GuigonisV , LacourB , et al. Randomized trial of oral versus sequential IV/oral antibiotic for acute pyelonephritis in children. Pediatrics2012;129(2):e269‐75. [MEDLINE: 22291112] ">Bocquet 2012</a>; <a href="./references#CD003772-bbs2-0006" title="BouissouF , MunzerC , DecramerS , RousselB , NovoR , MorinD , et al. Prospective, randomized trial comparing short and long intravenous antibiotic treatment of acute pyelonephritis in children: dimercaptosuccinic acid scintigraphic evaluation at 9 months. Pediatrics2008;121(3):e553‐60. [MEDLINE: 18267977] ">Bouissou 2008</a>; <a href="./references#CD003772-bbs2-0011" title="FrancoisP , BensmanA , BegueP , ArtazM‐A , CoudevilleL , LebrunT , et al. Assessment of the efficacy and cost efficiency of two strategies in the treatment of acute pyelonephritis in children: oral cefixime or parenteral ceftriaxone after an initial IV combination therapy [Evaluation de l'efficacité et du coût de deux stratégies thérapeutiques dans les pyélonéphrites de l'enfant: céfixime per os versus ceftriaxone parentérale en relais d'une bithérapie intraveineuse]. Medecine et Maladies Infectieuses1997;27(Spec Iss June):667‐73. [EMBASE: 1997230388] ">Francois 1997</a>; <a href="./references#CD003772-bbs2-0014" title="HobermanA , WaldER . Intravenous versus oral antibiotics for urinary tract infections. Pediatrics2000;106(4):865. [MEDLINE: 11183178] HobermanA , WaldER , HickeyRW , BaskinM , CharronM , MajdM , et al. Oral versus initial intravenous therapy for urinary tract infections in young febrile children. Pediatrics1999;104(1 Pt 1):79‐86. [MEDLINE: 10390264] ">Hoberman 1999</a>; <a href="./references#CD003772-bbs2-0016" title="KahnAJ , KumarK , EvansHE . Three‐day antimicrobial therapy of urinary tract infection. Journal of Pediatrics1981;99(6):992‐4. [MEDLINE: 7031217] ">Khan 1981</a>; <a href="./references#CD003772-bbs2-0017" title="LevtchenkoE , LahyC , LevyJ , HamH , PiepszA . Treatment of children with acute pyelonephritis: a prospective randomized study. Pediatric Nephrology2001;16(11):878‐84. [MEDLINE: 11685593] ">Levtchenko 2001</a>; <a href="./references#CD003772-bbs2-0018" title="MarildS , EsbjornerE , JakobssonB , LinneT , LubeckP , SjogrenI , et al. Randomised study of ceftibuten vs trimethoprim‐sulfamethoxazole in pyelonephritis in children [abstract no: P466]. Pediatric Nephrology2004;19(9):C208. MarildS , JodalU , SandbergT . Ceftibuten versus trimethoprim‐sulfamethoxazole for oral treatment of febrile urinary tract infection in children. Pediatric Nephrology2009;24(3):521‐6. [MEDLINE: 18818954] ">Marild 2009</a>; <a href="./references#CD003772-bbs2-0020" title="BuechnerK , GirardinF , BergerC , WilliU , NadafD , Neuhaus T for the Swiss Pyelonephritis Study Group. Randomised controlled trial of oral versus sequential intravenous/oral cephalosporins in DMSA scintigraphy‐documented acute pyelonephritis [abstract no: COD. OP 18]. Pediatric Nephrology2006;21(10):1511. [CENTRAL: CN‐00601934] NeuhausTJ , BergerC , BuechnerK , ParvexP , BischoffG , GoetschelP , et al. Randomised trial of oral versus sequential intravenous/oral cephalosporins in children with pyelonephritis. European Journal of Pediatrics2008;167(9):1037‐47. [MEDLINE: 18074149] NeuhausTJ , BüchnerK , GirardinE , WilliU , BergerC , NadalD . Oral versus sequential intravenous/oral cephalosporin‐therapy in DMSA‐scintigraphy documented acute pyelonephritis: randomized Swiss pyelonephritis‐study [abstract] [Orale versus sequentiell intravenös/orale Cephalosporin‐Therapie bei DMSA‐Szintigraphie dokumentierter akuter Pyelonephritis: Randomisierte Schweizer Pyelonephritis‐Studie]. Nieren‐ und Hochdruckkrankheiten2007;36(2):43. [CENTRAL: CN‐00615897] ">Neuhaus 2008</a>; <a href="./references#CD003772-bbs2-0021" title="NoorbakhshS , LariAR , MasjedianF , MostafaviH , AlaghehbandanR . Comparison of intravenous aminoglycoside therapy with switch therapy to cefixime in urinary tract infections. Saudi Medical Journal2004;25(10):1513‐5. [MEDLINE: 15494842] ">Noorbakhsh 2004</a>; <a href="./references#CD003772-bbs2-0023" title="RepettoHA , MacLoughlinGJ . Single‐dose cefotaxime in the treatment of urinary tract infections in children: a randomized clinical trial. Journal of Antimicrobial Chemotherapy1984;14(Suppl B):307‐10. [MEDLINE: 6094457] ">Repetto 1984</a>; <a href="./references#CD003772-bbs2-0026" title="ViganoA , PrincipiN , BrivioL , TommasiP , StasiP , VillaAD . Comparison of 5 milligrams of netilmicin per kilogram of body weight once daily versus 2 milligrams per kilogram thrice daily for treatment of gram‐negative pyelonephritis in children. Antimicrobial Agents &amp; Chemotherapy1992;36(7):1499‐503. [MEDLINE: 92378248] ">Vigano 1992</a>; <a href="./references#CD003772-bbs2-0027" title="VilaichoneA , WatanaD , ChaiwatanaratT . Oral ceftibuten switch therapy for acute pyelonephritis in children. Journal of the Medical Association of Thailand2001;84 Suppl(1):61‐7. [MEDLINE: 11529382] ">Vilaichone 2001</a>). </p> </li> <li> <p>Known sensitivity to study medications (17 studies: <a href="./references#CD003772-bbs2-0003" title="BanfiAG , Hill‐JuarezJM , KaufmanA , MoensE . Multinational comparative trial of ceftibuten and trimethoprim‐sulfamethoxazole in the treatment of children with complicated or recurrent urinary tract infections. Members of the ceftibuten urinary tract infection international study group. Pediatric Infectious Disease Journal1993;12(6 Suppl):S84‐S91. [CENTRAL: CN‐00334829] ">Banfi 1993</a>; <a href="./references#CD003772-bbs2-0001" title="BakerPC , NelsonDS , SchunkJE . The addition of ceftriaxone to oral therapy does not improve outcome in febrile children with urinary tract infections. Archives of Pediatrics &amp; Adolescent Medicine2001;155(2):135‐9. [MEDLINE: 11177086] ">Baker 2001</a>; <a href="./references#CD003772-bbs2-0004" title="BenadorD , NeuhausTJ , PapazyanJ‐P , WilliUV , Engel‐BicikI , NadalD , et al. Randomised controlled trial of three day versus 10 day intravenous antibiotics in acute pyelonephritis: effect on renal scarring. Archives of Disease in Childhood2001;84(3):241‐6. [MEDLINE: 11207174] GirardinE , NeuhausT , PapazyanJ , WilliUV , BicikI , NadalD , et al. Acute pyelonephritis: comparison of 3 vs 10 days IV antibiotic treatment [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):592A. [CENTRAL: CN‐00583905] ">Benador 2001</a>;<a href="./references#CD003772-bbs2-0005" title="BocquetN , Sergent AlaouiA , JaisJP , GajdosV , GuigonisV , LacourB , et al. Randomized trial of oral versus sequential IV/oral antibiotic for acute pyelonephritis in children. Pediatrics2012;129(2):e269‐75. [MEDLINE: 22291112] ">Bocquet 2012</a>; <a href="./references#CD003772-bbs2-0007" title="CarapetisJ , JaquieryA , ButteryJ , StarrM . A randomised controlled trial of once‐daily gentamicin in children with urinary tract infections [abstract]. Australian &amp; New Zealand Journal of Medicine1999;29:608. [CENTRAL: CN‐00583423] CarapetisJ , JaquieryA , ButteryJ , StarrM , CranswickN , KohnS , et al. Randomized, controlled trial comparing once daily and three times daily gentamicin in children with urinary tract infections. Pediatric Infectious Disease Journal2001;20(3):240‐6. [MEDLINE: 11303823] ">Carapetis 2001</a>; <a href="./references#CD003772-bbs2-0009" title="ChaoSM , ChongCY , Tan‐HendrickA , TanAS , NgWY . Efficacy and safety of once‐a‐day gentamicin in the treatment of childhood acute pyelonephritis [abstract]. Pediatric Nephrology2001;16(8):C105. [CENTRAL: CN‐00444755] ChongCY , TanAS , NgW , Tan‐KendrickA , BalakrishnanA , ChaoSM . Treatment of urinary tract infection with gentamicin once or three times daily. Acta Paediatrica2003;92(3):291‐6. [MEDLINE: 12725542] ">Chong 2003</a>; <a href="./references#CD003772-bbs2-0010" title="FischbachM , SimeoniU , MengusL , JehlF , MonteilH , GeisertJ , et al. Urinary tract infections with tissue penetration in children: cefotaxime compared with amoxycillin/clavulanate. Journal of Antimicrobial Chemotherapy1989;24(Suppl B):177‐83. [MEDLINE: 2691478] ">Fischbach 1989</a>; <a href="./references#CD003772-bbs2-0011" title="FrancoisP , BensmanA , BegueP , ArtazM‐A , CoudevilleL , LebrunT , et al. Assessment of the efficacy and cost efficiency of two strategies in the treatment of acute pyelonephritis in children: oral cefixime or parenteral ceftriaxone after an initial IV combination therapy [Evaluation de l'efficacité et du coût de deux stratégies thérapeutiques dans les pyélonéphrites de l'enfant: céfixime per os versus ceftriaxone parentérale en relais d'une bithérapie intraveineuse]. Medecine et Maladies Infectieuses1997;27(Spec Iss June):667‐73. [EMBASE: 1997230388] ">Francois 1997</a>; <a href="./references#CD003772-bbs2-0014" title="HobermanA , WaldER . Intravenous versus oral antibiotics for urinary tract infections. Pediatrics2000;106(4):865. [MEDLINE: 11183178] HobermanA , WaldER , HickeyRW , BaskinM , CharronM , MajdM , et al. Oral versus initial intravenous therapy for urinary tract infections in young febrile children. Pediatrics1999;104(1 Pt 1):79‐86. [MEDLINE: 10390264] ">Hoberman 1999</a>; <a href="./references#CD003772-bbs2-0015" title="KafetzisDA , MaltezouHC , MavrikouM , SiafasC , ParaskakisI , DelisD , et al. Isepamicin versus amikacin for the treatment of acute pyelonephritis in children. International Journal of Antimicrobial Agents2000;14(1):51‐5. [MEDLINE: 10717501] ">Kafetzis 2000</a>; <a href="./references#CD003772-bbs2-0018" title="MarildS , EsbjornerE , JakobssonB , LinneT , LubeckP , SjogrenI , et al. Randomised study of ceftibuten vs trimethoprim‐sulfamethoxazole in pyelonephritis in children [abstract no: P466]. Pediatric Nephrology2004;19(9):C208. MarildS , JodalU , SandbergT . Ceftibuten versus trimethoprim‐sulfamethoxazole for oral treatment of febrile urinary tract infection in children. Pediatric Nephrology2009;24(3):521‐6. [MEDLINE: 18818954] ">Marild 2009</a>; <a href="./references#CD003772-bbs2-0021" title="NoorbakhshS , LariAR , MasjedianF , MostafaviH , AlaghehbandanR . Comparison of intravenous aminoglycoside therapy with switch therapy to cefixime in urinary tract infections. Saudi Medical Journal2004;25(10):1513‐5. [MEDLINE: 15494842] ">Noorbakhsh 2004</a>; <a href="./references#CD003772-bbs2-0023" title="RepettoHA , MacLoughlinGJ . Single‐dose cefotaxime in the treatment of urinary tract infections in children: a randomized clinical trial. Journal of Antimicrobial Chemotherapy1984;14(Suppl B):307‐10. [MEDLINE: 6094457] ">Repetto 1984</a>; <a href="./references#CD003772-bbs2-0024" title="SchaadUB , EskolaJ , KafetzisD , FischbachM , AshekenaziS , SyriopoulouV , et al. Cefepine vs. ceftazidime treatment of pyelonephritis: a European, randomized, controlled study of 300 pediatric cases. European Society for Paediatric Infectious Diseases (ESPID) Pyelonephritis Study Group. Pediatric Infectious Disease Journal1998;17(7):639‐44. [MEDLINE: 9686732] ">Schaad 1998</a>; <a href="./references#CD003772-bbs2-0025" title="ToporovskiJ , SteffensL , NoackM , KranzA , BurdeskaA , KisslingM . Effectiveness of cefetamet pivoxil in the treatment of pyelonephritis in children. Journal of International Medical Research1992;20(1):87‐93. [MEDLINE: 1568523] ">Toporovski 1992</a>; <a href="./references#CD003772-bbs2-0026" title="ViganoA , PrincipiN , BrivioL , TommasiP , StasiP , VillaAD . Comparison of 5 milligrams of netilmicin per kilogram of body weight once daily versus 2 milligrams per kilogram thrice daily for treatment of gram‐negative pyelonephritis in children. Antimicrobial Agents &amp; Chemotherapy1992;36(7):1499‐503. [MEDLINE: 92378248] ">Vigano 1992</a>; <a href="./references#CD003772-bbs2-0027" title="VilaichoneA , WatanaD , ChaiwatanaratT . Oral ceftibuten switch therapy for acute pyelonephritis in children. Journal of the Medical Association of Thailand2001;84 Suppl(1):61‐7. [MEDLINE: 11529382] ">Vilaichone 2001</a>). </p> </li> </ul> </p> </section> <section id="CD003772-sec-0067"> <h5 class="title">Other exclusion criteria</h5> <p> <ul id="CD003772-list-0015"> <li> <p>Recent antibiotic use (10 studies: <a href="./references#CD003772-bbs2-0003" title="BanfiAG , Hill‐JuarezJM , KaufmanA , MoensE . Multinational comparative trial of ceftibuten and trimethoprim‐sulfamethoxazole in the treatment of children with complicated or recurrent urinary tract infections. Members of the ceftibuten urinary tract infection international study group. Pediatric Infectious Disease Journal1993;12(6 Suppl):S84‐S91. [CENTRAL: CN‐00334829] ">Banfi 1993</a>; <a href="./references#CD003772-bbs2-0001" title="BakerPC , NelsonDS , SchunkJE . The addition of ceftriaxone to oral therapy does not improve outcome in febrile children with urinary tract infections. Archives of Pediatrics &amp; Adolescent Medicine2001;155(2):135‐9. [MEDLINE: 11177086] ">Baker 2001</a>; <a href="./references#CD003772-bbs2-0005" title="BocquetN , Sergent AlaouiA , JaisJP , GajdosV , GuigonisV , LacourB , et al. Randomized trial of oral versus sequential IV/oral antibiotic for acute pyelonephritis in children. Pediatrics2012;129(2):e269‐75. [MEDLINE: 22291112] ">Bocquet 2012</a>; <a href="./references#CD003772-bbs2-0009" title="ChaoSM , ChongCY , Tan‐HendrickA , TanAS , NgWY . Efficacy and safety of once‐a‐day gentamicin in the treatment of childhood acute pyelonephritis [abstract]. Pediatric Nephrology2001;16(8):C105. [CENTRAL: CN‐00444755] ChongCY , TanAS , NgW , Tan‐KendrickA , BalakrishnanA , ChaoSM . Treatment of urinary tract infection with gentamicin once or three times daily. Acta Paediatrica2003;92(3):291‐6. [MEDLINE: 12725542] ">Chong 2003</a>; <a href="./references#CD003772-bbs2-0010" title="FischbachM , SimeoniU , MengusL , JehlF , MonteilH , GeisertJ , et al. Urinary tract infections with tissue penetration in children: cefotaxime compared with amoxycillin/clavulanate. Journal of Antimicrobial Chemotherapy1989;24(Suppl B):177‐83. [MEDLINE: 2691478] ">Fischbach 1989</a>; <a href="./references#CD003772-bbs2-0015" title="KafetzisDA , MaltezouHC , MavrikouM , SiafasC , ParaskakisI , DelisD , et al. Isepamicin versus amikacin for the treatment of acute pyelonephritis in children. International Journal of Antimicrobial Agents2000;14(1):51‐5. [MEDLINE: 10717501] ">Kafetzis 2000</a>; <a href="./references#CD003772-bbs2-0018" title="MarildS , EsbjornerE , JakobssonB , LinneT , LubeckP , SjogrenI , et al. Randomised study of ceftibuten vs trimethoprim‐sulfamethoxazole in pyelonephritis in children [abstract no: P466]. Pediatric Nephrology2004;19(9):C208. MarildS , JodalU , SandbergT . Ceftibuten versus trimethoprim‐sulfamethoxazole for oral treatment of febrile urinary tract infection in children. Pediatric Nephrology2009;24(3):521‐6. [MEDLINE: 18818954] ">Marild 2009</a>; <a href="./references#CD003772-bbs2-0019" title="HewittIK , TomasiL , PavanelloL , MaschioF , MolinariPP , ToffoloA , et al. Early treatment of acute pyelonephritis in children fails to reduce renal scarring [abstract no: SA‐PO1100]. Journal of the American Society of Nephrology2006;17(Abstracts):804A. [CENTRAL: CN‐00653791] HewittIK , ZucchettaP , RigonL , MaschioF , MolinariPP , TomasiL , et al. Early treatment of acute pyelonephritis in children fails to reduce renal scarring: data from the Italian Renal Infection Study Trials. Pediatrics2008;122(3):486‐90. [MEDLINE: 18762516] LaScolaC , DeMutiisC , HewittIK , PuccioG , ToffoloA , ZucchettaP , et al. Different guidelines for imaging after first UTI in febrile infants: yield, cost, and radiation. Pediatrics2013;131(3):e665‐71. [MEDLINE: 23439905] MontiniG , MurerL , GobberD , CommacchioS , ToffoloA , Dall'AmicoR , et al. Oral vs initial intravenous antibiotic treatment of urinary tract infections in children: a multicentre study [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):816. [CENTRAL: CN‐00446817] MontiniG , ToffoloA , ZucchettaP , Dall'AmicoR , GobberD , CalderonA , et al. Antibiotic treatment for pyelonephritis in children: multicentre randomised controlled non‐inferiority trial. BMJ2007;335(7616):386‐92. [MEDLINE: 17611232] MontiniG , ZucchettaP , GobberD , MurerL , RigonL , ToffoloA , et al. Usefulness of renal radiology and scintigraphy in children with a first episode of upper urinary tract infection [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):813. [CENTRAL: CN‐00446818] MontiniG , ZucchettaP , TomasiL , TalentiE , RigamontiW , PiccoG , et al. Value of imaging studies after a first febrile urinary tract infection in young children: data from Italian renal infection study 1. Pediatrics2009;123(2):e239‐46. [MEDLINE: 19139086] ">Montini 2007</a>; <a href="./references#CD003772-bbs2-0021" title="NoorbakhshS , LariAR , MasjedianF , MostafaviH , AlaghehbandanR . Comparison of intravenous aminoglycoside therapy with switch therapy to cefixime in urinary tract infections. Saudi Medical Journal2004;25(10):1513‐5. [MEDLINE: 15494842] ">Noorbakhsh 2004</a>; <a href="./references#CD003772-bbs2-0027" title="VilaichoneA , WatanaD , ChaiwatanaratT . Oral ceftibuten switch therapy for acute pyelonephritis in children. Journal of the Medical Association of Thailand2001;84 Suppl(1):61‐7. [MEDLINE: 11529382] ">Vilaichone 2001</a>). </p> </li> <li> <p>Previous UTI (seven studies: <a href="./references#CD003772-bbs2-0006" title="BouissouF , MunzerC , DecramerS , RousselB , NovoR , MorinD , et al. Prospective, randomized trial comparing short and long intravenous antibiotic treatment of acute pyelonephritis in children: dimercaptosuccinic acid scintigraphic evaluation at 9 months. Pediatrics2008;121(3):e553‐60. [MEDLINE: 18267977] ">Bouissou 2008</a>; <a href="./references#CD003772-bbs2-0010" title="FischbachM , SimeoniU , MengusL , JehlF , MonteilH , GeisertJ , et al. Urinary tract infections with tissue penetration in children: cefotaxime compared with amoxycillin/clavulanate. Journal of Antimicrobial Chemotherapy1989;24(Suppl B):177‐83. [MEDLINE: 2691478] ">Fischbach 1989</a>; <a href="./references#CD003772-bbs2-0011" title="FrancoisP , BensmanA , BegueP , ArtazM‐A , CoudevilleL , LebrunT , et al. Assessment of the efficacy and cost efficiency of two strategies in the treatment of acute pyelonephritis in children: oral cefixime or parenteral ceftriaxone after an initial IV combination therapy [Evaluation de l'efficacité et du coût de deux stratégies thérapeutiques dans les pyélonéphrites de l'enfant: céfixime per os versus ceftriaxone parentérale en relais d'une bithérapie intraveineuse]. Medecine et Maladies Infectieuses1997;27(Spec Iss June):667‐73. [EMBASE: 1997230388] ">Francois 1997</a>; <a href="./references#CD003772-bbs2-0014" title="HobermanA , WaldER . Intravenous versus oral antibiotics for urinary tract infections. Pediatrics2000;106(4):865. [MEDLINE: 11183178] HobermanA , WaldER , HickeyRW , BaskinM , CharronM , MajdM , et al. Oral versus initial intravenous therapy for urinary tract infections in young febrile children. Pediatrics1999;104(1 Pt 1):79‐86. [MEDLINE: 10390264] ">Hoberman 1999</a>; <a href="./references#CD003772-bbs2-0018" title="MarildS , EsbjornerE , JakobssonB , LinneT , LubeckP , SjogrenI , et al. Randomised study of ceftibuten vs trimethoprim‐sulfamethoxazole in pyelonephritis in children [abstract no: P466]. Pediatric Nephrology2004;19(9):C208. MarildS , JodalU , SandbergT . Ceftibuten versus trimethoprim‐sulfamethoxazole for oral treatment of febrile urinary tract infection in children. Pediatric Nephrology2009;24(3):521‐6. [MEDLINE: 18818954] ">Marild 2009</a>; <a href="./references#CD003772-bbs2-0019" title="HewittIK , TomasiL , PavanelloL , MaschioF , MolinariPP , ToffoloA , et al. Early treatment of acute pyelonephritis in children fails to reduce renal scarring [abstract no: SA‐PO1100]. Journal of the American Society of Nephrology2006;17(Abstracts):804A. [CENTRAL: CN‐00653791] HewittIK , ZucchettaP , RigonL , MaschioF , MolinariPP , TomasiL , et al. Early treatment of acute pyelonephritis in children fails to reduce renal scarring: data from the Italian Renal Infection Study Trials. Pediatrics2008;122(3):486‐90. [MEDLINE: 18762516] LaScolaC , DeMutiisC , HewittIK , PuccioG , ToffoloA , ZucchettaP , et al. Different guidelines for imaging after first UTI in febrile infants: yield, cost, and radiation. Pediatrics2013;131(3):e665‐71. [MEDLINE: 23439905] MontiniG , MurerL , GobberD , CommacchioS , ToffoloA , Dall'AmicoR , et al. Oral vs initial intravenous antibiotic treatment of urinary tract infections in children: a multicentre study [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):816. [CENTRAL: CN‐00446817] MontiniG , ToffoloA , ZucchettaP , Dall'AmicoR , GobberD , CalderonA , et al. Antibiotic treatment for pyelonephritis in children: multicentre randomised controlled non‐inferiority trial. BMJ2007;335(7616):386‐92. [MEDLINE: 17611232] MontiniG , ZucchettaP , GobberD , MurerL , RigonL , ToffoloA , et al. Usefulness of renal radiology and scintigraphy in children with a first episode of upper urinary tract infection [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):813. [CENTRAL: CN‐00446818] MontiniG , ZucchettaP , TomasiL , TalentiE , RigamontiW , PiccoG , et al. Value of imaging studies after a first febrile urinary tract infection in young children: data from Italian renal infection study 1. Pediatrics2009;123(2):e239‐46. [MEDLINE: 19139086] ">Montini 2007</a>; <a href="./references#CD003772-bbs2-0027" title="VilaichoneA , WatanaD , ChaiwatanaratT . Oral ceftibuten switch therapy for acute pyelonephritis in children. Journal of the Medical Association of Thailand2001;84 Suppl(1):61‐7. [MEDLINE: 11529382] ">Vilaichone 2001</a>). </p> </li> <li> <p>Clinical signs of shock at presentation (six studies: <a href="./references#CD003772-bbs2-0001" title="BakerPC , NelsonDS , SchunkJE . The addition of ceftriaxone to oral therapy does not improve outcome in febrile children with urinary tract infections. Archives of Pediatrics &amp; Adolescent Medicine2001;155(2):135‐9. [MEDLINE: 11177086] ">Baker 2001</a>; <a href="./references#CD003772-bbs2-0005" title="BocquetN , Sergent AlaouiA , JaisJP , GajdosV , GuigonisV , LacourB , et al. Randomized trial of oral versus sequential IV/oral antibiotic for acute pyelonephritis in children. Pediatrics2012;129(2):e269‐75. [MEDLINE: 22291112] ">Bocquet 2012</a>; <a href="./references#CD003772-bbs2-0011" title="FrancoisP , BensmanA , BegueP , ArtazM‐A , CoudevilleL , LebrunT , et al. Assessment of the efficacy and cost efficiency of two strategies in the treatment of acute pyelonephritis in children: oral cefixime or parenteral ceftriaxone after an initial IV combination therapy [Evaluation de l'efficacité et du coût de deux stratégies thérapeutiques dans les pyélonéphrites de l'enfant: céfixime per os versus ceftriaxone parentérale en relais d'une bithérapie intraveineuse]. Medecine et Maladies Infectieuses1997;27(Spec Iss June):667‐73. [EMBASE: 1997230388] ">Francois 1997</a>; <a href="./references#CD003772-bbs2-0014" title="HobermanA , WaldER . Intravenous versus oral antibiotics for urinary tract infections. Pediatrics2000;106(4):865. [MEDLINE: 11183178] HobermanA , WaldER , HickeyRW , BaskinM , CharronM , MajdM , et al. Oral versus initial intravenous therapy for urinary tract infections in young febrile children. Pediatrics1999;104(1 Pt 1):79‐86. [MEDLINE: 10390264] ">Hoberman 1999</a>; <a href="./references#CD003772-bbs2-0019" title="HewittIK , TomasiL , PavanelloL , MaschioF , MolinariPP , ToffoloA , et al. Early treatment of acute pyelonephritis in children fails to reduce renal scarring [abstract no: SA‐PO1100]. Journal of the American Society of Nephrology2006;17(Abstracts):804A. [CENTRAL: CN‐00653791] HewittIK , ZucchettaP , RigonL , MaschioF , MolinariPP , TomasiL , et al. Early treatment of acute pyelonephritis in children fails to reduce renal scarring: data from the Italian Renal Infection Study Trials. Pediatrics2008;122(3):486‐90. [MEDLINE: 18762516] LaScolaC , DeMutiisC , HewittIK , PuccioG , ToffoloA , ZucchettaP , et al. Different guidelines for imaging after first UTI in febrile infants: yield, cost, and radiation. Pediatrics2013;131(3):e665‐71. [MEDLINE: 23439905] MontiniG , MurerL , GobberD , CommacchioS , ToffoloA , Dall'AmicoR , et al. Oral vs initial intravenous antibiotic treatment of urinary tract infections in children: a multicentre study [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):816. [CENTRAL: CN‐00446817] MontiniG , ToffoloA , ZucchettaP , Dall'AmicoR , GobberD , CalderonA , et al. Antibiotic treatment for pyelonephritis in children: multicentre randomised controlled non‐inferiority trial. BMJ2007;335(7616):386‐92. [MEDLINE: 17611232] MontiniG , ZucchettaP , GobberD , MurerL , RigonL , ToffoloA , et al. Usefulness of renal radiology and scintigraphy in children with a first episode of upper urinary tract infection [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):813. [CENTRAL: CN‐00446818] MontiniG , ZucchettaP , TomasiL , TalentiE , RigamontiW , PiccoG , et al. Value of imaging studies after a first febrile urinary tract infection in young children: data from Italian renal infection study 1. Pediatrics2009;123(2):e239‐46. [MEDLINE: 19139086] ">Montini 2007</a>; <a href="./references#CD003772-bbs2-0020" title="BuechnerK , GirardinF , BergerC , WilliU , NadafD , Neuhaus T for the Swiss Pyelonephritis Study Group. Randomised controlled trial of oral versus sequential intravenous/oral cephalosporins in DMSA scintigraphy‐documented acute pyelonephritis [abstract no: COD. OP 18]. Pediatric Nephrology2006;21(10):1511. [CENTRAL: CN‐00601934] NeuhausTJ , BergerC , BuechnerK , ParvexP , BischoffG , GoetschelP , et al. Randomised trial of oral versus sequential intravenous/oral cephalosporins in children with pyelonephritis. European Journal of Pediatrics2008;167(9):1037‐47. [MEDLINE: 18074149] NeuhausTJ , BüchnerK , GirardinE , WilliU , BergerC , NadalD . Oral versus sequential intravenous/oral cephalosporin‐therapy in DMSA‐scintigraphy documented acute pyelonephritis: randomized Swiss pyelonephritis‐study [abstract] [Orale versus sequentiell intravenös/orale Cephalosporin‐Therapie bei DMSA‐Szintigraphie dokumentierter akuter Pyelonephritis: Randomisierte Schweizer Pyelonephritis‐Studie]. Nieren‐ und Hochdruckkrankheiten2007;36(2):43. [CENTRAL: CN‐00615897] ">Neuhaus 2008</a>). </p> </li> <li> <p>Immune compromise (six studies: <a href="./references#CD003772-bbs2-0003" title="BanfiAG , Hill‐JuarezJM , KaufmanA , MoensE . Multinational comparative trial of ceftibuten and trimethoprim‐sulfamethoxazole in the treatment of children with complicated or recurrent urinary tract infections. Members of the ceftibuten urinary tract infection international study group. Pediatric Infectious Disease Journal1993;12(6 Suppl):S84‐S91. [CENTRAL: CN‐00334829] ">Banfi 1993</a>; <a href="./references#CD003772-bbs2-0006" title="BouissouF , MunzerC , DecramerS , RousselB , NovoR , MorinD , et al. Prospective, randomized trial comparing short and long intravenous antibiotic treatment of acute pyelonephritis in children: dimercaptosuccinic acid scintigraphic evaluation at 9 months. Pediatrics2008;121(3):e553‐60. [MEDLINE: 18267977] ">Bouissou 2008</a>; <a href="./references#CD003772-bbs2-0007" title="CarapetisJ , JaquieryA , ButteryJ , StarrM . A randomised controlled trial of once‐daily gentamicin in children with urinary tract infections [abstract]. Australian &amp; New Zealand Journal of Medicine1999;29:608. [CENTRAL: CN‐00583423] CarapetisJ , JaquieryA , ButteryJ , StarrM , CranswickN , KohnS , et al. Randomized, controlled trial comparing once daily and three times daily gentamicin in children with urinary tract infections. Pediatric Infectious Disease Journal2001;20(3):240‐6. [MEDLINE: 11303823] ">Carapetis 2001</a>; <a href="./references#CD003772-bbs2-0011" title="FrancoisP , BensmanA , BegueP , ArtazM‐A , CoudevilleL , LebrunT , et al. Assessment of the efficacy and cost efficiency of two strategies in the treatment of acute pyelonephritis in children: oral cefixime or parenteral ceftriaxone after an initial IV combination therapy [Evaluation de l'efficacité et du coût de deux stratégies thérapeutiques dans les pyélonéphrites de l'enfant: céfixime per os versus ceftriaxone parentérale en relais d'une bithérapie intraveineuse]. Medecine et Maladies Infectieuses1997;27(Spec Iss June):667‐73. [EMBASE: 1997230388] ">Francois 1997</a>; <a href="./references#CD003772-bbs2-0021" title="NoorbakhshS , LariAR , MasjedianF , MostafaviH , AlaghehbandanR . Comparison of intravenous aminoglycoside therapy with switch therapy to cefixime in urinary tract infections. Saudi Medical Journal2004;25(10):1513‐5. [MEDLINE: 15494842] ">Noorbakhsh 2004</a>; <a href="./references#CD003772-bbs2-0024" title="SchaadUB , EskolaJ , KafetzisD , FischbachM , AshekenaziS , SyriopoulouV , et al. Cefepine vs. ceftazidime treatment of pyelonephritis: a European, randomized, controlled study of 300 pediatric cases. European Society for Paediatric Infectious Diseases (ESPID) Pyelonephritis Study Group. Pediatric Infectious Disease Journal1998;17(7):639‐44. [MEDLINE: 9686732] ">Schaad 1998</a>). </p> </li> <li> <p>Known hearing impairment (four studies: <a href="./references#CD003772-bbs2-0007" title="CarapetisJ , JaquieryA , ButteryJ , StarrM . A randomised controlled trial of once‐daily gentamicin in children with urinary tract infections [abstract]. Australian &amp; New Zealand Journal of Medicine1999;29:608. [CENTRAL: CN‐00583423] CarapetisJ , JaquieryA , ButteryJ , StarrM , CranswickN , KohnS , et al. Randomized, controlled trial comparing once daily and three times daily gentamicin in children with urinary tract infections. Pediatric Infectious Disease Journal2001;20(3):240‐6. [MEDLINE: 11303823] ">Carapetis 2001</a>; <a href="./references#CD003772-bbs2-0009" title="ChaoSM , ChongCY , Tan‐HendrickA , TanAS , NgWY . Efficacy and safety of once‐a‐day gentamicin in the treatment of childhood acute pyelonephritis [abstract]. Pediatric Nephrology2001;16(8):C105. [CENTRAL: CN‐00444755] ChongCY , TanAS , NgW , Tan‐KendrickA , BalakrishnanA , ChaoSM . Treatment of urinary tract infection with gentamicin once or three times daily. Acta Paediatrica2003;92(3):291‐6. [MEDLINE: 12725542] ">Chong 2003</a>; <a href="./references#CD003772-bbs2-0015" title="KafetzisDA , MaltezouHC , MavrikouM , SiafasC , ParaskakisI , DelisD , et al. Isepamicin versus amikacin for the treatment of acute pyelonephritis in children. International Journal of Antimicrobial Agents2000;14(1):51‐5. [MEDLINE: 10717501] ">Kafetzis 2000</a>; <a href="./references#CD003772-bbs2-0026" title="ViganoA , PrincipiN , BrivioL , TommasiP , StasiP , VillaAD . Comparison of 5 milligrams of netilmicin per kilogram of body weight once daily versus 2 milligrams per kilogram thrice daily for treatment of gram‐negative pyelonephritis in children. Antimicrobial Agents &amp; Chemotherapy1992;36(7):1499‐503. [MEDLINE: 92378248] ">Vigano 1992</a>). </p> </li> <li> <p>Uncomplicated acute pyelonephritis (APN) (one study: <a href="./references#CD003772-bbs2-0008" title="ChengCH , TsauYK , ChangCJ , ChangYC , KuoCY , TsaiIJ , et al. Acute lobar nephronia is associated with a high incidence of renal scarring in childhood urinary tract infections. Pediatric Infectious Disease Journal2010;29(7):624‐8. [MEDLINE: 20234330] ChengCH , TsauYK , LinTY . Effective duration of antimicrobial therapy for the treatment of acute lobar nephronia. Pediatrics2006;117(1):e84‐9. [MEDLINE: 16326693] ">Cheng 2006</a>). </p> </li> </ul> </p> <p>Four studies did not specify any exclusion criteria (<a href="./references#CD003772-bbs2-0002" title="BakkalogluA , SaatciU , SoylemezogluO , OzenS , TopalogluR , BesbasN , et al. Comparison of ceftriaxone versus cefotaxime for childhood upper urinary tract infections. Journal of Chemotherapy1996;8(1):59‐62. [MEDLINE: 8835111] ">Bakkaloglu 1996</a>; <a href="./references#CD003772-bbs2-0012" title="FujiiR , ShinozakiT , MeguroH , ArimasuO , IzumiK , OsanoM , et al. Comparative, controlled study on an ampicillin suppository (KS‐R 1) with an oral form of ampicillin in urinary tract infections. Japanese Journal of Antibiotics1987;40(3):476‐92. [MEDLINE: 3302342] ">Fujii 1987</a>; <a href="./references#CD003772-bbs2-0013" title="GrimwoodK , AbbottGD , FergussonDM . Single dose gentamicin treatment of urinary infections in children. New Zealand Medical Journal1988;101(852):539‐41. [MEDLINE: 3045718] ">Grimwood 1988</a>; <a href="./references#CD003772-bbs2-0022" title="PylkkänenJ , VilskaJ , KoskimiesO . The length of antimicrobial therapy in upper vs. lower urinary tract infection of childhood. Acta Paediatrica Scandinavica1981;70(6):885‐8. [MEDLINE: 7324942] PylkkänenJ , VilskaJ , KoskimiesO . The value of level diagnosis of childhood urinary tract infection in predicting renal injury. Acta Paediatrica Scandinavica1981;70(6):879‐83. [MEDLINE: 7324941] ">Pylkkänen 1981</a>). </p> </section> <section id="CD003772-sec-0068"> <h5 class="title">Study comparisons</h5> <p>The 27 included studies evaluated eight different comparisons.</p> <p> <ul id="CD003772-list-0016"> <li> <p>Four studies compared oral therapy with short duration IV therapy followed by oral therapy (<a href="./references#CD003772-bbs2-0005" title="BocquetN , Sergent AlaouiA , JaisJP , GajdosV , GuigonisV , LacourB , et al. Randomized trial of oral versus sequential IV/oral antibiotic for acute pyelonephritis in children. Pediatrics2012;129(2):e269‐75. [MEDLINE: 22291112] ">Bocquet 2012</a>; <a href="./references#CD003772-bbs2-0014" title="HobermanA , WaldER . Intravenous versus oral antibiotics for urinary tract infections. Pediatrics2000;106(4):865. [MEDLINE: 11183178] HobermanA , WaldER , HickeyRW , BaskinM , CharronM , MajdM , et al. Oral versus initial intravenous therapy for urinary tract infections in young febrile children. Pediatrics1999;104(1 Pt 1):79‐86. [MEDLINE: 10390264] ">Hoberman 1999</a>; <a href="./references#CD003772-bbs2-0019" title="HewittIK , TomasiL , PavanelloL , MaschioF , MolinariPP , ToffoloA , et al. Early treatment of acute pyelonephritis in children fails to reduce renal scarring [abstract no: SA‐PO1100]. Journal of the American Society of Nephrology2006;17(Abstracts):804A. [CENTRAL: CN‐00653791] HewittIK , ZucchettaP , RigonL , MaschioF , MolinariPP , TomasiL , et al. Early treatment of acute pyelonephritis in children fails to reduce renal scarring: data from the Italian Renal Infection Study Trials. Pediatrics2008;122(3):486‐90. [MEDLINE: 18762516] LaScolaC , DeMutiisC , HewittIK , PuccioG , ToffoloA , ZucchettaP , et al. Different guidelines for imaging after first UTI in febrile infants: yield, cost, and radiation. Pediatrics2013;131(3):e665‐71. [MEDLINE: 23439905] MontiniG , MurerL , GobberD , CommacchioS , ToffoloA , Dall'AmicoR , et al. Oral vs initial intravenous antibiotic treatment of urinary tract infections in children: a multicentre study [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):816. [CENTRAL: CN‐00446817] MontiniG , ToffoloA , ZucchettaP , Dall'AmicoR , GobberD , CalderonA , et al. Antibiotic treatment for pyelonephritis in children: multicentre randomised controlled non‐inferiority trial. BMJ2007;335(7616):386‐92. [MEDLINE: 17611232] MontiniG , ZucchettaP , GobberD , MurerL , RigonL , ToffoloA , et al. Usefulness of renal radiology and scintigraphy in children with a first episode of upper urinary tract infection [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):813. [CENTRAL: CN‐00446818] MontiniG , ZucchettaP , TomasiL , TalentiE , RigamontiW , PiccoG , et al. Value of imaging studies after a first febrile urinary tract infection in young children: data from Italian renal infection study 1. Pediatrics2009;123(2):e239‐46. [MEDLINE: 19139086] ">Montini 2007</a>; <a href="./references#CD003772-bbs2-0020" title="BuechnerK , GirardinF , BergerC , WilliU , NadafD , Neuhaus T for the Swiss Pyelonephritis Study Group. Randomised controlled trial of oral versus sequential intravenous/oral cephalosporins in DMSA scintigraphy‐documented acute pyelonephritis [abstract no: COD. OP 18]. Pediatric Nephrology2006;21(10):1511. [CENTRAL: CN‐00601934] NeuhausTJ , BergerC , BuechnerK , ParvexP , BischoffG , GoetschelP , et al. Randomised trial of oral versus sequential intravenous/oral cephalosporins in children with pyelonephritis. European Journal of Pediatrics2008;167(9):1037‐47. [MEDLINE: 18074149] NeuhausTJ , BüchnerK , GirardinE , WilliU , BergerC , NadalD . Oral versus sequential intravenous/oral cephalosporin‐therapy in DMSA‐scintigraphy documented acute pyelonephritis: randomized Swiss pyelonephritis‐study [abstract] [Orale versus sequentiell intravenös/orale Cephalosporin‐Therapie bei DMSA‐Szintigraphie dokumentierter akuter Pyelonephritis: Randomisierte Schweizer Pyelonephritis‐Studie]. Nieren‐ und Hochdruckkrankheiten2007;36(2):43. [CENTRAL: CN‐00615897] ">Neuhaus 2008</a>). </p> </li> <li> <p>In six studies, short duration IV therapy (three to four days) followed by oral therapy was compared with long duration IV therapy (seven to 14 days) (<a href="./references#CD003772-bbs2-0004" title="BenadorD , NeuhausTJ , PapazyanJ‐P , WilliUV , Engel‐BicikI , NadalD , et al. Randomised controlled trial of three day versus 10 day intravenous antibiotics in acute pyelonephritis: effect on renal scarring. Archives of Disease in Childhood2001;84(3):241‐6. [MEDLINE: 11207174] GirardinE , NeuhausT , PapazyanJ , WilliUV , BicikI , NadalD , et al. Acute pyelonephritis: comparison of 3 vs 10 days IV antibiotic treatment [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):592A. [CENTRAL: CN‐00583905] ">Benador 2001</a>; <a href="./references#CD003772-bbs2-0006" title="BouissouF , MunzerC , DecramerS , RousselB , NovoR , MorinD , et al. Prospective, randomized trial comparing short and long intravenous antibiotic treatment of acute pyelonephritis in children: dimercaptosuccinic acid scintigraphic evaluation at 9 months. Pediatrics2008;121(3):e553‐60. [MEDLINE: 18267977] ">Bouissou 2008</a>; <a href="./references#CD003772-bbs2-0011" title="FrancoisP , BensmanA , BegueP , ArtazM‐A , CoudevilleL , LebrunT , et al. Assessment of the efficacy and cost efficiency of two strategies in the treatment of acute pyelonephritis in children: oral cefixime or parenteral ceftriaxone after an initial IV combination therapy [Evaluation de l'efficacité et du coût de deux stratégies thérapeutiques dans les pyélonéphrites de l'enfant: céfixime per os versus ceftriaxone parentérale en relais d'une bithérapie intraveineuse]. Medecine et Maladies Infectieuses1997;27(Spec Iss June):667‐73. [EMBASE: 1997230388] ">Francois 1997</a>; <a href="./references#CD003772-bbs2-0017" title="LevtchenkoE , LahyC , LevyJ , HamH , PiepszA . Treatment of children with acute pyelonephritis: a prospective randomized study. Pediatric Nephrology2001;16(11):878‐84. [MEDLINE: 11685593] ">Levtchenko 2001</a>; <a href="./references#CD003772-bbs2-0021" title="NoorbakhshS , LariAR , MasjedianF , MostafaviH , AlaghehbandanR . Comparison of intravenous aminoglycoside therapy with switch therapy to cefixime in urinary tract infections. Saudi Medical Journal2004;25(10):1513‐5. [MEDLINE: 15494842] ">Noorbakhsh 2004</a>; <a href="./references#CD003772-bbs2-0027" title="VilaichoneA , WatanaD , ChaiwatanaratT . Oral ceftibuten switch therapy for acute pyelonephritis in children. Journal of the Medical Association of Thailand2001;84 Suppl(1):61‐7. [MEDLINE: 11529382] ">Vilaichone 2001</a>). </p> </li> <li> <p>A single dose of parenteral antibiotic added to oral therapy was compared to oral therapy alone in one study (<a href="./references#CD003772-bbs2-0001" title="BakerPC , NelsonDS , SchunkJE . The addition of ceftriaxone to oral therapy does not improve outcome in febrile children with urinary tract infections. Archives of Pediatrics &amp; Adolescent Medicine2001;155(2):135‐9. [MEDLINE: 11177086] ">Baker 2001</a>). </p> </li> <li> <p>Three studies compared different dosing frequencies of the same antibiotic agents (<a href="./references#CD003772-bbs2-0007" title="CarapetisJ , JaquieryA , ButteryJ , StarrM . A randomised controlled trial of once‐daily gentamicin in children with urinary tract infections [abstract]. Australian &amp; New Zealand Journal of Medicine1999;29:608. [CENTRAL: CN‐00583423] CarapetisJ , JaquieryA , ButteryJ , StarrM , CranswickN , KohnS , et al. Randomized, controlled trial comparing once daily and three times daily gentamicin in children with urinary tract infections. Pediatric Infectious Disease Journal2001;20(3):240‐6. [MEDLINE: 11303823] ">Carapetis 2001</a>; <a href="./references#CD003772-bbs2-0009" title="ChaoSM , ChongCY , Tan‐HendrickA , TanAS , NgWY . Efficacy and safety of once‐a‐day gentamicin in the treatment of childhood acute pyelonephritis [abstract]. Pediatric Nephrology2001;16(8):C105. [CENTRAL: CN‐00444755] ChongCY , TanAS , NgW , Tan‐KendrickA , BalakrishnanA , ChaoSM . Treatment of urinary tract infection with gentamicin once or three times daily. Acta Paediatrica2003;92(3):291‐6. [MEDLINE: 12725542] ">Chong 2003</a>; <a href="./references#CD003772-bbs2-0026" title="ViganoA , PrincipiN , BrivioL , TommasiP , StasiP , VillaAD . Comparison of 5 milligrams of netilmicin per kilogram of body weight once daily versus 2 milligrams per kilogram thrice daily for treatment of gram‐negative pyelonephritis in children. Antimicrobial Agents &amp; Chemotherapy1992;36(7):1499‐503. [MEDLINE: 92378248] ">Vigano 1992</a>). </p> </li> <li> <p>Seven studies compared different antibiotics (<a href="./references#CD003772-bbs2-0003" title="BanfiAG , Hill‐JuarezJM , KaufmanA , MoensE . Multinational comparative trial of ceftibuten and trimethoprim‐sulfamethoxazole in the treatment of children with complicated or recurrent urinary tract infections. Members of the ceftibuten urinary tract infection international study group. Pediatric Infectious Disease Journal1993;12(6 Suppl):S84‐S91. [CENTRAL: CN‐00334829] ">Banfi 1993</a>; <a href="./references#CD003772-bbs2-0002" title="BakkalogluA , SaatciU , SoylemezogluO , OzenS , TopalogluR , BesbasN , et al. Comparison of ceftriaxone versus cefotaxime for childhood upper urinary tract infections. Journal of Chemotherapy1996;8(1):59‐62. [MEDLINE: 8835111] ">Bakkaloglu 1996</a>; <a href="./references#CD003772-bbs2-0010" title="FischbachM , SimeoniU , MengusL , JehlF , MonteilH , GeisertJ , et al. Urinary tract infections with tissue penetration in children: cefotaxime compared with amoxycillin/clavulanate. Journal of Antimicrobial Chemotherapy1989;24(Suppl B):177‐83. [MEDLINE: 2691478] ">Fischbach 1989</a>; <a href="./references#CD003772-bbs2-0015" title="KafetzisDA , MaltezouHC , MavrikouM , SiafasC , ParaskakisI , DelisD , et al. Isepamicin versus amikacin for the treatment of acute pyelonephritis in children. International Journal of Antimicrobial Agents2000;14(1):51‐5. [MEDLINE: 10717501] ">Kafetzis 2000</a>; <a href="./references#CD003772-bbs2-0018" title="MarildS , EsbjornerE , JakobssonB , LinneT , LubeckP , SjogrenI , et al. Randomised study of ceftibuten vs trimethoprim‐sulfamethoxazole in pyelonephritis in children [abstract no: P466]. Pediatric Nephrology2004;19(9):C208. MarildS , JodalU , SandbergT . Ceftibuten versus trimethoprim‐sulfamethoxazole for oral treatment of febrile urinary tract infection in children. Pediatric Nephrology2009;24(3):521‐6. [MEDLINE: 18818954] ">Marild 2009</a>; <a href="./references#CD003772-bbs2-0024" title="SchaadUB , EskolaJ , KafetzisD , FischbachM , AshekenaziS , SyriopoulouV , et al. Cefepine vs. ceftazidime treatment of pyelonephritis: a European, randomized, controlled study of 300 pediatric cases. European Society for Paediatric Infectious Diseases (ESPID) Pyelonephritis Study Group. Pediatric Infectious Disease Journal1998;17(7):639‐44. [MEDLINE: 9686732] ">Schaad 1998</a>; <a href="./references#CD003772-bbs2-0025" title="ToporovskiJ , SteffensL , NoackM , KranzA , BurdeskaA , KisslingM . Effectiveness of cefetamet pivoxil in the treatment of pyelonephritis in children. Journal of International Medical Research1992;20(1):87‐93. [MEDLINE: 1568523] ">Toporovski 1992</a>). <a href="./references#CD003772-bbs2-0025" title="ToporovskiJ , SteffensL , NoackM , KranzA , BurdeskaA , KisslingM . Effectiveness of cefetamet pivoxil in the treatment of pyelonephritis in children. Journal of International Medical Research1992;20(1):87‐93. [MEDLINE: 1568523] ">Toporovski 1992</a> included two experimental groups who received different doses of antibiotic. Because treatment response did not differ, experimental group data were combined. </p> </li> <li> <p>Three studies compared different durations of antibiotics (<a href="./references#CD003772-bbs2-0008" title="ChengCH , TsauYK , ChangCJ , ChangYC , KuoCY , TsaiIJ , et al. Acute lobar nephronia is associated with a high incidence of renal scarring in childhood urinary tract infections. Pediatric Infectious Disease Journal2010;29(7):624‐8. [MEDLINE: 20234330] ChengCH , TsauYK , LinTY . Effective duration of antimicrobial therapy for the treatment of acute lobar nephronia. Pediatrics2006;117(1):e84‐9. [MEDLINE: 16326693] ">Cheng 2006</a>; <a href="./references#CD003772-bbs2-0016" title="KahnAJ , KumarK , EvansHE . Three‐day antimicrobial therapy of urinary tract infection. Journal of Pediatrics1981;99(6):992‐4. [MEDLINE: 7031217] ">Khan 1981</a>; <a href="./references#CD003772-bbs2-0022" title="PylkkänenJ , VilskaJ , KoskimiesO . The length of antimicrobial therapy in upper vs. lower urinary tract infection of childhood. Acta Paediatrica Scandinavica1981;70(6):885‐8. [MEDLINE: 7324942] PylkkänenJ , VilskaJ , KoskimiesO . The value of level diagnosis of childhood urinary tract infection in predicting renal injury. Acta Paediatrica Scandinavica1981;70(6):879‐83. [MEDLINE: 7324941] ">Pylkkänen 1981</a>). </p> </li> <li> <p>Two studies assessed single dose parenteral therapy against seven to 10 days of oral antibiotic therapy (<a href="./references#CD003772-bbs2-0013" title="GrimwoodK , AbbottGD , FergussonDM . Single dose gentamicin treatment of urinary infections in children. New Zealand Medical Journal1988;101(852):539‐41. [MEDLINE: 3045718] ">Grimwood 1988</a>; <a href="./references#CD003772-bbs2-0023" title="RepettoHA , MacLoughlinGJ . Single‐dose cefotaxime in the treatment of urinary tract infections in children: a randomized clinical trial. Journal of Antimicrobial Chemotherapy1984;14(Suppl B):307‐10. [MEDLINE: 6094457] ">Repetto 1984</a>). </p> </li> <li> <p>One study compared ampicillin suppositories with oral ampicillin (<a href="./references#CD003772-bbs2-0012" title="FujiiR , ShinozakiT , MeguroH , ArimasuO , IzumiK , OsanoM , et al. Comparative, controlled study on an ampicillin suppository (KS‐R 1) with an oral form of ampicillin in urinary tract infections. Japanese Journal of Antibiotics1987;40(3):476‐92. [MEDLINE: 3302342] ">Fujii 1987</a>). </p> </li> </ul> </p> </section> <section id="CD003772-sec-0069"> <h5 class="title">Reported outcomes</h5> <p>Not all studies reported the same outcomes. <a href="#CD003772-tbl-0005">Table 1</a>shows the outcomes reported for each study comparison. </p> <div class="table" id="CD003772-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Reported outcomes of included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Study/ comparisons</b> </p> <p><b> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b> Reported outcomes</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Persistent bacteriuria at 48 to 72 hours</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Bacteriuria at the end or ≥ 5 days of treatment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>UTI at follow‐up</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Resolution of clinical symptoms</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Symptomatic recurrence of UTI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Parenchymal renal damage on DSMA scan</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Oral therapy versus sequential short duration IV therapy and oral therapy</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003772-bbs2-0005" title="BocquetN , Sergent AlaouiA , JaisJP , GajdosV , GuigonisV , LacourB , et al. Randomized trial of oral versus sequential IV/oral antibiotic for acute pyelonephritis in children. Pediatrics2012;129(2):e269‐75. [MEDLINE: 22291112] ">Bocquet 2012</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003772-bbs2-0014" title="HobermanA , WaldER . Intravenous versus oral antibiotics for urinary tract infections. Pediatrics2000;106(4):865. [MEDLINE: 11183178] HobermanA , WaldER , HickeyRW , BaskinM , CharronM , MajdM , et al. Oral versus initial intravenous therapy for urinary tract infections in young febrile children. Pediatrics1999;104(1 Pt 1):79‐86. [MEDLINE: 10390264] ">Hoberman 1999</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003772-bbs2-0019" title="HewittIK , TomasiL , PavanelloL , MaschioF , MolinariPP , ToffoloA , et al. Early treatment of acute pyelonephritis in children fails to reduce renal scarring [abstract no: SA‐PO1100]. Journal of the American Society of Nephrology2006;17(Abstracts):804A. [CENTRAL: CN‐00653791] HewittIK , ZucchettaP , RigonL , MaschioF , MolinariPP , TomasiL , et al. Early treatment of acute pyelonephritis in children fails to reduce renal scarring: data from the Italian Renal Infection Study Trials. Pediatrics2008;122(3):486‐90. [MEDLINE: 18762516] LaScolaC , DeMutiisC , HewittIK , PuccioG , ToffoloA , ZucchettaP , et al. Different guidelines for imaging after first UTI in febrile infants: yield, cost, and radiation. Pediatrics2013;131(3):e665‐71. [MEDLINE: 23439905] MontiniG , MurerL , GobberD , CommacchioS , ToffoloA , Dall'AmicoR , et al. Oral vs initial intravenous antibiotic treatment of urinary tract infections in children: a multicentre study [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):816. [CENTRAL: CN‐00446817] MontiniG , ToffoloA , ZucchettaP , Dall'AmicoR , GobberD , CalderonA , et al. Antibiotic treatment for pyelonephritis in children: multicentre randomised controlled non‐inferiority trial. BMJ2007;335(7616):386‐92. [MEDLINE: 17611232] MontiniG , ZucchettaP , GobberD , MurerL , RigonL , ToffoloA , et al. Usefulness of renal radiology and scintigraphy in children with a first episode of upper urinary tract infection [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):813. [CENTRAL: CN‐00446818] MontiniG , ZucchettaP , TomasiL , TalentiE , RigamontiW , PiccoG , et al. Value of imaging studies after a first febrile urinary tract infection in young children: data from Italian renal infection study 1. Pediatrics2009;123(2):e239‐46. [MEDLINE: 19139086] ">Montini 2007</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003772-bbs2-0020" title="BuechnerK , GirardinF , BergerC , WilliU , NadafD , Neuhaus T for the Swiss Pyelonephritis Study Group. Randomised controlled trial of oral versus sequential intravenous/oral cephalosporins in DMSA scintigraphy‐documented acute pyelonephritis [abstract no: COD. OP 18]. Pediatric Nephrology2006;21(10):1511. [CENTRAL: CN‐00601934] NeuhausTJ , BergerC , BuechnerK , ParvexP , BischoffG , GoetschelP , et al. Randomised trial of oral versus sequential intravenous/oral cephalosporins in children with pyelonephritis. European Journal of Pediatrics2008;167(9):1037‐47. [MEDLINE: 18074149] NeuhausTJ , BüchnerK , GirardinE , WilliU , BergerC , NadalD . Oral versus sequential intravenous/oral cephalosporin‐therapy in DMSA‐scintigraphy documented acute pyelonephritis: randomized Swiss pyelonephritis‐study [abstract] [Orale versus sequentiell intravenös/orale Cephalosporin‐Therapie bei DMSA‐Szintigraphie dokumentierter akuter Pyelonephritis: Randomisierte Schweizer Pyelonephritis‐Studie]. Nieren‐ und Hochdruckkrankheiten2007;36(2):43. [CENTRAL: CN‐00615897] ">Neuhaus 2008</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Sequential short duration (3 to 4 days) IV therapy and oral therapy versus long duration (7to 14 days) IV therapy</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003772-bbs2-0004" title="BenadorD , NeuhausTJ , PapazyanJ‐P , WilliUV , Engel‐BicikI , NadalD , et al. Randomised controlled trial of three day versus 10 day intravenous antibiotics in acute pyelonephritis: effect on renal scarring. Archives of Disease in Childhood2001;84(3):241‐6. [MEDLINE: 11207174] GirardinE , NeuhausT , PapazyanJ , WilliUV , BicikI , NadalD , et al. Acute pyelonephritis: comparison of 3 vs 10 days IV antibiotic treatment [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):592A. [CENTRAL: CN‐00583905] ">Benador 2001</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003772-bbs2-0006" title="BouissouF , MunzerC , DecramerS , RousselB , NovoR , MorinD , et al. Prospective, randomized trial comparing short and long intravenous antibiotic treatment of acute pyelonephritis in children: dimercaptosuccinic acid scintigraphic evaluation at 9 months. Pediatrics2008;121(3):e553‐60. [MEDLINE: 18267977] ">Bouissou 2008</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003772-bbs2-0011" title="FrancoisP , BensmanA , BegueP , ArtazM‐A , CoudevilleL , LebrunT , et al. Assessment of the efficacy and cost efficiency of two strategies in the treatment of acute pyelonephritis in children: oral cefixime or parenteral ceftriaxone after an initial IV combination therapy [Evaluation de l'efficacité et du coût de deux stratégies thérapeutiques dans les pyélonéphrites de l'enfant: céfixime per os versus ceftriaxone parentérale en relais d'une bithérapie intraveineuse]. Medecine et Maladies Infectieuses1997;27(Spec Iss June):667‐73. [EMBASE: 1997230388] ">Francois 1997</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003772-bbs2-0017" title="LevtchenkoE , LahyC , LevyJ , HamH , PiepszA . Treatment of children with acute pyelonephritis: a prospective randomized study. Pediatric Nephrology2001;16(11):878‐84. [MEDLINE: 11685593] ">Levtchenko 2001</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003772-bbs2-0021" title="NoorbakhshS , LariAR , MasjedianF , MostafaviH , AlaghehbandanR . Comparison of intravenous aminoglycoside therapy with switch therapy to cefixime in urinary tract infections. Saudi Medical Journal2004;25(10):1513‐5. [MEDLINE: 15494842] ">Noorbakhsh 2004</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003772-bbs2-0027" title="VilaichoneA , WatanaD , ChaiwatanaratT . Oral ceftibuten switch therapy for acute pyelonephritis in children. Journal of the Medical Association of Thailand2001;84 Suppl(1):61‐7. [MEDLINE: 11529382] ">Vilaichone 2001</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Single dose parenteral therapy and oral therapy versus oral therapy alone</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003772-bbs2-0001" title="BakerPC , NelsonDS , SchunkJE . The addition of ceftriaxone to oral therapy does not improve outcome in febrile children with urinary tract infections. Archives of Pediatrics &amp; Adolescent Medicine2001;155(2):135‐9. [MEDLINE: 11177086] ">Baker 2001</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Different dosing regimens of aminoglycoside therapy</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003772-bbs2-0007" title="CarapetisJ , JaquieryA , ButteryJ , StarrM . A randomised controlled trial of once‐daily gentamicin in children with urinary tract infections [abstract]. Australian &amp; New Zealand Journal of Medicine1999;29:608. [CENTRAL: CN‐00583423] CarapetisJ , JaquieryA , ButteryJ , StarrM , CranswickN , KohnS , et al. Randomized, controlled trial comparing once daily and three times daily gentamicin in children with urinary tract infections. Pediatric Infectious Disease Journal2001;20(3):240‐6. [MEDLINE: 11303823] ">Carapetis 2001</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003772-bbs2-0009" title="ChaoSM , ChongCY , Tan‐HendrickA , TanAS , NgWY . Efficacy and safety of once‐a‐day gentamicin in the treatment of childhood acute pyelonephritis [abstract]. Pediatric Nephrology2001;16(8):C105. [CENTRAL: CN‐00444755] ChongCY , TanAS , NgW , Tan‐KendrickA , BalakrishnanA , ChaoSM . Treatment of urinary tract infection with gentamicin once or three times daily. Acta Paediatrica2003;92(3):291‐6. [MEDLINE: 12725542] ">Chong 2003</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003772-bbs2-0026" title="ViganoA , PrincipiN , BrivioL , TommasiP , StasiP , VillaAD . Comparison of 5 milligrams of netilmicin per kilogram of body weight once daily versus 2 milligrams per kilogram thrice daily for treatment of gram‐negative pyelonephritis in children. Antimicrobial Agents &amp; Chemotherapy1992;36(7):1499‐503. [MEDLINE: 92378248] ">Vigano 1992</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Third generation cephalosporins versus other antibiotics</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003772-bbs2-0003" title="BanfiAG , Hill‐JuarezJM , KaufmanA , MoensE . Multinational comparative trial of ceftibuten and trimethoprim‐sulfamethoxazole in the treatment of children with complicated or recurrent urinary tract infections. Members of the ceftibuten urinary tract infection international study group. Pediatric Infectious Disease Journal1993;12(6 Suppl):S84‐S91. [CENTRAL: CN‐00334829] ">Banfi 1993</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003772-bbs2-0010" title="FischbachM , SimeoniU , MengusL , JehlF , MonteilH , GeisertJ , et al. Urinary tract infections with tissue penetration in children: cefotaxime compared with amoxycillin/clavulanate. Journal of Antimicrobial Chemotherapy1989;24(Suppl B):177‐83. [MEDLINE: 2691478] ">Fischbach 1989</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003772-bbs2-0018" title="MarildS , EsbjornerE , JakobssonB , LinneT , LubeckP , SjogrenI , et al. Randomised study of ceftibuten vs trimethoprim‐sulfamethoxazole in pyelonephritis in children [abstract no: P466]. Pediatric Nephrology2004;19(9):C208. MarildS , JodalU , SandbergT . Ceftibuten versus trimethoprim‐sulfamethoxazole for oral treatment of febrile urinary tract infection in children. Pediatric Nephrology2009;24(3):521‐6. [MEDLINE: 18818954] ">Marild 2009</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003772-bbs2-0025" title="ToporovskiJ , SteffensL , NoackM , KranzA , BurdeskaA , KisslingM . Effectiveness of cefetamet pivoxil in the treatment of pyelonephritis in children. Journal of International Medical Research1992;20(1):87‐93. [MEDLINE: 1568523] ">Toporovski 1992</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Third generation cephalosporins versus fourth generation cephalosporins</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003772-bbs2-0024" title="SchaadUB , EskolaJ , KafetzisD , FischbachM , AshekenaziS , SyriopoulouV , et al. Cefepine vs. ceftazidime treatment of pyelonephritis: a European, randomized, controlled study of 300 pediatric cases. European Society for Paediatric Infectious Diseases (ESPID) Pyelonephritis Study Group. Pediatric Infectious Disease Journal1998;17(7):639‐44. [MEDLINE: 9686732] ">Schaad 1998</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Ceftriaxone versus cefotaxime</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003772-bbs2-0002" title="BakkalogluA , SaatciU , SoylemezogluO , OzenS , TopalogluR , BesbasN , et al. Comparison of ceftriaxone versus cefotaxime for childhood upper urinary tract infections. Journal of Chemotherapy1996;8(1):59‐62. [MEDLINE: 8835111] ">Bakkaloglu 1996</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Aminoglycosides versus aminoglycosides</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003772-bbs2-0015" title="KafetzisDA , MaltezouHC , MavrikouM , SiafasC , ParaskakisI , DelisD , et al. Isepamicin versus amikacin for the treatment of acute pyelonephritis in children. International Journal of Antimicrobial Agents2000;14(1):51‐5. [MEDLINE: 10717501] ">Kafetzis 2000</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Different durations of the same oral antibiotic</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003772-bbs2-0022" title="PylkkänenJ , VilskaJ , KoskimiesO . The length of antimicrobial therapy in upper vs. lower urinary tract infection of childhood. Acta Paediatrica Scandinavica1981;70(6):885‐8. [MEDLINE: 7324942] PylkkänenJ , VilskaJ , KoskimiesO . The value of level diagnosis of childhood urinary tract infection in predicting renal injury. Acta Paediatrica Scandinavica1981;70(6):879‐83. [MEDLINE: 7324941] ">Pylkkänen 1981</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Single dose parenteral therapy versus oral therapy alone</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003772-bbs2-0013" title="GrimwoodK , AbbottGD , FergussonDM . Single dose gentamicin treatment of urinary infections in children. New Zealand Medical Journal1988;101(852):539‐41. [MEDLINE: 3045718] ">Grimwood 1988</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003772-bbs2-0023" title="RepettoHA , MacLoughlinGJ . Single‐dose cefotaxime in the treatment of urinary tract infections in children: a randomized clinical trial. Journal of Antimicrobial Chemotherapy1984;14(Suppl B):307‐10. [MEDLINE: 6094457] ">Repetto 1984</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Different durations of different antibiotics</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003772-bbs2-0008" title="ChengCH , TsauYK , ChangCJ , ChangYC , KuoCY , TsaiIJ , et al. Acute lobar nephronia is associated with a high incidence of renal scarring in childhood urinary tract infections. Pediatric Infectious Disease Journal2010;29(7):624‐8. [MEDLINE: 20234330] ChengCH , TsauYK , LinTY . Effective duration of antimicrobial therapy for the treatment of acute lobar nephronia. Pediatrics2006;117(1):e84‐9. [MEDLINE: 16326693] ">Cheng 2006</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Different routes of antibiotic administration</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003772-bbs2-0012" title="FujiiR , ShinozakiT , MeguroH , ArimasuO , IzumiK , OsanoM , et al. Comparative, controlled study on an ampicillin suppository (KS‐R 1) with an oral form of ampicillin in urinary tract infections. Japanese Journal of Antibiotics1987;40(3):476‐92. [MEDLINE: 3302342] ">Fujii 1987</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Three days versus 10 days of oral therapy</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003772-bbs2-0016" title="KahnAJ , KumarK , EvansHE . Three‐day antimicrobial therapy of urinary tract infection. Journal of Pediatrics1981;99(6):992‐4. [MEDLINE: 7031217] ">Khan 1981</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> <div class="table-footnote"> <p>DMSA ‐ Tc99m‐dimercaptosuccinic acid nuclear scan; UTI ‐ urinary tract infection</p> </div> </div> </section> </section> <section id="CD003772-sec-0070"> <h4 class="title">Excluded studies</h4> <p>We excluded a total of 43 studies because: data from children with acute pyelonephritis could not be separated from those with lower UTI (18), children had lower UTI only (8), antibiotics were studied as prophylactic agents (5), the studies involved ineligible interventions or populations (5) or the study was not randomised (7). </p> </section> </section> <section id="CD003772-sec-0071"> <h3 class="title">Risk of bias in included studies</h3> <p>The assessment of risk of bias is shown in <a href="#CD003772-fig-0002">Figure 2</a> and <a href="#CD003772-fig-0003">Figure 3</a>. <a href="#CD003772-fig-0002">Figure 2</a> shows the proportion of studies assessed as low, high or unclear risk of bias for each risk of bias indicator. <a href="#CD003772-fig-0003">Figure 3</a> shows the risk of bias indicators for individual studies. </p> <div class="figure" id="CD003772-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD003772-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD003772-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003772-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD003772-sec-0072"> <h4 class="title">Allocation</h4> <p>Sequence generation was considered to be at low risk of bias in 12 studies (<a href="./references#CD003772-bbs2-0001" title="BakerPC , NelsonDS , SchunkJE . The addition of ceftriaxone to oral therapy does not improve outcome in febrile children with urinary tract infections. Archives of Pediatrics &amp; Adolescent Medicine2001;155(2):135‐9. [MEDLINE: 11177086] ">Baker 2001</a>; <a href="./references#CD003772-bbs2-0004" title="BenadorD , NeuhausTJ , PapazyanJ‐P , WilliUV , Engel‐BicikI , NadalD , et al. Randomised controlled trial of three day versus 10 day intravenous antibiotics in acute pyelonephritis: effect on renal scarring. Archives of Disease in Childhood2001;84(3):241‐6. [MEDLINE: 11207174] GirardinE , NeuhausT , PapazyanJ , WilliUV , BicikI , NadalD , et al. Acute pyelonephritis: comparison of 3 vs 10 days IV antibiotic treatment [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):592A. [CENTRAL: CN‐00583905] ">Benador 2001</a>; <a href="./references#CD003772-bbs2-0005" title="BocquetN , Sergent AlaouiA , JaisJP , GajdosV , GuigonisV , LacourB , et al. Randomized trial of oral versus sequential IV/oral antibiotic for acute pyelonephritis in children. Pediatrics2012;129(2):e269‐75. [MEDLINE: 22291112] ">Bocquet 2012</a>; <a href="./references#CD003772-bbs2-0006" title="BouissouF , MunzerC , DecramerS , RousselB , NovoR , MorinD , et al. Prospective, randomized trial comparing short and long intravenous antibiotic treatment of acute pyelonephritis in children: dimercaptosuccinic acid scintigraphic evaluation at 9 months. Pediatrics2008;121(3):e553‐60. [MEDLINE: 18267977] ">Bouissou 2008</a>; <a href="./references#CD003772-bbs2-0007" title="CarapetisJ , JaquieryA , ButteryJ , StarrM . A randomised controlled trial of once‐daily gentamicin in children with urinary tract infections [abstract]. Australian &amp; New Zealand Journal of Medicine1999;29:608. [CENTRAL: CN‐00583423] CarapetisJ , JaquieryA , ButteryJ , StarrM , CranswickN , KohnS , et al. Randomized, controlled trial comparing once daily and three times daily gentamicin in children with urinary tract infections. Pediatric Infectious Disease Journal2001;20(3):240‐6. [MEDLINE: 11303823] ">Carapetis 2001</a>; <a href="./references#CD003772-bbs2-0010" title="FischbachM , SimeoniU , MengusL , JehlF , MonteilH , GeisertJ , et al. Urinary tract infections with tissue penetration in children: cefotaxime compared with amoxycillin/clavulanate. Journal of Antimicrobial Chemotherapy1989;24(Suppl B):177‐83. [MEDLINE: 2691478] ">Fischbach 1989</a>; <a href="./references#CD003772-bbs2-0011" title="FrancoisP , BensmanA , BegueP , ArtazM‐A , CoudevilleL , LebrunT , et al. Assessment of the efficacy and cost efficiency of two strategies in the treatment of acute pyelonephritis in children: oral cefixime or parenteral ceftriaxone after an initial IV combination therapy [Evaluation de l'efficacité et du coût de deux stratégies thérapeutiques dans les pyélonéphrites de l'enfant: céfixime per os versus ceftriaxone parentérale en relais d'une bithérapie intraveineuse]. Medecine et Maladies Infectieuses1997;27(Spec Iss June):667‐73. [EMBASE: 1997230388] ">Francois 1997</a>; <a href="./references#CD003772-bbs2-0013" title="GrimwoodK , AbbottGD , FergussonDM . Single dose gentamicin treatment of urinary infections in children. New Zealand Medical Journal1988;101(852):539‐41. [MEDLINE: 3045718] ">Grimwood 1988</a>; <a href="./references#CD003772-bbs2-0018" title="MarildS , EsbjornerE , JakobssonB , LinneT , LubeckP , SjogrenI , et al. Randomised study of ceftibuten vs trimethoprim‐sulfamethoxazole in pyelonephritis in children [abstract no: P466]. Pediatric Nephrology2004;19(9):C208. MarildS , JodalU , SandbergT . Ceftibuten versus trimethoprim‐sulfamethoxazole for oral treatment of febrile urinary tract infection in children. Pediatric Nephrology2009;24(3):521‐6. [MEDLINE: 18818954] ">Marild 2009</a>; <a href="./references#CD003772-bbs2-0019" title="HewittIK , TomasiL , PavanelloL , MaschioF , MolinariPP , ToffoloA , et al. Early treatment of acute pyelonephritis in children fails to reduce renal scarring [abstract no: SA‐PO1100]. Journal of the American Society of Nephrology2006;17(Abstracts):804A. [CENTRAL: CN‐00653791] HewittIK , ZucchettaP , RigonL , MaschioF , MolinariPP , TomasiL , et al. Early treatment of acute pyelonephritis in children fails to reduce renal scarring: data from the Italian Renal Infection Study Trials. Pediatrics2008;122(3):486‐90. [MEDLINE: 18762516] LaScolaC , DeMutiisC , HewittIK , PuccioG , ToffoloA , ZucchettaP , et al. Different guidelines for imaging after first UTI in febrile infants: yield, cost, and radiation. Pediatrics2013;131(3):e665‐71. [MEDLINE: 23439905] MontiniG , MurerL , GobberD , CommacchioS , ToffoloA , Dall'AmicoR , et al. Oral vs initial intravenous antibiotic treatment of urinary tract infections in children: a multicentre study [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):816. [CENTRAL: CN‐00446817] MontiniG , ToffoloA , ZucchettaP , Dall'AmicoR , GobberD , CalderonA , et al. Antibiotic treatment for pyelonephritis in children: multicentre randomised controlled non‐inferiority trial. BMJ2007;335(7616):386‐92. [MEDLINE: 17611232] MontiniG , ZucchettaP , GobberD , MurerL , RigonL , ToffoloA , et al. Usefulness of renal radiology and scintigraphy in children with a first episode of upper urinary tract infection [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):813. [CENTRAL: CN‐00446818] MontiniG , ZucchettaP , TomasiL , TalentiE , RigamontiW , PiccoG , et al. Value of imaging studies after a first febrile urinary tract infection in young children: data from Italian renal infection study 1. Pediatrics2009;123(2):e239‐46. [MEDLINE: 19139086] ">Montini 2007</a>; <a href="./references#CD003772-bbs2-0020" title="BuechnerK , GirardinF , BergerC , WilliU , NadafD , Neuhaus T for the Swiss Pyelonephritis Study Group. Randomised controlled trial of oral versus sequential intravenous/oral cephalosporins in DMSA scintigraphy‐documented acute pyelonephritis [abstract no: COD. OP 18]. Pediatric Nephrology2006;21(10):1511. [CENTRAL: CN‐00601934] NeuhausTJ , BergerC , BuechnerK , ParvexP , BischoffG , GoetschelP , et al. Randomised trial of oral versus sequential intravenous/oral cephalosporins in children with pyelonephritis. European Journal of Pediatrics2008;167(9):1037‐47. [MEDLINE: 18074149] NeuhausTJ , BüchnerK , GirardinE , WilliU , BergerC , NadalD . Oral versus sequential intravenous/oral cephalosporin‐therapy in DMSA‐scintigraphy documented acute pyelonephritis: randomized Swiss pyelonephritis‐study [abstract] [Orale versus sequentiell intravenös/orale Cephalosporin‐Therapie bei DMSA‐Szintigraphie dokumentierter akuter Pyelonephritis: Randomisierte Schweizer Pyelonephritis‐Studie]. Nieren‐ und Hochdruckkrankheiten2007;36(2):43. [CENTRAL: CN‐00615897] ">Neuhaus 2008</a>; <a href="./references#CD003772-bbs2-0025" title="ToporovskiJ , SteffensL , NoackM , KranzA , BurdeskaA , KisslingM . Effectiveness of cefetamet pivoxil in the treatment of pyelonephritis in children. Journal of International Medical Research1992;20(1):87‐93. [MEDLINE: 1568523] ">Toporovski 1992</a>) and assessed at high risk in three studies (<a href="./references#CD003772-bbs2-0008" title="ChengCH , TsauYK , ChangCJ , ChangYC , KuoCY , TsaiIJ , et al. Acute lobar nephronia is associated with a high incidence of renal scarring in childhood urinary tract infections. Pediatric Infectious Disease Journal2010;29(7):624‐8. [MEDLINE: 20234330] ChengCH , TsauYK , LinTY . Effective duration of antimicrobial therapy for the treatment of acute lobar nephronia. Pediatrics2006;117(1):e84‐9. [MEDLINE: 16326693] ">Cheng 2006</a>; <a href="./references#CD003772-bbs2-0016" title="KahnAJ , KumarK , EvansHE . Three‐day antimicrobial therapy of urinary tract infection. Journal of Pediatrics1981;99(6):992‐4. [MEDLINE: 7031217] ">Khan 1981</a>; <a href="./references#CD003772-bbs2-0021" title="NoorbakhshS , LariAR , MasjedianF , MostafaviH , AlaghehbandanR . Comparison of intravenous aminoglycoside therapy with switch therapy to cefixime in urinary tract infections. Saudi Medical Journal2004;25(10):1513‐5. [MEDLINE: 15494842] ">Noorbakhsh 2004</a>). Randomisation methods were not reported in 12 studies. </p> <p>Allocation concealment was considered to be at low risk of bias in six studies (<a href="./references#CD003772-bbs2-0001" title="BakerPC , NelsonDS , SchunkJE . The addition of ceftriaxone to oral therapy does not improve outcome in febrile children with urinary tract infections. Archives of Pediatrics &amp; Adolescent Medicine2001;155(2):135‐9. [MEDLINE: 11177086] ">Baker 2001</a>; <a href="./references#CD003772-bbs2-0004" title="BenadorD , NeuhausTJ , PapazyanJ‐P , WilliUV , Engel‐BicikI , NadalD , et al. Randomised controlled trial of three day versus 10 day intravenous antibiotics in acute pyelonephritis: effect on renal scarring. Archives of Disease in Childhood2001;84(3):241‐6. [MEDLINE: 11207174] GirardinE , NeuhausT , PapazyanJ , WilliUV , BicikI , NadalD , et al. Acute pyelonephritis: comparison of 3 vs 10 days IV antibiotic treatment [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):592A. [CENTRAL: CN‐00583905] ">Benador 2001</a>; <a href="./references#CD003772-bbs2-0006" title="BouissouF , MunzerC , DecramerS , RousselB , NovoR , MorinD , et al. Prospective, randomized trial comparing short and long intravenous antibiotic treatment of acute pyelonephritis in children: dimercaptosuccinic acid scintigraphic evaluation at 9 months. Pediatrics2008;121(3):e553‐60. [MEDLINE: 18267977] ">Bouissou 2008</a>; <a href="./references#CD003772-bbs2-0018" title="MarildS , EsbjornerE , JakobssonB , LinneT , LubeckP , SjogrenI , et al. Randomised study of ceftibuten vs trimethoprim‐sulfamethoxazole in pyelonephritis in children [abstract no: P466]. Pediatric Nephrology2004;19(9):C208. MarildS , JodalU , SandbergT . Ceftibuten versus trimethoprim‐sulfamethoxazole for oral treatment of febrile urinary tract infection in children. Pediatric Nephrology2009;24(3):521‐6. [MEDLINE: 18818954] ">Marild 2009</a>; <a href="./references#CD003772-bbs2-0019" title="HewittIK , TomasiL , PavanelloL , MaschioF , MolinariPP , ToffoloA , et al. Early treatment of acute pyelonephritis in children fails to reduce renal scarring [abstract no: SA‐PO1100]. Journal of the American Society of Nephrology2006;17(Abstracts):804A. [CENTRAL: CN‐00653791] HewittIK , ZucchettaP , RigonL , MaschioF , MolinariPP , TomasiL , et al. Early treatment of acute pyelonephritis in children fails to reduce renal scarring: data from the Italian Renal Infection Study Trials. Pediatrics2008;122(3):486‐90. [MEDLINE: 18762516] LaScolaC , DeMutiisC , HewittIK , PuccioG , ToffoloA , ZucchettaP , et al. Different guidelines for imaging after first UTI in febrile infants: yield, cost, and radiation. Pediatrics2013;131(3):e665‐71. [MEDLINE: 23439905] MontiniG , MurerL , GobberD , CommacchioS , ToffoloA , Dall'AmicoR , et al. Oral vs initial intravenous antibiotic treatment of urinary tract infections in children: a multicentre study [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):816. [CENTRAL: CN‐00446817] MontiniG , ToffoloA , ZucchettaP , Dall'AmicoR , GobberD , CalderonA , et al. Antibiotic treatment for pyelonephritis in children: multicentre randomised controlled non‐inferiority trial. BMJ2007;335(7616):386‐92. [MEDLINE: 17611232] MontiniG , ZucchettaP , GobberD , MurerL , RigonL , ToffoloA , et al. Usefulness of renal radiology and scintigraphy in children with a first episode of upper urinary tract infection [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):813. [CENTRAL: CN‐00446818] MontiniG , ZucchettaP , TomasiL , TalentiE , RigamontiW , PiccoG , et al. Value of imaging studies after a first febrile urinary tract infection in young children: data from Italian renal infection study 1. Pediatrics2009;123(2):e239‐46. [MEDLINE: 19139086] ">Montini 2007</a>; <a href="./references#CD003772-bbs2-0020" title="BuechnerK , GirardinF , BergerC , WilliU , NadafD , Neuhaus T for the Swiss Pyelonephritis Study Group. Randomised controlled trial of oral versus sequential intravenous/oral cephalosporins in DMSA scintigraphy‐documented acute pyelonephritis [abstract no: COD. OP 18]. Pediatric Nephrology2006;21(10):1511. [CENTRAL: CN‐00601934] NeuhausTJ , BergerC , BuechnerK , ParvexP , BischoffG , GoetschelP , et al. Randomised trial of oral versus sequential intravenous/oral cephalosporins in children with pyelonephritis. European Journal of Pediatrics2008;167(9):1037‐47. [MEDLINE: 18074149] NeuhausTJ , BüchnerK , GirardinE , WilliU , BergerC , NadalD . Oral versus sequential intravenous/oral cephalosporin‐therapy in DMSA‐scintigraphy documented acute pyelonephritis: randomized Swiss pyelonephritis‐study [abstract] [Orale versus sequentiell intravenös/orale Cephalosporin‐Therapie bei DMSA‐Szintigraphie dokumentierter akuter Pyelonephritis: Randomisierte Schweizer Pyelonephritis‐Studie]. Nieren‐ und Hochdruckkrankheiten2007;36(2):43. [CENTRAL: CN‐00615897] ">Neuhaus 2008</a>) and high risk in three studies (<a href="./references#CD003772-bbs2-0008" title="ChengCH , TsauYK , ChangCJ , ChangYC , KuoCY , TsaiIJ , et al. Acute lobar nephronia is associated with a high incidence of renal scarring in childhood urinary tract infections. Pediatric Infectious Disease Journal2010;29(7):624‐8. [MEDLINE: 20234330] ChengCH , TsauYK , LinTY . Effective duration of antimicrobial therapy for the treatment of acute lobar nephronia. Pediatrics2006;117(1):e84‐9. [MEDLINE: 16326693] ">Cheng 2006</a>; <a href="./references#CD003772-bbs2-0016" title="KahnAJ , KumarK , EvansHE . Three‐day antimicrobial therapy of urinary tract infection. Journal of Pediatrics1981;99(6):992‐4. [MEDLINE: 7031217] ">Khan 1981</a>;<a href="./references#CD003772-bbs2-0021" title="NoorbakhshS , LariAR , MasjedianF , MostafaviH , AlaghehbandanR . Comparison of intravenous aminoglycoside therapy with switch therapy to cefixime in urinary tract infections. Saudi Medical Journal2004;25(10):1513‐5. [MEDLINE: 15494842] ">Noorbakhsh 2004</a>). Allocation concealment was assessed as unclear in 18 studies. </p> </section> <section id="CD003772-sec-0073"> <h4 class="title">Blinding</h4> <p>Participants and investigators were not blinded in any of the included studies. The absence of blinding was considered to be a high risk of bias because symptom reporting and clinical management could be influenced by knowledge of the treatment group (performance bias). <a href="./references#CD003772-bbs2-0002" title="BakkalogluA , SaatciU , SoylemezogluO , OzenS , TopalogluR , BesbasN , et al. Comparison of ceftriaxone versus cefotaxime for childhood upper urinary tract infections. Journal of Chemotherapy1996;8(1):59‐62. [MEDLINE: 8835111] ">Bakkaloglu 1996</a> was reported to be double‐blinded but antibiotics were administered at different frequencies and no placebos were given. </p> <p>Outcome assessors (detection bias) were blinded in 17 studies (<a href="./references#CD003772-bbs2-0001" title="BakerPC , NelsonDS , SchunkJE . The addition of ceftriaxone to oral therapy does not improve outcome in febrile children with urinary tract infections. Archives of Pediatrics &amp; Adolescent Medicine2001;155(2):135‐9. [MEDLINE: 11177086] ">Baker 2001</a>; <a href="./references#CD003772-bbs2-0004" title="BenadorD , NeuhausTJ , PapazyanJ‐P , WilliUV , Engel‐BicikI , NadalD , et al. Randomised controlled trial of three day versus 10 day intravenous antibiotics in acute pyelonephritis: effect on renal scarring. Archives of Disease in Childhood2001;84(3):241‐6. [MEDLINE: 11207174] GirardinE , NeuhausT , PapazyanJ , WilliUV , BicikI , NadalD , et al. Acute pyelonephritis: comparison of 3 vs 10 days IV antibiotic treatment [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):592A. [CENTRAL: CN‐00583905] ">Benador 2001</a>; <a href="./references#CD003772-bbs2-0005" title="BocquetN , Sergent AlaouiA , JaisJP , GajdosV , GuigonisV , LacourB , et al. Randomized trial of oral versus sequential IV/oral antibiotic for acute pyelonephritis in children. Pediatrics2012;129(2):e269‐75. [MEDLINE: 22291112] ">Bocquet 2012</a>; <a href="./references#CD003772-bbs2-0006" title="BouissouF , MunzerC , DecramerS , RousselB , NovoR , MorinD , et al. Prospective, randomized trial comparing short and long intravenous antibiotic treatment of acute pyelonephritis in children: dimercaptosuccinic acid scintigraphic evaluation at 9 months. Pediatrics2008;121(3):e553‐60. [MEDLINE: 18267977] ">Bouissou 2008</a>; <a href="./references#CD003772-bbs2-0009" title="ChaoSM , ChongCY , Tan‐HendrickA , TanAS , NgWY . Efficacy and safety of once‐a‐day gentamicin in the treatment of childhood acute pyelonephritis [abstract]. Pediatric Nephrology2001;16(8):C105. [CENTRAL: CN‐00444755] ChongCY , TanAS , NgW , Tan‐KendrickA , BalakrishnanA , ChaoSM . Treatment of urinary tract infection with gentamicin once or three times daily. Acta Paediatrica2003;92(3):291‐6. [MEDLINE: 12725542] ">Chong 2003</a>; <a href="./references#CD003772-bbs2-0011" title="FrancoisP , BensmanA , BegueP , ArtazM‐A , CoudevilleL , LebrunT , et al. Assessment of the efficacy and cost efficiency of two strategies in the treatment of acute pyelonephritis in children: oral cefixime or parenteral ceftriaxone after an initial IV combination therapy [Evaluation de l'efficacité et du coût de deux stratégies thérapeutiques dans les pyélonéphrites de l'enfant: céfixime per os versus ceftriaxone parentérale en relais d'une bithérapie intraveineuse]. Medecine et Maladies Infectieuses1997;27(Spec Iss June):667‐73. [EMBASE: 1997230388] ">Francois 1997</a>; <a href="./references#CD003772-bbs2-0013" title="GrimwoodK , AbbottGD , FergussonDM . Single dose gentamicin treatment of urinary infections in children. New Zealand Medical Journal1988;101(852):539‐41. [MEDLINE: 3045718] ">Grimwood 1988</a>; <a href="./references#CD003772-bbs2-0014" title="HobermanA , WaldER . Intravenous versus oral antibiotics for urinary tract infections. Pediatrics2000;106(4):865. [MEDLINE: 11183178] HobermanA , WaldER , HickeyRW , BaskinM , CharronM , MajdM , et al. Oral versus initial intravenous therapy for urinary tract infections in young febrile children. Pediatrics1999;104(1 Pt 1):79‐86. [MEDLINE: 10390264] ">Hoberman 1999</a>; <a href="./references#CD003772-bbs2-0015" title="KafetzisDA , MaltezouHC , MavrikouM , SiafasC , ParaskakisI , DelisD , et al. Isepamicin versus amikacin for the treatment of acute pyelonephritis in children. International Journal of Antimicrobial Agents2000;14(1):51‐5. [MEDLINE: 10717501] ">Kafetzis 2000</a>; <a href="./references#CD003772-bbs2-0016" title="KahnAJ , KumarK , EvansHE . Three‐day antimicrobial therapy of urinary tract infection. Journal of Pediatrics1981;99(6):992‐4. [MEDLINE: 7031217] ">Khan 1981</a>; <a href="./references#CD003772-bbs2-0017" title="LevtchenkoE , LahyC , LevyJ , HamH , PiepszA . Treatment of children with acute pyelonephritis: a prospective randomized study. Pediatric Nephrology2001;16(11):878‐84. [MEDLINE: 11685593] ">Levtchenko 2001</a>; <a href="./references#CD003772-bbs2-0019" title="HewittIK , TomasiL , PavanelloL , MaschioF , MolinariPP , ToffoloA , et al. Early treatment of acute pyelonephritis in children fails to reduce renal scarring [abstract no: SA‐PO1100]. Journal of the American Society of Nephrology2006;17(Abstracts):804A. [CENTRAL: CN‐00653791] HewittIK , ZucchettaP , RigonL , MaschioF , MolinariPP , TomasiL , et al. Early treatment of acute pyelonephritis in children fails to reduce renal scarring: data from the Italian Renal Infection Study Trials. Pediatrics2008;122(3):486‐90. [MEDLINE: 18762516] LaScolaC , DeMutiisC , HewittIK , PuccioG , ToffoloA , ZucchettaP , et al. Different guidelines for imaging after first UTI in febrile infants: yield, cost, and radiation. Pediatrics2013;131(3):e665‐71. [MEDLINE: 23439905] MontiniG , MurerL , GobberD , CommacchioS , ToffoloA , Dall'AmicoR , et al. Oral vs initial intravenous antibiotic treatment of urinary tract infections in children: a multicentre study [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):816. [CENTRAL: CN‐00446817] MontiniG , ToffoloA , ZucchettaP , Dall'AmicoR , GobberD , CalderonA , et al. Antibiotic treatment for pyelonephritis in children: multicentre randomised controlled non‐inferiority trial. BMJ2007;335(7616):386‐92. [MEDLINE: 17611232] MontiniG , ZucchettaP , GobberD , MurerL , RigonL , ToffoloA , et al. Usefulness of renal radiology and scintigraphy in children with a first episode of upper urinary tract infection [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):813. [CENTRAL: CN‐00446818] MontiniG , ZucchettaP , TomasiL , TalentiE , RigamontiW , PiccoG , et al. Value of imaging studies after a first febrile urinary tract infection in young children: data from Italian renal infection study 1. Pediatrics2009;123(2):e239‐46. [MEDLINE: 19139086] ">Montini 2007</a>; <a href="./references#CD003772-bbs2-0020" title="BuechnerK , GirardinF , BergerC , WilliU , NadafD , Neuhaus T for the Swiss Pyelonephritis Study Group. Randomised controlled trial of oral versus sequential intravenous/oral cephalosporins in DMSA scintigraphy‐documented acute pyelonephritis [abstract no: COD. OP 18]. Pediatric Nephrology2006;21(10):1511. [CENTRAL: CN‐00601934] NeuhausTJ , BergerC , BuechnerK , ParvexP , BischoffG , GoetschelP , et al. Randomised trial of oral versus sequential intravenous/oral cephalosporins in children with pyelonephritis. European Journal of Pediatrics2008;167(9):1037‐47. [MEDLINE: 18074149] NeuhausTJ , BüchnerK , GirardinE , WilliU , BergerC , NadalD . Oral versus sequential intravenous/oral cephalosporin‐therapy in DMSA‐scintigraphy documented acute pyelonephritis: randomized Swiss pyelonephritis‐study [abstract] [Orale versus sequentiell intravenös/orale Cephalosporin‐Therapie bei DMSA‐Szintigraphie dokumentierter akuter Pyelonephritis: Randomisierte Schweizer Pyelonephritis‐Studie]. Nieren‐ und Hochdruckkrankheiten2007;36(2):43. [CENTRAL: CN‐00615897] ">Neuhaus 2008</a>; <a href="./references#CD003772-bbs2-0022" title="PylkkänenJ , VilskaJ , KoskimiesO . The length of antimicrobial therapy in upper vs. lower urinary tract infection of childhood. Acta Paediatrica Scandinavica1981;70(6):885‐8. [MEDLINE: 7324942] PylkkänenJ , VilskaJ , KoskimiesO . The value of level diagnosis of childhood urinary tract infection in predicting renal injury. Acta Paediatrica Scandinavica1981;70(6):879‐83. [MEDLINE: 7324941] ">Pylkkänen 1981</a>; <a href="./references#CD003772-bbs2-0024" title="SchaadUB , EskolaJ , KafetzisD , FischbachM , AshekenaziS , SyriopoulouV , et al. Cefepine vs. ceftazidime treatment of pyelonephritis: a European, randomized, controlled study of 300 pediatric cases. European Society for Paediatric Infectious Diseases (ESPID) Pyelonephritis Study Group. Pediatric Infectious Disease Journal1998;17(7):639‐44. [MEDLINE: 9686732] ">Schaad 1998</a>; <a href="./references#CD003772-bbs2-0026" title="ViganoA , PrincipiN , BrivioL , TommasiP , StasiP , VillaAD . Comparison of 5 milligrams of netilmicin per kilogram of body weight once daily versus 2 milligrams per kilogram thrice daily for treatment of gram‐negative pyelonephritis in children. Antimicrobial Agents &amp; Chemotherapy1992;36(7):1499‐503. [MEDLINE: 92378248] ">Vigano 1992</a>; <a href="./references#CD003772-bbs2-0027" title="VilaichoneA , WatanaD , ChaiwatanaratT . Oral ceftibuten switch therapy for acute pyelonephritis in children. Journal of the Medical Association of Thailand2001;84 Suppl(1):61‐7. [MEDLINE: 11529382] ">Vilaichone 2001</a>). Blinding of outcome assessors was not carried out in nine studies (<a href="./references#CD003772-bbs2-0002" title="BakkalogluA , SaatciU , SoylemezogluO , OzenS , TopalogluR , BesbasN , et al. Comparison of ceftriaxone versus cefotaxime for childhood upper urinary tract infections. Journal of Chemotherapy1996;8(1):59‐62. [MEDLINE: 8835111] ">Bakkaloglu 1996</a>; <a href="./references#CD003772-bbs2-0003" title="BanfiAG , Hill‐JuarezJM , KaufmanA , MoensE . Multinational comparative trial of ceftibuten and trimethoprim‐sulfamethoxazole in the treatment of children with complicated or recurrent urinary tract infections. Members of the ceftibuten urinary tract infection international study group. Pediatric Infectious Disease Journal1993;12(6 Suppl):S84‐S91. [CENTRAL: CN‐00334829] ">Banfi 1993</a>; <a href="./references#CD003772-bbs2-0007" title="CarapetisJ , JaquieryA , ButteryJ , StarrM . A randomised controlled trial of once‐daily gentamicin in children with urinary tract infections [abstract]. Australian &amp; New Zealand Journal of Medicine1999;29:608. [CENTRAL: CN‐00583423] CarapetisJ , JaquieryA , ButteryJ , StarrM , CranswickN , KohnS , et al. Randomized, controlled trial comparing once daily and three times daily gentamicin in children with urinary tract infections. Pediatric Infectious Disease Journal2001;20(3):240‐6. [MEDLINE: 11303823] ">Carapetis 2001</a>; <a href="./references#CD003772-bbs2-0008" title="ChengCH , TsauYK , ChangCJ , ChangYC , KuoCY , TsaiIJ , et al. Acute lobar nephronia is associated with a high incidence of renal scarring in childhood urinary tract infections. Pediatric Infectious Disease Journal2010;29(7):624‐8. [MEDLINE: 20234330] ChengCH , TsauYK , LinTY . Effective duration of antimicrobial therapy for the treatment of acute lobar nephronia. Pediatrics2006;117(1):e84‐9. [MEDLINE: 16326693] ">Cheng 2006</a>; <a href="./references#CD003772-bbs2-0010" title="FischbachM , SimeoniU , MengusL , JehlF , MonteilH , GeisertJ , et al. Urinary tract infections with tissue penetration in children: cefotaxime compared with amoxycillin/clavulanate. Journal of Antimicrobial Chemotherapy1989;24(Suppl B):177‐83. [MEDLINE: 2691478] ">Fischbach 1989</a>; <a href="./references#CD003772-bbs2-0018" title="MarildS , EsbjornerE , JakobssonB , LinneT , LubeckP , SjogrenI , et al. Randomised study of ceftibuten vs trimethoprim‐sulfamethoxazole in pyelonephritis in children [abstract no: P466]. Pediatric Nephrology2004;19(9):C208. MarildS , JodalU , SandbergT . Ceftibuten versus trimethoprim‐sulfamethoxazole for oral treatment of febrile urinary tract infection in children. Pediatric Nephrology2009;24(3):521‐6. [MEDLINE: 18818954] ">Marild 2009</a>; <a href="./references#CD003772-bbs2-0021" title="NoorbakhshS , LariAR , MasjedianF , MostafaviH , AlaghehbandanR . Comparison of intravenous aminoglycoside therapy with switch therapy to cefixime in urinary tract infections. Saudi Medical Journal2004;25(10):1513‐5. [MEDLINE: 15494842] ">Noorbakhsh 2004</a>; <a href="./references#CD003772-bbs2-0023" title="RepettoHA , MacLoughlinGJ . Single‐dose cefotaxime in the treatment of urinary tract infections in children: a randomized clinical trial. Journal of Antimicrobial Chemotherapy1984;14(Suppl B):307‐10. [MEDLINE: 6094457] ">Repetto 1984</a>; <a href="./references#CD003772-bbs2-0025" title="ToporovskiJ , SteffensL , NoackM , KranzA , BurdeskaA , KisslingM . Effectiveness of cefetamet pivoxil in the treatment of pyelonephritis in children. Journal of International Medical Research1992;20(1):87‐93. [MEDLINE: 1568523] ">Toporovski 1992</a>). There was no reporting of outcome assessment blinding in <a href="./references#CD003772-bbs2-0012" title="FujiiR , ShinozakiT , MeguroH , ArimasuO , IzumiK , OsanoM , et al. Comparative, controlled study on an ampicillin suppository (KS‐R 1) with an oral form of ampicillin in urinary tract infections. Japanese Journal of Antibiotics1987;40(3):476‐92. [MEDLINE: 3302342] ">Fujii 1987</a> (abstract only available). </p> </section> <section id="CD003772-sec-0074"> <h4 class="title">Incomplete outcome data</h4> <p>Not all studies reported all outcomes. The reported outcomes from each of the included studies are summarised in <a href="#CD003772-tbl-0005">Table 1</a>. Incomplete outcome data was considered to be at low risk of bias in 19 studies because they reported outcomes in more than 90% of participants (<a href="./references#CD003772-bbs2-0001" title="BakerPC , NelsonDS , SchunkJE . The addition of ceftriaxone to oral therapy does not improve outcome in febrile children with urinary tract infections. Archives of Pediatrics &amp; Adolescent Medicine2001;155(2):135‐9. [MEDLINE: 11177086] ">Baker 2001</a>; <a href="./references#CD003772-bbs2-0002" title="BakkalogluA , SaatciU , SoylemezogluO , OzenS , TopalogluR , BesbasN , et al. Comparison of ceftriaxone versus cefotaxime for childhood upper urinary tract infections. Journal of Chemotherapy1996;8(1):59‐62. [MEDLINE: 8835111] ">Bakkaloglu 1996</a>; <a href="./references#CD003772-bbs2-0004" title="BenadorD , NeuhausTJ , PapazyanJ‐P , WilliUV , Engel‐BicikI , NadalD , et al. Randomised controlled trial of three day versus 10 day intravenous antibiotics in acute pyelonephritis: effect on renal scarring. Archives of Disease in Childhood2001;84(3):241‐6. [MEDLINE: 11207174] GirardinE , NeuhausT , PapazyanJ , WilliUV , BicikI , NadalD , et al. Acute pyelonephritis: comparison of 3 vs 10 days IV antibiotic treatment [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):592A. [CENTRAL: CN‐00583905] ">Benador 2001</a>; <a href="./references#CD003772-bbs2-0007" title="CarapetisJ , JaquieryA , ButteryJ , StarrM . A randomised controlled trial of once‐daily gentamicin in children with urinary tract infections [abstract]. Australian &amp; New Zealand Journal of Medicine1999;29:608. [CENTRAL: CN‐00583423] CarapetisJ , JaquieryA , ButteryJ , StarrM , CranswickN , KohnS , et al. Randomized, controlled trial comparing once daily and three times daily gentamicin in children with urinary tract infections. Pediatric Infectious Disease Journal2001;20(3):240‐6. [MEDLINE: 11303823] ">Carapetis 2001</a>; <a href="./references#CD003772-bbs2-0008" title="ChengCH , TsauYK , ChangCJ , ChangYC , KuoCY , TsaiIJ , et al. Acute lobar nephronia is associated with a high incidence of renal scarring in childhood urinary tract infections. Pediatric Infectious Disease Journal2010;29(7):624‐8. [MEDLINE: 20234330] ChengCH , TsauYK , LinTY . Effective duration of antimicrobial therapy for the treatment of acute lobar nephronia. Pediatrics2006;117(1):e84‐9. [MEDLINE: 16326693] ">Cheng 2006</a>; <a href="./references#CD003772-bbs2-0009" title="ChaoSM , ChongCY , Tan‐HendrickA , TanAS , NgWY . Efficacy and safety of once‐a‐day gentamicin in the treatment of childhood acute pyelonephritis [abstract]. Pediatric Nephrology2001;16(8):C105. [CENTRAL: CN‐00444755] ChongCY , TanAS , NgW , Tan‐KendrickA , BalakrishnanA , ChaoSM . Treatment of urinary tract infection with gentamicin once or three times daily. Acta Paediatrica2003;92(3):291‐6. [MEDLINE: 12725542] ">Chong 2003</a>; <a href="./references#CD003772-bbs2-0010" title="FischbachM , SimeoniU , MengusL , JehlF , MonteilH , GeisertJ , et al. Urinary tract infections with tissue penetration in children: cefotaxime compared with amoxycillin/clavulanate. Journal of Antimicrobial Chemotherapy1989;24(Suppl B):177‐83. [MEDLINE: 2691478] ">Fischbach 1989</a>; <a href="./references#CD003772-bbs2-0011" title="FrancoisP , BensmanA , BegueP , ArtazM‐A , CoudevilleL , LebrunT , et al. Assessment of the efficacy and cost efficiency of two strategies in the treatment of acute pyelonephritis in children: oral cefixime or parenteral ceftriaxone after an initial IV combination therapy [Evaluation de l'efficacité et du coût de deux stratégies thérapeutiques dans les pyélonéphrites de l'enfant: céfixime per os versus ceftriaxone parentérale en relais d'une bithérapie intraveineuse]. Medecine et Maladies Infectieuses1997;27(Spec Iss June):667‐73. [EMBASE: 1997230388] ">Francois 1997</a>; <a href="./references#CD003772-bbs2-0012" title="FujiiR , ShinozakiT , MeguroH , ArimasuO , IzumiK , OsanoM , et al. Comparative, controlled study on an ampicillin suppository (KS‐R 1) with an oral form of ampicillin in urinary tract infections. Japanese Journal of Antibiotics1987;40(3):476‐92. [MEDLINE: 3302342] ">Fujii 1987</a>; <a href="./references#CD003772-bbs2-0013" title="GrimwoodK , AbbottGD , FergussonDM . Single dose gentamicin treatment of urinary infections in children. New Zealand Medical Journal1988;101(852):539‐41. [MEDLINE: 3045718] ">Grimwood 1988</a>; <a href="./references#CD003772-bbs2-0015" title="KafetzisDA , MaltezouHC , MavrikouM , SiafasC , ParaskakisI , DelisD , et al. Isepamicin versus amikacin for the treatment of acute pyelonephritis in children. International Journal of Antimicrobial Agents2000;14(1):51‐5. [MEDLINE: 10717501] ">Kafetzis 2000</a>; <a href="./references#CD003772-bbs2-0017" title="LevtchenkoE , LahyC , LevyJ , HamH , PiepszA . Treatment of children with acute pyelonephritis: a prospective randomized study. Pediatric Nephrology2001;16(11):878‐84. [MEDLINE: 11685593] ">Levtchenko 2001</a>; <a href="./references#CD003772-bbs2-0018" title="MarildS , EsbjornerE , JakobssonB , LinneT , LubeckP , SjogrenI , et al. Randomised study of ceftibuten vs trimethoprim‐sulfamethoxazole in pyelonephritis in children [abstract no: P466]. Pediatric Nephrology2004;19(9):C208. MarildS , JodalU , SandbergT . Ceftibuten versus trimethoprim‐sulfamethoxazole for oral treatment of febrile urinary tract infection in children. Pediatric Nephrology2009;24(3):521‐6. [MEDLINE: 18818954] ">Marild 2009</a>; <a href="./references#CD003772-bbs2-0021" title="NoorbakhshS , LariAR , MasjedianF , MostafaviH , AlaghehbandanR . Comparison of intravenous aminoglycoside therapy with switch therapy to cefixime in urinary tract infections. Saudi Medical Journal2004;25(10):1513‐5. [MEDLINE: 15494842] ">Noorbakhsh 2004</a>; <a href="./references#CD003772-bbs2-0023" title="RepettoHA , MacLoughlinGJ . Single‐dose cefotaxime in the treatment of urinary tract infections in children: a randomized clinical trial. Journal of Antimicrobial Chemotherapy1984;14(Suppl B):307‐10. [MEDLINE: 6094457] ">Repetto 1984</a>; <a href="./references#CD003772-bbs2-0024" title="SchaadUB , EskolaJ , KafetzisD , FischbachM , AshekenaziS , SyriopoulouV , et al. Cefepine vs. ceftazidime treatment of pyelonephritis: a European, randomized, controlled study of 300 pediatric cases. European Society for Paediatric Infectious Diseases (ESPID) Pyelonephritis Study Group. Pediatric Infectious Disease Journal1998;17(7):639‐44. [MEDLINE: 9686732] ">Schaad 1998</a>; <a href="./references#CD003772-bbs2-0025" title="ToporovskiJ , SteffensL , NoackM , KranzA , BurdeskaA , KisslingM . Effectiveness of cefetamet pivoxil in the treatment of pyelonephritis in children. Journal of International Medical Research1992;20(1):87‐93. [MEDLINE: 1568523] ">Toporovski 1992</a>; <a href="./references#CD003772-bbs2-0026" title="ViganoA , PrincipiN , BrivioL , TommasiP , StasiP , VillaAD . Comparison of 5 milligrams of netilmicin per kilogram of body weight once daily versus 2 milligrams per kilogram thrice daily for treatment of gram‐negative pyelonephritis in children. Antimicrobial Agents &amp; Chemotherapy1992;36(7):1499‐503. [MEDLINE: 92378248] ">Vigano 1992</a>; <a href="./references#CD003772-bbs2-0027" title="VilaichoneA , WatanaD , ChaiwatanaratT . Oral ceftibuten switch therapy for acute pyelonephritis in children. Journal of the Medical Association of Thailand2001;84 Suppl(1):61‐7. [MEDLINE: 11529382] ">Vilaichone 2001</a>). Attrition and exclusion of participants after the randomisation process was considered to be at a high risk of bias in seven studies (<a href="./references#CD003772-bbs2-0003" title="BanfiAG , Hill‐JuarezJM , KaufmanA , MoensE . Multinational comparative trial of ceftibuten and trimethoprim‐sulfamethoxazole in the treatment of children with complicated or recurrent urinary tract infections. Members of the ceftibuten urinary tract infection international study group. Pediatric Infectious Disease Journal1993;12(6 Suppl):S84‐S91. [CENTRAL: CN‐00334829] ">Banfi 1993</a>; <a href="./references#CD003772-bbs2-0005" title="BocquetN , Sergent AlaouiA , JaisJP , GajdosV , GuigonisV , LacourB , et al. Randomized trial of oral versus sequential IV/oral antibiotic for acute pyelonephritis in children. Pediatrics2012;129(2):e269‐75. [MEDLINE: 22291112] ">Bocquet 2012</a>; <a href="./references#CD003772-bbs2-0006" title="BouissouF , MunzerC , DecramerS , RousselB , NovoR , MorinD , et al. Prospective, randomized trial comparing short and long intravenous antibiotic treatment of acute pyelonephritis in children: dimercaptosuccinic acid scintigraphic evaluation at 9 months. Pediatrics2008;121(3):e553‐60. [MEDLINE: 18267977] ">Bouissou 2008</a>; <a href="./references#CD003772-bbs2-0014" title="HobermanA , WaldER . Intravenous versus oral antibiotics for urinary tract infections. Pediatrics2000;106(4):865. [MEDLINE: 11183178] HobermanA , WaldER , HickeyRW , BaskinM , CharronM , MajdM , et al. Oral versus initial intravenous therapy for urinary tract infections in young febrile children. Pediatrics1999;104(1 Pt 1):79‐86. [MEDLINE: 10390264] ">Hoberman 1999</a>; <a href="./references#CD003772-bbs2-0019" title="HewittIK , TomasiL , PavanelloL , MaschioF , MolinariPP , ToffoloA , et al. Early treatment of acute pyelonephritis in children fails to reduce renal scarring [abstract no: SA‐PO1100]. Journal of the American Society of Nephrology2006;17(Abstracts):804A. [CENTRAL: CN‐00653791] HewittIK , ZucchettaP , RigonL , MaschioF , MolinariPP , TomasiL , et al. Early treatment of acute pyelonephritis in children fails to reduce renal scarring: data from the Italian Renal Infection Study Trials. Pediatrics2008;122(3):486‐90. [MEDLINE: 18762516] LaScolaC , DeMutiisC , HewittIK , PuccioG , ToffoloA , ZucchettaP , et al. Different guidelines for imaging after first UTI in febrile infants: yield, cost, and radiation. Pediatrics2013;131(3):e665‐71. [MEDLINE: 23439905] MontiniG , MurerL , GobberD , CommacchioS , ToffoloA , Dall'AmicoR , et al. Oral vs initial intravenous antibiotic treatment of urinary tract infections in children: a multicentre study [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):816. [CENTRAL: CN‐00446817] MontiniG , ToffoloA , ZucchettaP , Dall'AmicoR , GobberD , CalderonA , et al. Antibiotic treatment for pyelonephritis in children: multicentre randomised controlled non‐inferiority trial. BMJ2007;335(7616):386‐92. [MEDLINE: 17611232] MontiniG , ZucchettaP , GobberD , MurerL , RigonL , ToffoloA , et al. Usefulness of renal radiology and scintigraphy in children with a first episode of upper urinary tract infection [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):813. [CENTRAL: CN‐00446818] MontiniG , ZucchettaP , TomasiL , TalentiE , RigamontiW , PiccoG , et al. Value of imaging studies after a first febrile urinary tract infection in young children: data from Italian renal infection study 1. Pediatrics2009;123(2):e239‐46. [MEDLINE: 19139086] ">Montini 2007</a>; <a href="./references#CD003772-bbs2-0020" title="BuechnerK , GirardinF , BergerC , WilliU , NadafD , Neuhaus T for the Swiss Pyelonephritis Study Group. Randomised controlled trial of oral versus sequential intravenous/oral cephalosporins in DMSA scintigraphy‐documented acute pyelonephritis [abstract no: COD. OP 18]. Pediatric Nephrology2006;21(10):1511. [CENTRAL: CN‐00601934] NeuhausTJ , BergerC , BuechnerK , ParvexP , BischoffG , GoetschelP , et al. Randomised trial of oral versus sequential intravenous/oral cephalosporins in children with pyelonephritis. European Journal of Pediatrics2008;167(9):1037‐47. [MEDLINE: 18074149] NeuhausTJ , BüchnerK , GirardinE , WilliU , BergerC , NadalD . Oral versus sequential intravenous/oral cephalosporin‐therapy in DMSA‐scintigraphy documented acute pyelonephritis: randomized Swiss pyelonephritis‐study [abstract] [Orale versus sequentiell intravenös/orale Cephalosporin‐Therapie bei DMSA‐Szintigraphie dokumentierter akuter Pyelonephritis: Randomisierte Schweizer Pyelonephritis‐Studie]. Nieren‐ und Hochdruckkrankheiten2007;36(2):43. [CENTRAL: CN‐00615897] ">Neuhaus 2008</a>; <a href="./references#CD003772-bbs2-0022" title="PylkkänenJ , VilskaJ , KoskimiesO . The length of antimicrobial therapy in upper vs. lower urinary tract infection of childhood. Acta Paediatrica Scandinavica1981;70(6):885‐8. [MEDLINE: 7324942] PylkkänenJ , VilskaJ , KoskimiesO . The value of level diagnosis of childhood urinary tract infection in predicting renal injury. Acta Paediatrica Scandinavica1981;70(6):879‐83. [MEDLINE: 7324941] ">Pylkkänen 1981</a>) and unclear in <a href="./references#CD003772-bbs2-0016" title="KahnAJ , KumarK , EvansHE . Three‐day antimicrobial therapy of urinary tract infection. Journal of Pediatrics1981;99(6):992‐4. [MEDLINE: 7031217] ">Khan 1981</a>. </p> </section> <section id="CD003772-sec-0075"> <h4 class="title">Selective reporting</h4> <p>There were 13 studies that reported bacteriological, clinical and adverse outcomes and were considered at low risk of bias (<a href="./references#CD003772-bbs2-0001" title="BakerPC , NelsonDS , SchunkJE . The addition of ceftriaxone to oral therapy does not improve outcome in febrile children with urinary tract infections. Archives of Pediatrics &amp; Adolescent Medicine2001;155(2):135‐9. [MEDLINE: 11177086] ">Baker 2001</a>; <a href="./references#CD003772-bbs2-0002" title="BakkalogluA , SaatciU , SoylemezogluO , OzenS , TopalogluR , BesbasN , et al. Comparison of ceftriaxone versus cefotaxime for childhood upper urinary tract infections. Journal of Chemotherapy1996;8(1):59‐62. [MEDLINE: 8835111] ">Bakkaloglu 1996</a>; <a href="./references#CD003772-bbs2-0003" title="BanfiAG , Hill‐JuarezJM , KaufmanA , MoensE . Multinational comparative trial of ceftibuten and trimethoprim‐sulfamethoxazole in the treatment of children with complicated or recurrent urinary tract infections. Members of the ceftibuten urinary tract infection international study group. Pediatric Infectious Disease Journal1993;12(6 Suppl):S84‐S91. [CENTRAL: CN‐00334829] ">Banfi 1993</a>; <a href="./references#CD003772-bbs2-0004" title="BenadorD , NeuhausTJ , PapazyanJ‐P , WilliUV , Engel‐BicikI , NadalD , et al. Randomised controlled trial of three day versus 10 day intravenous antibiotics in acute pyelonephritis: effect on renal scarring. Archives of Disease in Childhood2001;84(3):241‐6. [MEDLINE: 11207174] GirardinE , NeuhausT , PapazyanJ , WilliUV , BicikI , NadalD , et al. Acute pyelonephritis: comparison of 3 vs 10 days IV antibiotic treatment [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):592A. [CENTRAL: CN‐00583905] ">Benador 2001</a>; <a href="./references#CD003772-bbs2-0007" title="CarapetisJ , JaquieryA , ButteryJ , StarrM . A randomised controlled trial of once‐daily gentamicin in children with urinary tract infections [abstract]. Australian &amp; New Zealand Journal of Medicine1999;29:608. [CENTRAL: CN‐00583423] CarapetisJ , JaquieryA , ButteryJ , StarrM , CranswickN , KohnS , et al. Randomized, controlled trial comparing once daily and three times daily gentamicin in children with urinary tract infections. Pediatric Infectious Disease Journal2001;20(3):240‐6. [MEDLINE: 11303823] ">Carapetis 2001</a>; <a href="./references#CD003772-bbs2-0009" title="ChaoSM , ChongCY , Tan‐HendrickA , TanAS , NgWY . Efficacy and safety of once‐a‐day gentamicin in the treatment of childhood acute pyelonephritis [abstract]. Pediatric Nephrology2001;16(8):C105. [CENTRAL: CN‐00444755] ChongCY , TanAS , NgW , Tan‐KendrickA , BalakrishnanA , ChaoSM . Treatment of urinary tract infection with gentamicin once or three times daily. Acta Paediatrica2003;92(3):291‐6. [MEDLINE: 12725542] ">Chong 2003</a>; <a href="./references#CD003772-bbs2-0010" title="FischbachM , SimeoniU , MengusL , JehlF , MonteilH , GeisertJ , et al. Urinary tract infections with tissue penetration in children: cefotaxime compared with amoxycillin/clavulanate. Journal of Antimicrobial Chemotherapy1989;24(Suppl B):177‐83. [MEDLINE: 2691478] ">Fischbach 1989</a>; <a href="./references#CD003772-bbs2-0011" title="FrancoisP , BensmanA , BegueP , ArtazM‐A , CoudevilleL , LebrunT , et al. Assessment of the efficacy and cost efficiency of two strategies in the treatment of acute pyelonephritis in children: oral cefixime or parenteral ceftriaxone after an initial IV combination therapy [Evaluation de l'efficacité et du coût de deux stratégies thérapeutiques dans les pyélonéphrites de l'enfant: céfixime per os versus ceftriaxone parentérale en relais d'une bithérapie intraveineuse]. Medecine et Maladies Infectieuses1997;27(Spec Iss June):667‐73. [EMBASE: 1997230388] ">Francois 1997</a>; <a href="./references#CD003772-bbs2-0015" title="KafetzisDA , MaltezouHC , MavrikouM , SiafasC , ParaskakisI , DelisD , et al. Isepamicin versus amikacin for the treatment of acute pyelonephritis in children. International Journal of Antimicrobial Agents2000;14(1):51‐5. [MEDLINE: 10717501] ">Kafetzis 2000</a>; <a href="./references#CD003772-bbs2-0018" title="MarildS , EsbjornerE , JakobssonB , LinneT , LubeckP , SjogrenI , et al. Randomised study of ceftibuten vs trimethoprim‐sulfamethoxazole in pyelonephritis in children [abstract no: P466]. Pediatric Nephrology2004;19(9):C208. MarildS , JodalU , SandbergT . Ceftibuten versus trimethoprim‐sulfamethoxazole for oral treatment of febrile urinary tract infection in children. Pediatric Nephrology2009;24(3):521‐6. [MEDLINE: 18818954] ">Marild 2009</a>; <a href="./references#CD003772-bbs2-0019" title="HewittIK , TomasiL , PavanelloL , MaschioF , MolinariPP , ToffoloA , et al. Early treatment of acute pyelonephritis in children fails to reduce renal scarring [abstract no: SA‐PO1100]. Journal of the American Society of Nephrology2006;17(Abstracts):804A. [CENTRAL: CN‐00653791] HewittIK , ZucchettaP , RigonL , MaschioF , MolinariPP , TomasiL , et al. Early treatment of acute pyelonephritis in children fails to reduce renal scarring: data from the Italian Renal Infection Study Trials. Pediatrics2008;122(3):486‐90. [MEDLINE: 18762516] LaScolaC , DeMutiisC , HewittIK , PuccioG , ToffoloA , ZucchettaP , et al. Different guidelines for imaging after first UTI in febrile infants: yield, cost, and radiation. Pediatrics2013;131(3):e665‐71. [MEDLINE: 23439905] MontiniG , MurerL , GobberD , CommacchioS , ToffoloA , Dall'AmicoR , et al. Oral vs initial intravenous antibiotic treatment of urinary tract infections in children: a multicentre study [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):816. [CENTRAL: CN‐00446817] MontiniG , ToffoloA , ZucchettaP , Dall'AmicoR , GobberD , CalderonA , et al. Antibiotic treatment for pyelonephritis in children: multicentre randomised controlled non‐inferiority trial. BMJ2007;335(7616):386‐92. [MEDLINE: 17611232] MontiniG , ZucchettaP , GobberD , MurerL , RigonL , ToffoloA , et al. Usefulness of renal radiology and scintigraphy in children with a first episode of upper urinary tract infection [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):813. [CENTRAL: CN‐00446818] MontiniG , ZucchettaP , TomasiL , TalentiE , RigamontiW , PiccoG , et al. Value of imaging studies after a first febrile urinary tract infection in young children: data from Italian renal infection study 1. Pediatrics2009;123(2):e239‐46. [MEDLINE: 19139086] ">Montini 2007</a>; <a href="./references#CD003772-bbs2-0024" title="SchaadUB , EskolaJ , KafetzisD , FischbachM , AshekenaziS , SyriopoulouV , et al. Cefepine vs. ceftazidime treatment of pyelonephritis: a European, randomized, controlled study of 300 pediatric cases. European Society for Paediatric Infectious Diseases (ESPID) Pyelonephritis Study Group. Pediatric Infectious Disease Journal1998;17(7):639‐44. [MEDLINE: 9686732] ">Schaad 1998</a>; <a href="./references#CD003772-bbs2-0025" title="ToporovskiJ , SteffensL , NoackM , KranzA , BurdeskaA , KisslingM . Effectiveness of cefetamet pivoxil in the treatment of pyelonephritis in children. Journal of International Medical Research1992;20(1):87‐93. [MEDLINE: 1568523] ">Toporovski 1992</a>). <a href="./references#CD003772-bbs2-0012" title="FujiiR , ShinozakiT , MeguroH , ArimasuO , IzumiK , OsanoM , et al. Comparative, controlled study on an ampicillin suppository (KS‐R 1) with an oral form of ampicillin in urinary tract infections. Japanese Journal of Antibiotics1987;40(3):476‐92. [MEDLINE: 3302342] ">Fujii 1987</a> was an abstract and did not clearly indicate outcomes investigated. The remaining 13 studies did not report all three types of outcomes and were considered at high risk of bias. </p> </section> <section id="CD003772-sec-0076"> <h4 class="title">Other potential sources of bias</h4> <p>We assessed that 11 studies were at high risk of bias because they reported receiving funding from pharmaceutical companies (<a href="./references#CD003772-bbs2-0001" title="BakerPC , NelsonDS , SchunkJE . The addition of ceftriaxone to oral therapy does not improve outcome in febrile children with urinary tract infections. Archives of Pediatrics &amp; Adolescent Medicine2001;155(2):135‐9. [MEDLINE: 11177086] ">Baker 2001</a>; <a href="./references#CD003772-bbs2-0003" title="BanfiAG , Hill‐JuarezJM , KaufmanA , MoensE . Multinational comparative trial of ceftibuten and trimethoprim‐sulfamethoxazole in the treatment of children with complicated or recurrent urinary tract infections. Members of the ceftibuten urinary tract infection international study group. Pediatric Infectious Disease Journal1993;12(6 Suppl):S84‐S91. [CENTRAL: CN‐00334829] ">Banfi 1993</a>; <a href="./references#CD003772-bbs2-0006" title="BouissouF , MunzerC , DecramerS , RousselB , NovoR , MorinD , et al. Prospective, randomized trial comparing short and long intravenous antibiotic treatment of acute pyelonephritis in children: dimercaptosuccinic acid scintigraphic evaluation at 9 months. Pediatrics2008;121(3):e553‐60. [MEDLINE: 18267977] ">Bouissou 2008</a>; <a href="./references#CD003772-bbs2-0014" title="HobermanA , WaldER . Intravenous versus oral antibiotics for urinary tract infections. Pediatrics2000;106(4):865. [MEDLINE: 11183178] HobermanA , WaldER , HickeyRW , BaskinM , CharronM , MajdM , et al. Oral versus initial intravenous therapy for urinary tract infections in young febrile children. Pediatrics1999;104(1 Pt 1):79‐86. [MEDLINE: 10390264] ">Hoberman 1999</a>; <a href="./references#CD003772-bbs2-0015" title="KafetzisDA , MaltezouHC , MavrikouM , SiafasC , ParaskakisI , DelisD , et al. Isepamicin versus amikacin for the treatment of acute pyelonephritis in children. International Journal of Antimicrobial Agents2000;14(1):51‐5. [MEDLINE: 10717501] ">Kafetzis 2000</a>; <a href="./references#CD003772-bbs2-0018" title="MarildS , EsbjornerE , JakobssonB , LinneT , LubeckP , SjogrenI , et al. Randomised study of ceftibuten vs trimethoprim‐sulfamethoxazole in pyelonephritis in children [abstract no: P466]. Pediatric Nephrology2004;19(9):C208. MarildS , JodalU , SandbergT . Ceftibuten versus trimethoprim‐sulfamethoxazole for oral treatment of febrile urinary tract infection in children. Pediatric Nephrology2009;24(3):521‐6. [MEDLINE: 18818954] ">Marild 2009</a>; <a href="./references#CD003772-bbs2-0020" title="BuechnerK , GirardinF , BergerC , WilliU , NadafD , Neuhaus T for the Swiss Pyelonephritis Study Group. Randomised controlled trial of oral versus sequential intravenous/oral cephalosporins in DMSA scintigraphy‐documented acute pyelonephritis [abstract no: COD. OP 18]. Pediatric Nephrology2006;21(10):1511. [CENTRAL: CN‐00601934] NeuhausTJ , BergerC , BuechnerK , ParvexP , BischoffG , GoetschelP , et al. Randomised trial of oral versus sequential intravenous/oral cephalosporins in children with pyelonephritis. European Journal of Pediatrics2008;167(9):1037‐47. [MEDLINE: 18074149] NeuhausTJ , BüchnerK , GirardinE , WilliU , BergerC , NadalD . Oral versus sequential intravenous/oral cephalosporin‐therapy in DMSA‐scintigraphy documented acute pyelonephritis: randomized Swiss pyelonephritis‐study [abstract] [Orale versus sequentiell intravenös/orale Cephalosporin‐Therapie bei DMSA‐Szintigraphie dokumentierter akuter Pyelonephritis: Randomisierte Schweizer Pyelonephritis‐Studie]. Nieren‐ und Hochdruckkrankheiten2007;36(2):43. [CENTRAL: CN‐00615897] ">Neuhaus 2008</a>; <a href="./references#CD003772-bbs2-0021" title="NoorbakhshS , LariAR , MasjedianF , MostafaviH , AlaghehbandanR . Comparison of intravenous aminoglycoside therapy with switch therapy to cefixime in urinary tract infections. Saudi Medical Journal2004;25(10):1513‐5. [MEDLINE: 15494842] ">Noorbakhsh 2004</a>; <a href="./references#CD003772-bbs2-0022" title="PylkkänenJ , VilskaJ , KoskimiesO . The length of antimicrobial therapy in upper vs. lower urinary tract infection of childhood. Acta Paediatrica Scandinavica1981;70(6):885‐8. [MEDLINE: 7324942] PylkkänenJ , VilskaJ , KoskimiesO . The value of level diagnosis of childhood urinary tract infection in predicting renal injury. Acta Paediatrica Scandinavica1981;70(6):879‐83. [MEDLINE: 7324941] ">Pylkkänen 1981</a>; <a href="./references#CD003772-bbs2-0024" title="SchaadUB , EskolaJ , KafetzisD , FischbachM , AshekenaziS , SyriopoulouV , et al. Cefepine vs. ceftazidime treatment of pyelonephritis: a European, randomized, controlled study of 300 pediatric cases. European Society for Paediatric Infectious Diseases (ESPID) Pyelonephritis Study Group. Pediatric Infectious Disease Journal1998;17(7):639‐44. [MEDLINE: 9686732] ">Schaad 1998</a>; <a href="./references#CD003772-bbs2-0025" title="ToporovskiJ , SteffensL , NoackM , KranzA , BurdeskaA , KisslingM . Effectiveness of cefetamet pivoxil in the treatment of pyelonephritis in children. Journal of International Medical Research1992;20(1):87‐93. [MEDLINE: 1568523] ">Toporovski 1992</a>). Four received funding from hospital grants (<a href="./references#CD003772-bbs2-0005" title="BocquetN , Sergent AlaouiA , JaisJP , GajdosV , GuigonisV , LacourB , et al. Randomized trial of oral versus sequential IV/oral antibiotic for acute pyelonephritis in children. Pediatrics2012;129(2):e269‐75. [MEDLINE: 22291112] ">Bocquet 2012</a>; <a href="./references#CD003772-bbs2-0009" title="ChaoSM , ChongCY , Tan‐HendrickA , TanAS , NgWY . Efficacy and safety of once‐a‐day gentamicin in the treatment of childhood acute pyelonephritis [abstract]. Pediatric Nephrology2001;16(8):C105. [CENTRAL: CN‐00444755] ChongCY , TanAS , NgW , Tan‐KendrickA , BalakrishnanA , ChaoSM . Treatment of urinary tract infection with gentamicin once or three times daily. Acta Paediatrica2003;92(3):291‐6. [MEDLINE: 12725542] ">Chong 2003</a>; <a href="./references#CD003772-bbs2-0013" title="GrimwoodK , AbbottGD , FergussonDM . Single dose gentamicin treatment of urinary infections in children. New Zealand Medical Journal1988;101(852):539‐41. [MEDLINE: 3045718] ">Grimwood 1988</a>) or a government grant (<a href="./references#CD003772-bbs2-0019" title="HewittIK , TomasiL , PavanelloL , MaschioF , MolinariPP , ToffoloA , et al. Early treatment of acute pyelonephritis in children fails to reduce renal scarring [abstract no: SA‐PO1100]. Journal of the American Society of Nephrology2006;17(Abstracts):804A. [CENTRAL: CN‐00653791] HewittIK , ZucchettaP , RigonL , MaschioF , MolinariPP , TomasiL , et al. Early treatment of acute pyelonephritis in children fails to reduce renal scarring: data from the Italian Renal Infection Study Trials. Pediatrics2008;122(3):486‐90. [MEDLINE: 18762516] LaScolaC , DeMutiisC , HewittIK , PuccioG , ToffoloA , ZucchettaP , et al. Different guidelines for imaging after first UTI in febrile infants: yield, cost, and radiation. Pediatrics2013;131(3):e665‐71. [MEDLINE: 23439905] MontiniG , MurerL , GobberD , CommacchioS , ToffoloA , Dall'AmicoR , et al. Oral vs initial intravenous antibiotic treatment of urinary tract infections in children: a multicentre study [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):816. [CENTRAL: CN‐00446817] MontiniG , ToffoloA , ZucchettaP , Dall'AmicoR , GobberD , CalderonA , et al. Antibiotic treatment for pyelonephritis in children: multicentre randomised controlled non‐inferiority trial. BMJ2007;335(7616):386‐92. [MEDLINE: 17611232] MontiniG , ZucchettaP , GobberD , MurerL , RigonL , ToffoloA , et al. Usefulness of renal radiology and scintigraphy in children with a first episode of upper urinary tract infection [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):813. [CENTRAL: CN‐00446818] MontiniG , ZucchettaP , TomasiL , TalentiE , RigamontiW , PiccoG , et al. Value of imaging studies after a first febrile urinary tract infection in young children: data from Italian renal infection study 1. Pediatrics2009;123(2):e239‐46. [MEDLINE: 19139086] ">Montini 2007</a>) and were considered at low risk of bias. The source of funding in the remaining 12 studies was unclear. </p> </section> </section> <section id="CD003772-sec-0077"> <h3 class="title" id="CD003772-sec-0077">Effects of interventions</h3> <p>See: <a href="./full#CD003772-tbl-0001"><b>Summary of findings for the main comparison</b> Oral versus IV followed by oral (11 days) therapy for acute pyelonephritis in children</a>; <a href="./full#CD003772-tbl-0002"><b>Summary of findings 2</b> Short duration (3 to 4 days) versus long duration (7 to 14 days) IV therapy for acute pyelonephritis in children</a>; <a href="./full#CD003772-tbl-0003"><b>Summary of findings 3</b> Different dosing regimens of aminoglycosides (daily versus 8 hourly) for acute pyelonephritis in children</a>; <a href="./full#CD003772-tbl-0004"><b>Summary of findings 4</b> Agent: Third generation cephalosporin versus other antibiotic for acute pyelonephritis in children</a> </p> <p>Because results from random and fixed‐effect models did not differ, only results from the random‐effects model were reported. Few studies were available for pooling in meta‐analyses. No pre‐planned subgroup analyses for outcomes according to patient age (infant, child, adolescent) were possible from the available data. Post hoc subgroup analyses were reported for age (less than or greater than one year of age, <a href="./references#CD003772-bbs2-0004" title="BenadorD , NeuhausTJ , PapazyanJ‐P , WilliUV , Engel‐BicikI , NadalD , et al. Randomised controlled trial of three day versus 10 day intravenous antibiotics in acute pyelonephritis: effect on renal scarring. Archives of Disease in Childhood2001;84(3):241‐6. [MEDLINE: 11207174] GirardinE , NeuhausT , PapazyanJ , WilliUV , BicikI , NadalD , et al. Acute pyelonephritis: comparison of 3 vs 10 days IV antibiotic treatment [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):592A. [CENTRAL: CN‐00583905] ">Benador 2001</a>) and VUR (<a href="./references#CD003772-bbs2-0004" title="BenadorD , NeuhausTJ , PapazyanJ‐P , WilliUV , Engel‐BicikI , NadalD , et al. Randomised controlled trial of three day versus 10 day intravenous antibiotics in acute pyelonephritis: effect on renal scarring. Archives of Disease in Childhood2001;84(3):241‐6. [MEDLINE: 11207174] GirardinE , NeuhausT , PapazyanJ , WilliUV , BicikI , NadalD , et al. Acute pyelonephritis: comparison of 3 vs 10 days IV antibiotic treatment [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):592A. [CENTRAL: CN‐00583905] ">Benador 2001</a>; <a href="./references#CD003772-bbs2-0014" title="HobermanA , WaldER . Intravenous versus oral antibiotics for urinary tract infections. Pediatrics2000;106(4):865. [MEDLINE: 11183178] HobermanA , WaldER , HickeyRW , BaskinM , CharronM , MajdM , et al. Oral versus initial intravenous therapy for urinary tract infections in young febrile children. Pediatrics1999;104(1 Pt 1):79‐86. [MEDLINE: 10390264] ">Hoberman 1999</a>; <a href="./references#CD003772-bbs2-0027" title="VilaichoneA , WatanaD , ChaiwatanaratT . Oral ceftibuten switch therapy for acute pyelonephritis in children. Journal of the Medical Association of Thailand2001;84 Suppl(1):61‐7. [MEDLINE: 11529382] ">Vilaichone 2001</a>) and delay in treatment (less than or greater than seven days, <a href="./references#CD003772-bbs2-0017" title="LevtchenkoE , LahyC , LevyJ , HamH , PiepszA . Treatment of children with acute pyelonephritis: a prospective randomized study. Pediatric Nephrology2001;16(11):878‐84. [MEDLINE: 11685593] ">Levtchenko 2001</a>). </p> <section id="CD003772-sec-0078"> <h4 class="title">Oral therapy versus sequential IV therapy and oral therapy</h4> <p>We found four studies (<a href="./references#CD003772-bbs2-0005" title="BocquetN , Sergent AlaouiA , JaisJP , GajdosV , GuigonisV , LacourB , et al. Randomized trial of oral versus sequential IV/oral antibiotic for acute pyelonephritis in children. Pediatrics2012;129(2):e269‐75. [MEDLINE: 22291112] ">Bocquet 2012</a>; <a href="./references#CD003772-bbs2-0014" title="HobermanA , WaldER . Intravenous versus oral antibiotics for urinary tract infections. Pediatrics2000;106(4):865. [MEDLINE: 11183178] HobermanA , WaldER , HickeyRW , BaskinM , CharronM , MajdM , et al. Oral versus initial intravenous therapy for urinary tract infections in young febrile children. Pediatrics1999;104(1 Pt 1):79‐86. [MEDLINE: 10390264] ">Hoberman 1999</a>; <a href="./references#CD003772-bbs2-0019" title="HewittIK , TomasiL , PavanelloL , MaschioF , MolinariPP , ToffoloA , et al. Early treatment of acute pyelonephritis in children fails to reduce renal scarring [abstract no: SA‐PO1100]. Journal of the American Society of Nephrology2006;17(Abstracts):804A. [CENTRAL: CN‐00653791] HewittIK , ZucchettaP , RigonL , MaschioF , MolinariPP , TomasiL , et al. Early treatment of acute pyelonephritis in children fails to reduce renal scarring: data from the Italian Renal Infection Study Trials. Pediatrics2008;122(3):486‐90. [MEDLINE: 18762516] LaScolaC , DeMutiisC , HewittIK , PuccioG , ToffoloA , ZucchettaP , et al. Different guidelines for imaging after first UTI in febrile infants: yield, cost, and radiation. Pediatrics2013;131(3):e665‐71. [MEDLINE: 23439905] MontiniG , MurerL , GobberD , CommacchioS , ToffoloA , Dall'AmicoR , et al. Oral vs initial intravenous antibiotic treatment of urinary tract infections in children: a multicentre study [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):816. [CENTRAL: CN‐00446817] MontiniG , ToffoloA , ZucchettaP , Dall'AmicoR , GobberD , CalderonA , et al. Antibiotic treatment for pyelonephritis in children: multicentre randomised controlled non‐inferiority trial. BMJ2007;335(7616):386‐92. [MEDLINE: 17611232] MontiniG , ZucchettaP , GobberD , MurerL , RigonL , ToffoloA , et al. Usefulness of renal radiology and scintigraphy in children with a first episode of upper urinary tract infection [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):813. [CENTRAL: CN‐00446818] MontiniG , ZucchettaP , TomasiL , TalentiE , RigamontiW , PiccoG , et al. Value of imaging studies after a first febrile urinary tract infection in young children: data from Italian renal infection study 1. Pediatrics2009;123(2):e239‐46. [MEDLINE: 19139086] ">Montini 2007</a>; <a href="./references#CD003772-bbs2-0020" title="BuechnerK , GirardinF , BergerC , WilliU , NadafD , Neuhaus T for the Swiss Pyelonephritis Study Group. Randomised controlled trial of oral versus sequential intravenous/oral cephalosporins in DMSA scintigraphy‐documented acute pyelonephritis [abstract no: COD. OP 18]. Pediatric Nephrology2006;21(10):1511. [CENTRAL: CN‐00601934] NeuhausTJ , BergerC , BuechnerK , ParvexP , BischoffG , GoetschelP , et al. Randomised trial of oral versus sequential intravenous/oral cephalosporins in children with pyelonephritis. European Journal of Pediatrics2008;167(9):1037‐47. [MEDLINE: 18074149] NeuhausTJ , BüchnerK , GirardinE , WilliU , BergerC , NadalD . Oral versus sequential intravenous/oral cephalosporin‐therapy in DMSA‐scintigraphy documented acute pyelonephritis: randomized Swiss pyelonephritis‐study [abstract] [Orale versus sequentiell intravenös/orale Cephalosporin‐Therapie bei DMSA‐Szintigraphie dokumentierter akuter Pyelonephritis: Randomisierte Schweizer Pyelonephritis‐Studie]. Nieren‐ und Hochdruckkrankheiten2007;36(2):43. [CENTRAL: CN‐00615897] ">Neuhaus 2008</a>) involving 1131 children compared oral antibiotics (cefixime, ceftibuten or amoxicillin/clavulanic acid) for 10 to 14 days with IV cefotaxime (<a href="./references#CD003772-bbs2-0014" title="HobermanA , WaldER . Intravenous versus oral antibiotics for urinary tract infections. Pediatrics2000;106(4):865. [MEDLINE: 11183178] HobermanA , WaldER , HickeyRW , BaskinM , CharronM , MajdM , et al. Oral versus initial intravenous therapy for urinary tract infections in young febrile children. Pediatrics1999;104(1 Pt 1):79‐86. [MEDLINE: 10390264] ">Hoberman 1999</a>) or ceftriaxone (<a href="./references#CD003772-bbs2-0005" title="BocquetN , Sergent AlaouiA , JaisJP , GajdosV , GuigonisV , LacourB , et al. Randomized trial of oral versus sequential IV/oral antibiotic for acute pyelonephritis in children. Pediatrics2012;129(2):e269‐75. [MEDLINE: 22291112] ">Bocquet 2012</a>; <a href="./references#CD003772-bbs2-0019" title="HewittIK , TomasiL , PavanelloL , MaschioF , MolinariPP , ToffoloA , et al. Early treatment of acute pyelonephritis in children fails to reduce renal scarring [abstract no: SA‐PO1100]. Journal of the American Society of Nephrology2006;17(Abstracts):804A. [CENTRAL: CN‐00653791] HewittIK , ZucchettaP , RigonL , MaschioF , MolinariPP , TomasiL , et al. Early treatment of acute pyelonephritis in children fails to reduce renal scarring: data from the Italian Renal Infection Study Trials. Pediatrics2008;122(3):486‐90. [MEDLINE: 18762516] LaScolaC , DeMutiisC , HewittIK , PuccioG , ToffoloA , ZucchettaP , et al. Different guidelines for imaging after first UTI in febrile infants: yield, cost, and radiation. Pediatrics2013;131(3):e665‐71. [MEDLINE: 23439905] MontiniG , MurerL , GobberD , CommacchioS , ToffoloA , Dall'AmicoR , et al. Oral vs initial intravenous antibiotic treatment of urinary tract infections in children: a multicentre study [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):816. [CENTRAL: CN‐00446817] MontiniG , ToffoloA , ZucchettaP , Dall'AmicoR , GobberD , CalderonA , et al. Antibiotic treatment for pyelonephritis in children: multicentre randomised controlled non‐inferiority trial. BMJ2007;335(7616):386‐92. [MEDLINE: 17611232] MontiniG , ZucchettaP , GobberD , MurerL , RigonL , ToffoloA , et al. Usefulness of renal radiology and scintigraphy in children with a first episode of upper urinary tract infection [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):813. [CENTRAL: CN‐00446818] MontiniG , ZucchettaP , TomasiL , TalentiE , RigamontiW , PiccoG , et al. Value of imaging studies after a first febrile urinary tract infection in young children: data from Italian renal infection study 1. Pediatrics2009;123(2):e239‐46. [MEDLINE: 19139086] ">Montini 2007</a>; <a href="./references#CD003772-bbs2-0020" title="BuechnerK , GirardinF , BergerC , WilliU , NadafD , Neuhaus T for the Swiss Pyelonephritis Study Group. Randomised controlled trial of oral versus sequential intravenous/oral cephalosporins in DMSA scintigraphy‐documented acute pyelonephritis [abstract no: COD. OP 18]. Pediatric Nephrology2006;21(10):1511. [CENTRAL: CN‐00601934] NeuhausTJ , BergerC , BuechnerK , ParvexP , BischoffG , GoetschelP , et al. Randomised trial of oral versus sequential intravenous/oral cephalosporins in children with pyelonephritis. European Journal of Pediatrics2008;167(9):1037‐47. [MEDLINE: 18074149] NeuhausTJ , BüchnerK , GirardinE , WilliU , BergerC , NadalD . Oral versus sequential intravenous/oral cephalosporin‐therapy in DMSA‐scintigraphy documented acute pyelonephritis: randomized Swiss pyelonephritis‐study [abstract] [Orale versus sequentiell intravenös/orale Cephalosporin‐Therapie bei DMSA‐Szintigraphie dokumentierter akuter Pyelonephritis: Randomisierte Schweizer Pyelonephritis‐Studie]. Nieren‐ und Hochdruckkrankheiten2007;36(2):43. [CENTRAL: CN‐00615897] ">Neuhaus 2008</a>) for three to four days or until resolution of fever followed by oral antibiotics to complete the course of therapy. </p> <p> <ul id="CD003772-list-0017"> <li> <p>Time to resolution of fever did not differ significantly between groups (<a href="./references#CD003772-fig-0004" title="">Analysis 1.1</a> (2 studies, 808 children): MD 2.05 hours, 95% CI ‐0.84 to 4.94; I² = 0%). <a href="./references#CD003772-bbs2-0020" title="BuechnerK , GirardinF , BergerC , WilliU , NadafD , Neuhaus T for the Swiss Pyelonephritis Study Group. Randomised controlled trial of oral versus sequential intravenous/oral cephalosporins in DMSA scintigraphy‐documented acute pyelonephritis [abstract no: COD. OP 18]. Pediatric Nephrology2006;21(10):1511. [CENTRAL: CN‐00601934] NeuhausTJ , BergerC , BuechnerK , ParvexP , BischoffG , GoetschelP , et al. Randomised trial of oral versus sequential intravenous/oral cephalosporins in children with pyelonephritis. European Journal of Pediatrics2008;167(9):1037‐47. [MEDLINE: 18074149] NeuhausTJ , BüchnerK , GirardinE , WilliU , BergerC , NadalD . Oral versus sequential intravenous/oral cephalosporin‐therapy in DMSA‐scintigraphy documented acute pyelonephritis: randomized Swiss pyelonephritis‐study [abstract] [Orale versus sequentiell intravenös/orale Cephalosporin‐Therapie bei DMSA‐Szintigraphie dokumentierter akuter Pyelonephritis: Randomisierte Schweizer Pyelonephritis‐Studie]. Nieren‐ und Hochdruckkrankheiten2007;36(2):43. [CENTRAL: CN‐00615897] ">Neuhaus 2008</a> reported the number of children with fever on day three did not differ significantly between groups (<a href="./references#CD003772-fig-0005" title="">Analysis 1.2</a> (1 study, 152 children): RR 0.79, 95% CI 0.30 to 2.06). </p> </li> <li> <p>The number of children with persistent UTI at 72 hours after commencing therapy did not differ significantly between groups (<a href="./references#CD003772-fig-0006" title="">Analysis 1.3</a> (2 studies, 542 children): RR 1.10, 95% CI 0.07 to 17.41). </p> </li> <li> <p><a href="./references#CD003772-bbs2-0019" title="HewittIK , TomasiL , PavanelloL , MaschioF , MolinariPP , ToffoloA , et al. Early treatment of acute pyelonephritis in children fails to reduce renal scarring [abstract no: SA‐PO1100]. Journal of the American Society of Nephrology2006;17(Abstracts):804A. [CENTRAL: CN‐00653791] HewittIK , ZucchettaP , RigonL , MaschioF , MolinariPP , TomasiL , et al. Early treatment of acute pyelonephritis in children fails to reduce renal scarring: data from the Italian Renal Infection Study Trials. Pediatrics2008;122(3):486‐90. [MEDLINE: 18762516] LaScolaC , DeMutiisC , HewittIK , PuccioG , ToffoloA , ZucchettaP , et al. Different guidelines for imaging after first UTI in febrile infants: yield, cost, and radiation. Pediatrics2013;131(3):e665‐71. [MEDLINE: 23439905] MontiniG , MurerL , GobberD , CommacchioS , ToffoloA , Dall'AmicoR , et al. Oral vs initial intravenous antibiotic treatment of urinary tract infections in children: a multicentre study [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):816. [CENTRAL: CN‐00446817] MontiniG , ToffoloA , ZucchettaP , Dall'AmicoR , GobberD , CalderonA , et al. Antibiotic treatment for pyelonephritis in children: multicentre randomised controlled non‐inferiority trial. BMJ2007;335(7616):386‐92. [MEDLINE: 17611232] MontiniG , ZucchettaP , GobberD , MurerL , RigonL , ToffoloA , et al. Usefulness of renal radiology and scintigraphy in children with a first episode of upper urinary tract infection [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):813. [CENTRAL: CN‐00446818] MontiniG , ZucchettaP , TomasiL , TalentiE , RigamontiW , PiccoG , et al. Value of imaging studies after a first febrile urinary tract infection in young children: data from Italian renal infection study 1. Pediatrics2009;123(2):e239‐46. [MEDLINE: 19139086] ">Montini 2007</a> reported no significant difference between groups in the mean levels of inflammatory markers: WCC (<a href="./references#CD003772-fig-0007" title="">Analysis 1.4</a>.1 (1 study, 473 children): MD 0.30 x 10⁹/L, 95% CI ‐0.30 to 0.90), ESR (<a href="./references#CD003772-fig-0007" title="">Analysis 1.4</a>.2 (1 study, 338 children): MD ‐1.80 mm/60 min, 95% CI‐8.20 to 4.60]) or CRP (<a href="./references#CD003772-fig-0007" title="">Analysis 1.4</a> (1 study, 486 children): MD 1.10 mg/L, 95% CI ‐2.18 to 4.38). </p> </li> <li> <p><a href="./references#CD003772-bbs2-0014" title="HobermanA , WaldER . Intravenous versus oral antibiotics for urinary tract infections. Pediatrics2000;106(4):865. [MEDLINE: 11183178] HobermanA , WaldER , HickeyRW , BaskinM , CharronM , MajdM , et al. Oral versus initial intravenous therapy for urinary tract infections in young febrile children. Pediatrics1999;104(1 Pt 1):79‐86. [MEDLINE: 10390264] ">Hoberman 1999</a> reported no significant difference between groups in the rate of recurrences of bacteriuria (<a href="./references#CD003772-fig-0008" title="">Analysis 1.5</a>.1 (1 study, 287 children): RR 0.65, 95% CI 0.28 to 1.51) or symptomatic UTI within six months (<a href="./references#CD003772-fig-0008" title="">Analysis 1.5</a>.2 (1 study, 287 children): RR 0.67, 95% CI 0.27 to 1.67). </p> </li> <li> <p>There were no significant differences among treatment groups in the rate of persistent kidney parenchymal defects on DMSA scan whether considered in relation to the total number of children with acute pyelonephritis (<a href="./references#CD003772-fig-0009" title="">Analysis 1.6</a>.1 (4 studies, 943 children): RR 0.82, 95% CI 0.59 to 1.12; I² = 41%) or only those with defects on the initial DMSA scan (<a href="./references#CD003772-fig-0009" title="">Analysis 1.6</a>.2 (4 studies, 681 children): RR 0.79, 95% CI 0.31 to 1.03; I² = 19%). <a href="./references#CD003772-bbs2-0014" title="HobermanA , WaldER . Intravenous versus oral antibiotics for urinary tract infections. Pediatrics2000;106(4):865. [MEDLINE: 11183178] HobermanA , WaldER , HickeyRW , BaskinM , CharronM , MajdM , et al. Oral versus initial intravenous therapy for urinary tract infections in young febrile children. Pediatrics1999;104(1 Pt 1):79‐86. [MEDLINE: 10390264] ">Hoberman 1999</a> reported no significant difference between groups in the size of persistent kidney parenchymal defects on DMSA scan (<a href="./references#CD003772-fig-0010" title="">Analysis 1.7</a> (1 study, 272 children): MD ‐0.70, 95% CI ‐1.74 to 0.34). </p> </li> <li> <p>Post hoc subgroup analysis (<a href="./references#CD003772-fig-0011" title="">Analysis 1.8</a>) by <a href="./references#CD003772-bbs2-0014" title="HobermanA , WaldER . Intravenous versus oral antibiotics for urinary tract infections. Pediatrics2000;106(4):865. [MEDLINE: 11183178] HobermanA , WaldER , HickeyRW , BaskinM , CharronM , MajdM , et al. Oral versus initial intravenous therapy for urinary tract infections in young febrile children. Pediatrics1999;104(1 Pt 1):79‐86. [MEDLINE: 10390264] ">Hoberman 1999</a> found no difference in the number of kidney parenchymal defects on DMSA scan at six months between children with VUR (<a href="./references#CD003772-fig-0011" title="">Analysis 1.8</a>.1 (1 study, 107 children): RR 1.88, 95% CI 0.83 to 4.24) and those without VUR (<a href="./references#CD003772-fig-0011" title="">Analysis 1.8</a>.2 (1 study, 107 children): RR 0.80, 95% CI 0.23 to 2.73). However, post hoc analysis (<a href="./references#CD003772-fig-0011" title="">Analysis 1.8</a>.4) raised the possibility that among children with VUR (grades III‐V), persistent kidney parenchymal defects on DMSA scan at six months occurred more frequently after oral than IV therapy (RR 7.33, 95% CI 1.00 to 54.01). </p> </li> <li> <p>The average cost of treatment for each patient was USD 3630 and USD 7382 for oral and IV groups respectively (<a href="./references#CD003772-bbs2-0014" title="HobermanA , WaldER . Intravenous versus oral antibiotics for urinary tract infections. Pediatrics2000;106(4):865. [MEDLINE: 11183178] HobermanA , WaldER , HickeyRW , BaskinM , CharronM , MajdM , et al. Oral versus initial intravenous therapy for urinary tract infections in young febrile children. Pediatrics1999;104(1 Pt 1):79‐86. [MEDLINE: 10390264] ">Hoberman 1999</a>). </p> </li> <li> <p>Adverse effects were reported in three studies (<a href="./references#CD003772-bbs2-0005" title="BocquetN , Sergent AlaouiA , JaisJP , GajdosV , GuigonisV , LacourB , et al. Randomized trial of oral versus sequential IV/oral antibiotic for acute pyelonephritis in children. Pediatrics2012;129(2):e269‐75. [MEDLINE: 22291112] ">Bocquet 2012</a>; <a href="./references#CD003772-bbs2-0019" title="HewittIK , TomasiL , PavanelloL , MaschioF , MolinariPP , ToffoloA , et al. Early treatment of acute pyelonephritis in children fails to reduce renal scarring [abstract no: SA‐PO1100]. Journal of the American Society of Nephrology2006;17(Abstracts):804A. [CENTRAL: CN‐00653791] HewittIK , ZucchettaP , RigonL , MaschioF , MolinariPP , TomasiL , et al. Early treatment of acute pyelonephritis in children fails to reduce renal scarring: data from the Italian Renal Infection Study Trials. Pediatrics2008;122(3):486‐90. [MEDLINE: 18762516] LaScolaC , DeMutiisC , HewittIK , PuccioG , ToffoloA , ZucchettaP , et al. Different guidelines for imaging after first UTI in febrile infants: yield, cost, and radiation. Pediatrics2013;131(3):e665‐71. [MEDLINE: 23439905] MontiniG , MurerL , GobberD , CommacchioS , ToffoloA , Dall'AmicoR , et al. Oral vs initial intravenous antibiotic treatment of urinary tract infections in children: a multicentre study [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):816. [CENTRAL: CN‐00446817] MontiniG , ToffoloA , ZucchettaP , Dall'AmicoR , GobberD , CalderonA , et al. Antibiotic treatment for pyelonephritis in children: multicentre randomised controlled non‐inferiority trial. BMJ2007;335(7616):386‐92. [MEDLINE: 17611232] MontiniG , ZucchettaP , GobberD , MurerL , RigonL , ToffoloA , et al. Usefulness of renal radiology and scintigraphy in children with a first episode of upper urinary tract infection [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):813. [CENTRAL: CN‐00446818] MontiniG , ZucchettaP , TomasiL , TalentiE , RigamontiW , PiccoG , et al. Value of imaging studies after a first febrile urinary tract infection in young children: data from Italian renal infection study 1. Pediatrics2009;123(2):e239‐46. [MEDLINE: 19139086] ">Montini 2007</a>; <a href="./references#CD003772-bbs2-0020" title="BuechnerK , GirardinF , BergerC , WilliU , NadafD , Neuhaus T for the Swiss Pyelonephritis Study Group. Randomised controlled trial of oral versus sequential intravenous/oral cephalosporins in DMSA scintigraphy‐documented acute pyelonephritis [abstract no: COD. OP 18]. Pediatric Nephrology2006;21(10):1511. [CENTRAL: CN‐00601934] NeuhausTJ , BergerC , BuechnerK , ParvexP , BischoffG , GoetschelP , et al. Randomised trial of oral versus sequential intravenous/oral cephalosporins in children with pyelonephritis. European Journal of Pediatrics2008;167(9):1037‐47. [MEDLINE: 18074149] NeuhausTJ , BüchnerK , GirardinE , WilliU , BergerC , NadalD . Oral versus sequential intravenous/oral cephalosporin‐therapy in DMSA‐scintigraphy documented acute pyelonephritis: randomized Swiss pyelonephritis‐study [abstract] [Orale versus sequentiell intravenös/orale Cephalosporin‐Therapie bei DMSA‐Szintigraphie dokumentierter akuter Pyelonephritis: Randomisierte Schweizer Pyelonephritis‐Studie]. Nieren‐ und Hochdruckkrankheiten2007;36(2):43. [CENTRAL: CN‐00615897] ">Neuhaus 2008</a>). No children experienced therapy‐related adverse effects in <a href="./references#CD003772-bbs2-0020" title="BuechnerK , GirardinF , BergerC , WilliU , NadafD , Neuhaus T for the Swiss Pyelonephritis Study Group. Randomised controlled trial of oral versus sequential intravenous/oral cephalosporins in DMSA scintigraphy‐documented acute pyelonephritis [abstract no: COD. OP 18]. Pediatric Nephrology2006;21(10):1511. [CENTRAL: CN‐00601934] NeuhausTJ , BergerC , BuechnerK , ParvexP , BischoffG , GoetschelP , et al. Randomised trial of oral versus sequential intravenous/oral cephalosporins in children with pyelonephritis. European Journal of Pediatrics2008;167(9):1037‐47. [MEDLINE: 18074149] NeuhausTJ , BüchnerK , GirardinE , WilliU , BergerC , NadalD . Oral versus sequential intravenous/oral cephalosporin‐therapy in DMSA‐scintigraphy documented acute pyelonephritis: randomized Swiss pyelonephritis‐study [abstract] [Orale versus sequentiell intravenös/orale Cephalosporin‐Therapie bei DMSA‐Szintigraphie dokumentierter akuter Pyelonephritis: Randomisierte Schweizer Pyelonephritis‐Studie]. Nieren‐ und Hochdruckkrankheiten2007;36(2):43. [CENTRAL: CN‐00615897] ">Neuhaus 2008</a>. In <a href="./references#CD003772-bbs2-0005" title="BocquetN , Sergent AlaouiA , JaisJP , GajdosV , GuigonisV , LacourB , et al. Randomized trial of oral versus sequential IV/oral antibiotic for acute pyelonephritis in children. Pediatrics2012;129(2):e269‐75. [MEDLINE: 22291112] ">Bocquet 2012</a> two children experienced vomiting with oral cefixime and required change to parenteral therapy. In <a href="./references#CD003772-bbs2-0019" title="HewittIK , TomasiL , PavanelloL , MaschioF , MolinariPP , ToffoloA , et al. Early treatment of acute pyelonephritis in children fails to reduce renal scarring [abstract no: SA‐PO1100]. Journal of the American Society of Nephrology2006;17(Abstracts):804A. [CENTRAL: CN‐00653791] HewittIK , ZucchettaP , RigonL , MaschioF , MolinariPP , TomasiL , et al. Early treatment of acute pyelonephritis in children fails to reduce renal scarring: data from the Italian Renal Infection Study Trials. Pediatrics2008;122(3):486‐90. [MEDLINE: 18762516] LaScolaC , DeMutiisC , HewittIK , PuccioG , ToffoloA , ZucchettaP , et al. Different guidelines for imaging after first UTI in febrile infants: yield, cost, and radiation. Pediatrics2013;131(3):e665‐71. [MEDLINE: 23439905] MontiniG , MurerL , GobberD , CommacchioS , ToffoloA , Dall'AmicoR , et al. Oral vs initial intravenous antibiotic treatment of urinary tract infections in children: a multicentre study [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):816. [CENTRAL: CN‐00446817] MontiniG , ToffoloA , ZucchettaP , Dall'AmicoR , GobberD , CalderonA , et al. Antibiotic treatment for pyelonephritis in children: multicentre randomised controlled non‐inferiority trial. BMJ2007;335(7616):386‐92. [MEDLINE: 17611232] MontiniG , ZucchettaP , GobberD , MurerL , RigonL , ToffoloA , et al. Usefulness of renal radiology and scintigraphy in children with a first episode of upper urinary tract infection [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):813. [CENTRAL: CN‐00446818] MontiniG , ZucchettaP , TomasiL , TalentiE , RigamontiW , PiccoG , et al. Value of imaging studies after a first febrile urinary tract infection in young children: data from Italian renal infection study 1. Pediatrics2009;123(2):e239‐46. [MEDLINE: 19139086] ">Montini 2007</a> 15 children experienced diarrhoea or vomiting (13), erythema (1) and leucopenia (1) with oral amoxicillin and clavulanic acid; 10 required a change of antibiotics. In the same study three children experienced diarrhoea (1), erythema (1) and candida (1) with ceftriaxone; none required change of treatment. <a href="./references#CD003772-bbs2-0014" title="HobermanA , WaldER . Intravenous versus oral antibiotics for urinary tract infections. Pediatrics2000;106(4):865. [MEDLINE: 11183178] HobermanA , WaldER , HickeyRW , BaskinM , CharronM , MajdM , et al. Oral versus initial intravenous therapy for urinary tract infections in young febrile children. Pediatrics1999;104(1 Pt 1):79‐86. [MEDLINE: 10390264] ">Hoberman 1999</a> did not report on adverse effects. </p> </li> </ul> </p> </section> <section id="CD003772-sec-0079"> <h4 class="title">Sequential short duration (three to four days) IV therapy and oral therapy versus long duration (seven to 14 days) IV therapy </h4> <p>There were six studies (<a href="./references#CD003772-bbs2-0004" title="BenadorD , NeuhausTJ , PapazyanJ‐P , WilliUV , Engel‐BicikI , NadalD , et al. Randomised controlled trial of three day versus 10 day intravenous antibiotics in acute pyelonephritis: effect on renal scarring. Archives of Disease in Childhood2001;84(3):241‐6. [MEDLINE: 11207174] GirardinE , NeuhausT , PapazyanJ , WilliUV , BicikI , NadalD , et al. Acute pyelonephritis: comparison of 3 vs 10 days IV antibiotic treatment [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):592A. [CENTRAL: CN‐00583905] ">Benador 2001</a>; <a href="./references#CD003772-bbs2-0006" title="BouissouF , MunzerC , DecramerS , RousselB , NovoR , MorinD , et al. Prospective, randomized trial comparing short and long intravenous antibiotic treatment of acute pyelonephritis in children: dimercaptosuccinic acid scintigraphic evaluation at 9 months. Pediatrics2008;121(3):e553‐60. [MEDLINE: 18267977] ">Bouissou 2008</a>; <a href="./references#CD003772-bbs2-0011" title="FrancoisP , BensmanA , BegueP , ArtazM‐A , CoudevilleL , LebrunT , et al. Assessment of the efficacy and cost efficiency of two strategies in the treatment of acute pyelonephritis in children: oral cefixime or parenteral ceftriaxone after an initial IV combination therapy [Evaluation de l'efficacité et du coût de deux stratégies thérapeutiques dans les pyélonéphrites de l'enfant: céfixime per os versus ceftriaxone parentérale en relais d'une bithérapie intraveineuse]. Medecine et Maladies Infectieuses1997;27(Spec Iss June):667‐73. [EMBASE: 1997230388] ">Francois 1997</a>; <a href="./references#CD003772-bbs2-0017" title="LevtchenkoE , LahyC , LevyJ , HamH , PiepszA . Treatment of children with acute pyelonephritis: a prospective randomized study. Pediatric Nephrology2001;16(11):878‐84. [MEDLINE: 11685593] ">Levtchenko 2001</a>; <a href="./references#CD003772-bbs2-0021" title="NoorbakhshS , LariAR , MasjedianF , MostafaviH , AlaghehbandanR . Comparison of intravenous aminoglycoside therapy with switch therapy to cefixime in urinary tract infections. Saudi Medical Journal2004;25(10):1513‐5. [MEDLINE: 15494842] ">Noorbakhsh 2004</a>; <a href="./references#CD003772-bbs2-0027" title="VilaichoneA , WatanaD , ChaiwatanaratT . Oral ceftibuten switch therapy for acute pyelonephritis in children. Journal of the Medical Association of Thailand2001;84 Suppl(1):61‐7. [MEDLINE: 11529382] ">Vilaichone 2001</a>) involving 917 children that compared oral therapy after an initial three to four days of IV therapy with a long duration of IV therapy alone. Two studies compared IV ceftriaxone (three to four days) followed by oral cefixime (<a href="./references#CD003772-bbs2-0004" title="BenadorD , NeuhausTJ , PapazyanJ‐P , WilliUV , Engel‐BicikI , NadalD , et al. Randomised controlled trial of three day versus 10 day intravenous antibiotics in acute pyelonephritis: effect on renal scarring. Archives of Disease in Childhood2001;84(3):241‐6. [MEDLINE: 11207174] GirardinE , NeuhausT , PapazyanJ , WilliUV , BicikI , NadalD , et al. Acute pyelonephritis: comparison of 3 vs 10 days IV antibiotic treatment [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):592A. [CENTRAL: CN‐00583905] ">Benador 2001</a>) or ceftibuten (<a href="./references#CD003772-bbs2-0027" title="VilaichoneA , WatanaD , ChaiwatanaratT . Oral ceftibuten switch therapy for acute pyelonephritis in children. Journal of the Medical Association of Thailand2001;84 Suppl(1):61‐7. [MEDLINE: 11529382] ">Vilaichone 2001</a>) with IV ceftriaxone (10 days). <a href="./references#CD003772-bbs2-0017" title="LevtchenkoE , LahyC , LevyJ , HamH , PiepszA . Treatment of children with acute pyelonephritis: a prospective randomized study. Pediatric Nephrology2001;16(11):878‐84. [MEDLINE: 11685593] ">Levtchenko 2001</a> compared IV temocillin (three days) followed by oral amoxicillin or amoxicillin/clavulanic acid with IV temocillin (seven days). <a href="./references#CD003772-bbs2-0021" title="NoorbakhshS , LariAR , MasjedianF , MostafaviH , AlaghehbandanR . Comparison of intravenous aminoglycoside therapy with switch therapy to cefixime in urinary tract infections. Saudi Medical Journal2004;25(10):1513‐5. [MEDLINE: 15494842] ">Noorbakhsh 2004</a> compared IV ceftriaxone (two to three days) followed by oral ceftibuten with IV amikacin or gentamicin with IV ampicillin (14 days). <a href="./references#CD003772-bbs2-0011" title="FrancoisP , BensmanA , BegueP , ArtazM‐A , CoudevilleL , LebrunT , et al. Assessment of the efficacy and cost efficiency of two strategies in the treatment of acute pyelonephritis in children: oral cefixime or parenteral ceftriaxone after an initial IV combination therapy [Evaluation de l'efficacité et du coût de deux stratégies thérapeutiques dans les pyélonéphrites de l'enfant: céfixime per os versus ceftriaxone parentérale en relais d'une bithérapie intraveineuse]. Medecine et Maladies Infectieuses1997;27(Spec Iss June):667‐73. [EMBASE: 1997230388] ">Francois 1997</a> compared IV cefotaxime (four days) followed by oral amoxicillin/clavulanic acid with IV cefotaxime (14 days). <a href="./references#CD003772-bbs2-0006" title="BouissouF , MunzerC , DecramerS , RousselB , NovoR , MorinD , et al. Prospective, randomized trial comparing short and long intravenous antibiotic treatment of acute pyelonephritis in children: dimercaptosuccinic acid scintigraphic evaluation at 9 months. Pediatrics2008;121(3):e553‐60. [MEDLINE: 18267977] ">Bouissou 2008</a> compared IV netilmicin (two days) and ceftriaxone (three days) followed by oral antibiotics (cefixime, amoxicillin/clavulanic acid, TMP/SMX) chosen according to sensitivity with IV netilmicin (two days) and ceftriaxone (eight days). <a href="./references#CD003772-bbs2-0004" title="BenadorD , NeuhausTJ , PapazyanJ‐P , WilliUV , Engel‐BicikI , NadalD , et al. Randomised controlled trial of three day versus 10 day intravenous antibiotics in acute pyelonephritis: effect on renal scarring. Archives of Disease in Childhood2001;84(3):241‐6. [MEDLINE: 11207174] GirardinE , NeuhausT , PapazyanJ , WilliUV , BicikI , NadalD , et al. Acute pyelonephritis: comparison of 3 vs 10 days IV antibiotic treatment [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):592A. [CENTRAL: CN‐00583905] ">Benador 2001</a> and <a href="./references#CD003772-bbs2-0017" title="LevtchenkoE , LahyC , LevyJ , HamH , PiepszA . Treatment of children with acute pyelonephritis: a prospective randomized study. Pediatric Nephrology2001;16(11):878‐84. [MEDLINE: 11685593] ">Levtchenko 2001</a> also converted the IV group to oral therapy after seven to 10 days to complete 15 to 21 days of treatment. </p> <p> <ul id="CD003772-list-0018"> <li> <p>There was no significant difference between the risk of persistent bacteriuria at the end of treatment (<a href="./references#CD003772-fig-0012" title="">Analysis 2.1</a> (4 studies, 305 children): RR 0.78, 95% CI 0.24 to 2.55; I² = 0%). </p> </li> <li> <p>There was no significant difference between groups for recurrent UTI within six months (<a href="./references#CD003772-fig-0013" title="">Analysis 2.2</a> (5 studies, 993 children): RR 0.97, 95% CI 0.58 to 1.62; I² = 0%). </p> </li> <li> <p>The number of persisting kidney parenchymal defects seen on DMSA scan at three to six months did not differ significantly between treatment groups when considered in relation to the total number of children with acute pyelonephritis (<a href="./references#CD003772-fig-0014" title="">Analysis 2.3</a>.1 (4 studies, 726 children): RR 1.01, 95% CI 0.80 to 1.29; I² = 0%) or only those with defects on the initial DMSA scan (<a href="./references#CD003772-fig-0014" title="">Analysis 2.3</a>.2 (3 studies, 315 children): RR 1.10, 95% CI 0.84 to 1.45; I² = 0%). </p> </li> <li> <p>Post hoc subgroup analysis showed that the number of children with persisting kidney parenchymal defects on DMSA scan did not differ between those with VUR (<a href="./references#CD003772-fig-0015" title="">Analysis 2.4</a>.1 (2 studies, 81 children): RR 0.99, 95% CI 0.69 to 1.43; I² = 0%) and without VUR (<a href="./references#CD003772-fig-0015" title="">Analysis 2.4</a>.2 (2 studies, 173 children): RR 1.19, 95% CI 0.81 to 1.76; I² = 0%), those aged under one year (<a href="./references#CD003772-fig-0015" title="">Analysis 2.4</a>.3 (1 study, 22 children): RR 1.46, 95% CI 0.71 to 3.01) and aged one year and over (<a href="./references#CD003772-fig-0015" title="">Analysis 2.4</a>.4 (1 study, 54 children): RR 0.89, 95% CI 0.59 to 1.34), and those who had a delay of treatment of less than seven days (<a href="./references#CD003772-fig-0015" title="">Analysis 2.4</a>.5 (1 study, 13 children): RR 1.52, 95% CI 0.59 to 3.92) or more than seven days (<a href="./references#CD003772-fig-0015" title="">Analysis 2.4</a>.6 (1 study, 8 children): RR 2.10, 95% CI 0.92 to 4.77). </p> </li> <li> <p>Adverse effects were reported in <a href="./references#CD003772-bbs2-0011" title="FrancoisP , BensmanA , BegueP , ArtazM‐A , CoudevilleL , LebrunT , et al. Assessment of the efficacy and cost efficiency of two strategies in the treatment of acute pyelonephritis in children: oral cefixime or parenteral ceftriaxone after an initial IV combination therapy [Evaluation de l'efficacité et du coût de deux stratégies thérapeutiques dans les pyélonéphrites de l'enfant: céfixime per os versus ceftriaxone parentérale en relais d'une bithérapie intraveineuse]. Medecine et Maladies Infectieuses1997;27(Spec Iss June):667‐73. [EMBASE: 1997230388] ">Francois 1997</a> and <a href="./references#CD003772-bbs2-0027" title="VilaichoneA , WatanaD , ChaiwatanaratT . Oral ceftibuten switch therapy for acute pyelonephritis in children. Journal of the Medical Association of Thailand2001;84 Suppl(1):61‐7. [MEDLINE: 11529382] ">Vilaichone 2001</a>; both related to gastrointestinal upsets, and frequency did not differ between therapy routes (<a href="./references#CD003772-fig-0016" title="">Analysis 2.5</a>.1 (2 studies, 175 children): RR 1.29, 95% CI 0.55 to 3.05; I² = 0%). Four studies did not report on adverse effects (<a href="./references#CD003772-bbs2-0004" title="BenadorD , NeuhausTJ , PapazyanJ‐P , WilliUV , Engel‐BicikI , NadalD , et al. Randomised controlled trial of three day versus 10 day intravenous antibiotics in acute pyelonephritis: effect on renal scarring. Archives of Disease in Childhood2001;84(3):241‐6. [MEDLINE: 11207174] GirardinE , NeuhausT , PapazyanJ , WilliUV , BicikI , NadalD , et al. Acute pyelonephritis: comparison of 3 vs 10 days IV antibiotic treatment [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):592A. [CENTRAL: CN‐00583905] ">Benador 2001</a>; <a href="./references#CD003772-bbs2-0006" title="BouissouF , MunzerC , DecramerS , RousselB , NovoR , MorinD , et al. Prospective, randomized trial comparing short and long intravenous antibiotic treatment of acute pyelonephritis in children: dimercaptosuccinic acid scintigraphic evaluation at 9 months. Pediatrics2008;121(3):e553‐60. [MEDLINE: 18267977] ">Bouissou 2008</a>; <a href="./references#CD003772-bbs2-0017" title="LevtchenkoE , LahyC , LevyJ , HamH , PiepszA . Treatment of children with acute pyelonephritis: a prospective randomized study. Pediatric Nephrology2001;16(11):878‐84. [MEDLINE: 11685593] ">Levtchenko 2001</a>; <a href="./references#CD003772-bbs2-0021" title="NoorbakhshS , LariAR , MasjedianF , MostafaviH , AlaghehbandanR . Comparison of intravenous aminoglycoside therapy with switch therapy to cefixime in urinary tract infections. Saudi Medical Journal2004;25(10):1513‐5. [MEDLINE: 15494842] ">Noorbakhsh 2004</a>). </p> </li> <li> <p>Duration of hospitalisation was 4.9 days for the IV and oral group compared with 9.8 days for the IV group (<a href="./references#CD003772-bbs2-0027" title="VilaichoneA , WatanaD , ChaiwatanaratT . Oral ceftibuten switch therapy for acute pyelonephritis in children. Journal of the Medical Association of Thailand2001;84 Suppl(1):61‐7. [MEDLINE: 11529382] ">Vilaichone 2001</a>). </p> </li> <li> <p>Costs of treatment for four days of IV therapy followed by six days of oral therapy were 513 French Francs (range 176 to 896) compared with 3545 French Francs (range 2478 to 4673) for 10 days of IV therapy (<a href="./references#CD003772-bbs2-0011" title="FrancoisP , BensmanA , BegueP , ArtazM‐A , CoudevilleL , LebrunT , et al. Assessment of the efficacy and cost efficiency of two strategies in the treatment of acute pyelonephritis in children: oral cefixime or parenteral ceftriaxone after an initial IV combination therapy [Evaluation de l'efficacité et du coût de deux stratégies thérapeutiques dans les pyélonéphrites de l'enfant: céfixime per os versus ceftriaxone parentérale en relais d'une bithérapie intraveineuse]. Medecine et Maladies Infectieuses1997;27(Spec Iss June):667‐73. [EMBASE: 1997230388] ">Francois 1997</a>). </p> </li> </ul> </p> </section> <section id="CD003772-sec-0080"> <h4 class="title">Single dose parenteral therapy and oral treatment versus oral therapy alone</h4> <p><a href="./references#CD003772-bbs2-0001" title="BakerPC , NelsonDS , SchunkJE . The addition of ceftriaxone to oral therapy does not improve outcome in febrile children with urinary tract infections. Archives of Pediatrics &amp; Adolescent Medicine2001;155(2):135‐9. [MEDLINE: 11177086] ">Baker 2001</a> (69 children) compared the addition of a single intramuscular dose of the third generation cephalosporin, ceftriaxone, to an oral course of TMP/SMX. There was no significant difference in: </p> <p> <ul id="CD003772-list-0019"> <li> <p>persistence of bacteriuria after 48 hours (<a href="./references#CD003772-fig-0017" title="">Analysis 3.1</a>: RR 0.77, 95% CI 0.19 to 3.20) </p> </li> <li> <p>persistence of clinical symptoms (<a href="./references#CD003772-fig-0018" title="">Analysis 3.2</a>: RR 0.82, 95% CI 0.24 to 2.81), or </p> </li> <li> <p>total adverse events (<a href="./references#CD003772-fig-0020" title="">Analysis 3.4</a>.1: RR 1.37, 95% CI 0.33 to 5.68) between groups. </p> </li> </ul> </p> <p>No child developed symptomatic UTI during one month after treatment.</p> </section> <section id="CD003772-sec-0081"> <h4 class="title">Different dosing regimens of aminoglycoside therapy</h4> <p>Three studies that involved 495 children compared daily parenteral administration of gentamicin (<a href="./references#CD003772-bbs2-0007" title="CarapetisJ , JaquieryA , ButteryJ , StarrM . A randomised controlled trial of once‐daily gentamicin in children with urinary tract infections [abstract]. Australian &amp; New Zealand Journal of Medicine1999;29:608. [CENTRAL: CN‐00583423] CarapetisJ , JaquieryA , ButteryJ , StarrM , CranswickN , KohnS , et al. Randomized, controlled trial comparing once daily and three times daily gentamicin in children with urinary tract infections. Pediatric Infectious Disease Journal2001;20(3):240‐6. [MEDLINE: 11303823] ">Carapetis 2001</a>; <a href="./references#CD003772-bbs2-0009" title="ChaoSM , ChongCY , Tan‐HendrickA , TanAS , NgWY . Efficacy and safety of once‐a‐day gentamicin in the treatment of childhood acute pyelonephritis [abstract]. Pediatric Nephrology2001;16(8):C105. [CENTRAL: CN‐00444755] ChongCY , TanAS , NgW , Tan‐KendrickA , BalakrishnanA , ChaoSM . Treatment of urinary tract infection with gentamicin once or three times daily. Acta Paediatrica2003;92(3):291‐6. [MEDLINE: 12725542] ">Chong 2003</a>) or netilmicin (<a href="./references#CD003772-bbs2-0026" title="ViganoA , PrincipiN , BrivioL , TommasiP , StasiP , VillaAD . Comparison of 5 milligrams of netilmicin per kilogram of body weight once daily versus 2 milligrams per kilogram thrice daily for treatment of gram‐negative pyelonephritis in children. Antimicrobial Agents &amp; Chemotherapy1992;36(7):1499‐503. [MEDLINE: 92378248] ">Vigano 1992</a>) to eight‐hourly administration of aminoglycosides. </p> <p> <ul id="CD003772-list-0020"> <li> <p>There was no significant difference in the risk for persisting bacteriuria one to three days after commencing treatment with either dose frequency (<a href="./references#CD003772-fig-0021" title="">Analysis 4.1</a> (3 studies, 435 children): RR 1.05, 95% CI 0.15 to 7.27). </p> </li> <li> <p><a href="./references#CD003772-bbs2-0007" title="CarapetisJ , JaquieryA , ButteryJ , StarrM . A randomised controlled trial of once‐daily gentamicin in children with urinary tract infections [abstract]. Australian &amp; New Zealand Journal of Medicine1999;29:608. [CENTRAL: CN‐00583423] CarapetisJ , JaquieryA , ButteryJ , StarrM , CranswickN , KohnS , et al. Randomized, controlled trial comparing once daily and three times daily gentamicin in children with urinary tract infections. Pediatric Infectious Disease Journal2001;20(3):240‐6. [MEDLINE: 11303823] ">Carapetis 2001</a> reported no difference in numbers of children with persisting clinical symptoms after three days of gentamicin (<a href="./references#CD003772-fig-0022" title="">Analysis 4.2</a> (1 study, 179 children): RR 1.98, 95% CI 0.37 to 10.53). </p> </li> <li> <p><a href="./references#CD003772-bbs2-0026" title="ViganoA , PrincipiN , BrivioL , TommasiP , StasiP , VillaAD . Comparison of 5 milligrams of netilmicin per kilogram of body weight once daily versus 2 milligrams per kilogram thrice daily for treatment of gram‐negative pyelonephritis in children. Antimicrobial Agents &amp; Chemotherapy1992;36(7):1499‐503. [MEDLINE: 92378248] ">Vigano 1992</a> reported persisting bacteriuria one week after (<a href="./references#CD003772-fig-0023" title="">Analysis 4.3</a> (1 study, 144 children): RR 2.84, 95% CI 0.12 to 68.57) and recurrent UTI within one month (<a href="./references#CD003772-fig-0024" title="">Analysis 4.4</a> (1 study, 144 children): RR 1.18, 95% CI 0.33 to 4.23) after completing netilmicin treatment did not differ between treatment groups. </p> </li> <li> <p>There was no significant difference in numbers of children with hearing impairment (<a href="./references#CD003772-fig-0025" title="">Analysis 4.5</a> (3 studies, 271 children): RR 2.83, 95% CI 0.33 to 24.56; I² = 0%) or kidney dysfunction (<a href="./references#CD003772-fig-0026" title="">Analysis 4.6</a> (3 studies, 419 children): RR 0.75, 95% CI 0.20 to 2.82; I² = 0%). </p> </li> <li> <p><a href="./references#CD003772-bbs2-0009" title="ChaoSM , ChongCY , Tan‐HendrickA , TanAS , NgWY . Efficacy and safety of once‐a‐day gentamicin in the treatment of childhood acute pyelonephritis [abstract]. Pediatric Nephrology2001;16(8):C105. [CENTRAL: CN‐00444755] ChongCY , TanAS , NgW , Tan‐KendrickA , BalakrishnanA , ChaoSM . Treatment of urinary tract infection with gentamicin once or three times daily. Acta Paediatrica2003;92(3):291‐6. [MEDLINE: 12725542] ">Chong 2003</a> reported mean time to resolution of fever with gentamicin did not differ between groups (<a href="./references#CD003772-fig-0027" title="">Analysis 4.7</a> (1 study, 172 children): MD 2.40 hours, 95% CI ‐7.90 to 12.70). Median time to resolution of fever was 27 hours (interquartile range 15 to 48 hours) with daily dosing and 33 hours (interquartile range 12 to 48 hours) with eight‐hourly dosing in a second study (<a href="./references#CD003772-bbs2-0007" title="CarapetisJ , JaquieryA , ButteryJ , StarrM . A randomised controlled trial of once‐daily gentamicin in children with urinary tract infections [abstract]. Australian &amp; New Zealand Journal of Medicine1999;29:608. [CENTRAL: CN‐00583423] CarapetisJ , JaquieryA , ButteryJ , StarrM , CranswickN , KohnS , et al. Randomized, controlled trial comparing once daily and three times daily gentamicin in children with urinary tract infections. Pediatric Infectious Disease Journal2001;20(3):240‐6. [MEDLINE: 11303823] ">Carapetis 2001</a>). </p> </li> </ul> </p> </section> <section id="CD003772-sec-0082"> <h4 class="title">Different antibiotic agents</h4> <p>Six studies compared different antibiotics (<a href="./references#CD003772-bbs2-0002" title="BakkalogluA , SaatciU , SoylemezogluO , OzenS , TopalogluR , BesbasN , et al. Comparison of ceftriaxone versus cefotaxime for childhood upper urinary tract infections. Journal of Chemotherapy1996;8(1):59‐62. [MEDLINE: 8835111] ">Bakkaloglu 1996</a>; <a href="./references#CD003772-bbs2-0007" title="CarapetisJ , JaquieryA , ButteryJ , StarrM . A randomised controlled trial of once‐daily gentamicin in children with urinary tract infections [abstract]. Australian &amp; New Zealand Journal of Medicine1999;29:608. [CENTRAL: CN‐00583423] CarapetisJ , JaquieryA , ButteryJ , StarrM , CranswickN , KohnS , et al. Randomized, controlled trial comparing once daily and three times daily gentamicin in children with urinary tract infections. Pediatric Infectious Disease Journal2001;20(3):240‐6. [MEDLINE: 11303823] ">Carapetis 2001</a>; <a href="./references#CD003772-bbs2-0009" title="ChaoSM , ChongCY , Tan‐HendrickA , TanAS , NgWY . Efficacy and safety of once‐a‐day gentamicin in the treatment of childhood acute pyelonephritis [abstract]. Pediatric Nephrology2001;16(8):C105. [CENTRAL: CN‐00444755] ChongCY , TanAS , NgW , Tan‐KendrickA , BalakrishnanA , ChaoSM . Treatment of urinary tract infection with gentamicin once or three times daily. Acta Paediatrica2003;92(3):291‐6. [MEDLINE: 12725542] ">Chong 2003</a>; <a href="./references#CD003772-bbs2-0015" title="KafetzisDA , MaltezouHC , MavrikouM , SiafasC , ParaskakisI , DelisD , et al. Isepamicin versus amikacin for the treatment of acute pyelonephritis in children. International Journal of Antimicrobial Agents2000;14(1):51‐5. [MEDLINE: 10717501] ">Kafetzis 2000</a>; <a href="./references#CD003772-bbs2-0024" title="SchaadUB , EskolaJ , KafetzisD , FischbachM , AshekenaziS , SyriopoulouV , et al. Cefepine vs. ceftazidime treatment of pyelonephritis: a European, randomized, controlled study of 300 pediatric cases. European Society for Paediatric Infectious Diseases (ESPID) Pyelonephritis Study Group. Pediatric Infectious Disease Journal1998;17(7):639‐44. [MEDLINE: 9686732] ">Schaad 1998</a>; <a href="./references#CD003772-bbs2-0026" title="ViganoA , PrincipiN , BrivioL , TommasiP , StasiP , VillaAD . Comparison of 5 milligrams of netilmicin per kilogram of body weight once daily versus 2 milligrams per kilogram thrice daily for treatment of gram‐negative pyelonephritis in children. Antimicrobial Agents &amp; Chemotherapy1992;36(7):1499‐503. [MEDLINE: 92378248] ">Vigano 1992</a>). </p> <section id="CD003772-sec-0083"> <h5 class="title">Third generation cephalosporins versus other antibiotics</h5> <p>In four studies involving 491 children treatment with third generation cephalosporins (IV cefotaxime (<a href="./references#CD003772-bbs2-0010" title="FischbachM , SimeoniU , MengusL , JehlF , MonteilH , GeisertJ , et al. Urinary tract infections with tissue penetration in children: cefotaxime compared with amoxycillin/clavulanate. Journal of Antimicrobial Chemotherapy1989;24(Suppl B):177‐83. [MEDLINE: 2691478] ">Fischbach 1989</a>), oral cefetamet (<a href="./references#CD003772-bbs2-0025" title="ToporovskiJ , SteffensL , NoackM , KranzA , BurdeskaA , KisslingM . Effectiveness of cefetamet pivoxil in the treatment of pyelonephritis in children. Journal of International Medical Research1992;20(1):87‐93. [MEDLINE: 1568523] ">Toporovski 1992</a>) or oral ceftibuten (<a href="./references#CD003772-bbs2-0003" title="BanfiAG , Hill‐JuarezJM , KaufmanA , MoensE . Multinational comparative trial of ceftibuten and trimethoprim‐sulfamethoxazole in the treatment of children with complicated or recurrent urinary tract infections. Members of the ceftibuten urinary tract infection international study group. Pediatric Infectious Disease Journal1993;12(6 Suppl):S84‐S91. [CENTRAL: CN‐00334829] ">Banfi 1993</a>; <a href="./references#CD003772-bbs2-0018" title="MarildS , EsbjornerE , JakobssonB , LinneT , LubeckP , SjogrenI , et al. Randomised study of ceftibuten vs trimethoprim‐sulfamethoxazole in pyelonephritis in children [abstract no: P466]. Pediatric Nephrology2004;19(9):C208. MarildS , JodalU , SandbergT . Ceftibuten versus trimethoprim‐sulfamethoxazole for oral treatment of febrile urinary tract infection in children. Pediatric Nephrology2009;24(3):521‐6. [MEDLINE: 18818954] ">Marild 2009</a>) were compared with amoxicillin/clavulanic acid (<a href="./references#CD003772-bbs2-0010" title="FischbachM , SimeoniU , MengusL , JehlF , MonteilH , GeisertJ , et al. Urinary tract infections with tissue penetration in children: cefotaxime compared with amoxycillin/clavulanate. Journal of Antimicrobial Chemotherapy1989;24(Suppl B):177‐83. [MEDLINE: 2691478] ">Fischbach 1989</a>; <a href="./references#CD003772-bbs2-0025" title="ToporovskiJ , SteffensL , NoackM , KranzA , BurdeskaA , KisslingM . Effectiveness of cefetamet pivoxil in the treatment of pyelonephritis in children. Journal of International Medical Research1992;20(1):87‐93. [MEDLINE: 1568523] ">Toporovski 1992</a>) or TMP/SMX (<a href="./references#CD003772-bbs2-0003" title="BanfiAG , Hill‐JuarezJM , KaufmanA , MoensE . Multinational comparative trial of ceftibuten and trimethoprim‐sulfamethoxazole in the treatment of children with complicated or recurrent urinary tract infections. Members of the ceftibuten urinary tract infection international study group. Pediatric Infectious Disease Journal1993;12(6 Suppl):S84‐S91. [CENTRAL: CN‐00334829] ">Banfi 1993</a>; <a href="./references#CD003772-bbs2-0018" title="MarildS , EsbjornerE , JakobssonB , LinneT , LubeckP , SjogrenI , et al. Randomised study of ceftibuten vs trimethoprim‐sulfamethoxazole in pyelonephritis in children [abstract no: P466]. Pediatric Nephrology2004;19(9):C208. MarildS , JodalU , SandbergT . Ceftibuten versus trimethoprim‐sulfamethoxazole for oral treatment of febrile urinary tract infection in children. Pediatric Nephrology2009;24(3):521‐6. [MEDLINE: 18818954] ">Marild 2009</a>). </p> <p> <ul id="CD003772-list-0021"> <li> <p>There was no significant difference in the number of children with persistent bacteriuria after 48 hours of therapy (<a href="./references#CD003772-fig-0029" title="">Analysis 5.1</a> (3 studies, 433 children): RR 2.41, 95% CI 0.98 to 5.93; I² = 0%). </p> </li> <li> <p>There was no significant difference in numbers of children who had recurrent UTI at 4 to 10 days after treatment (<a href="./references#CD003772-fig-0030" title="">Analysis 5.2</a> (4 studies, 419 children): RR 1.23, 95% CI 0.32 to 4.74; I² = 0%). </p> </li> <li> <p>A significantly greater number of children treated with TMP/SMX had persistent clinical symptoms at four to 10 days after treatment compared with those treated with a third generation cephalosporin (<a href="./references#CD003772-fig-0031" title="">Analysis 5.3</a> (3 studies, 471 children): RR 0.28, 95% CI 0.13 to 0.62; I² = 0%). The study by <a href="./references#CD003772-bbs2-0018" title="MarildS , EsbjornerE , JakobssonB , LinneT , LubeckP , SjogrenI , et al. Randomised study of ceftibuten vs trimethoprim‐sulfamethoxazole in pyelonephritis in children [abstract no: P466]. Pediatric Nephrology2004;19(9):C208. MarildS , JodalU , SandbergT . Ceftibuten versus trimethoprim‐sulfamethoxazole for oral treatment of febrile urinary tract infection in children. Pediatric Nephrology2009;24(3):521‐6. [MEDLINE: 18818954] ">Marild 2009</a> contributed to 94% of the weight of this result. </p> </li> <li> <p><a href="./references#CD003772-bbs2-0010" title="FischbachM , SimeoniU , MengusL , JehlF , MonteilH , GeisertJ , et al. Urinary tract infections with tissue penetration in children: cefotaxime compared with amoxycillin/clavulanate. Journal of Antimicrobial Chemotherapy1989;24(Suppl B):177‐83. [MEDLINE: 2691478] ">Fischbach 1989</a> reported no significant difference in numbers of children with persistent fever for more than 48 hours (<a href="./references#CD003772-fig-0032" title="">Analysis 5.4</a> (1 study, 20 children): RR 5.00, 95% CI 0.27 to 92.62). </p> </li> <li> <p><a href="./references#CD003772-bbs2-0003" title="BanfiAG , Hill‐JuarezJM , KaufmanA , MoensE . Multinational comparative trial of ceftibuten and trimethoprim‐sulfamethoxazole in the treatment of children with complicated or recurrent urinary tract infections. Members of the ceftibuten urinary tract infection international study group. Pediatric Infectious Disease Journal1993;12(6 Suppl):S84‐S91. [CENTRAL: CN‐00334829] ">Banfi 1993</a> reported no significant difference between groups in the rate of recurrences of bacteriuria (<a href="./references#CD003772-fig-0033" title="">Analysis 5.5</a> (1 study, 28 children): RR 2.14, 95% CI 0.11 to 40.30) or symptomatic UTI at four to six weeks (<a href="./references#CD003772-fig-0034" title="">Analysis 5.6</a>; no symptomatic UTIs in either group). </p> </li> <li> <p>All four studies reported adverse effects. There was no significant difference in numbers of children who experienced gastrointestinal adverse effects (<a href="./references#CD003772-fig-0035" title="">Analysis 5.7</a> (4 studies, 591 children): RR 0.93, 95% CI 0.34 to 2.58; I² = 0%). <a href="./references#CD003772-bbs2-0018" title="MarildS , EsbjornerE , JakobssonB , LinneT , LubeckP , SjogrenI , et al. Randomised study of ceftibuten vs trimethoprim‐sulfamethoxazole in pyelonephritis in children [abstract no: P466]. Pediatric Nephrology2004;19(9):C208. MarildS , JodalU , SandbergT . Ceftibuten versus trimethoprim‐sulfamethoxazole for oral treatment of febrile urinary tract infection in children. Pediatric Nephrology2009;24(3):521‐6. [MEDLINE: 18818954] ">Marild 2009</a> reported that four children in each group discontinued treatment because of adverse reactions (<a href="./references#CD003772-fig-0036" title="">Analysis 5.8</a> (1 study, 461 children): RR 0.49, 95% CI 0.12 to 1.94). </p> </li> </ul> </p> </section> <section id="CD003772-sec-0084"> <h5 class="title">Third generation cephalosporins versus fourth generation cephalosporins (Analysis 6) </h5> <p>In <a href="./references#CD003772-bbs2-0024" title="SchaadUB , EskolaJ , KafetzisD , FischbachM , AshekenaziS , SyriopoulouV , et al. Cefepine vs. ceftazidime treatment of pyelonephritis: a European, randomized, controlled study of 300 pediatric cases. European Society for Paediatric Infectious Diseases (ESPID) Pyelonephritis Study Group. Pediatric Infectious Disease Journal1998;17(7):639‐44. [MEDLINE: 9686732] ">Schaad 1998</a>, which included 299 children, IV cefepime (a fourth generation cephalosporin) was compared to IV ceftazidime (a third generation cephalosporin). </p> <p> <ul id="CD003772-list-0022"> <li> <p>No significant differences between groups were detected in numbers of children with persistent or recurrent bacteriuria with the same pathogen at different time points after therapy (<a href="./references#CD003772-fig-0037" title="">Analysis 6.1</a>). </p> </li> <li> <p>Recurrent UTI with a different pathogenic organism at four to six weeks did not differ between groups (<a href="./references#CD003772-fig-0038" title="">Analysis 6.2</a>: RR 1.19, 95% CI 0.45 to 3.18). </p> </li> <li> <p>There were no significant differences in the occurrence of an unsatisfactory clinical response at different time points after therapy (<a href="./references#CD003772-fig-0039" title="">Analysis 6.3</a>). </p> </li> <li> <p>The frequency of adverse effects did not differ between treatment groups (<a href="./references#CD003772-fig-0040" title="">Analysis 6.4</a>). </p> </li> </ul> </p> </section> <section id="CD003772-sec-0085"> <h5 class="title">Ceftriaxone versus cefotaxime</h5> <p><a href="./references#CD003772-bbs2-0002" title="BakkalogluA , SaatciU , SoylemezogluO , OzenS , TopalogluR , BesbasN , et al. Comparison of ceftriaxone versus cefotaxime for childhood upper urinary tract infections. Journal of Chemotherapy1996;8(1):59‐62. [MEDLINE: 8835111] ">Bakkaloglu 1996</a> compared ceftriaxone and cefotaxime in 100 children aged over 24 months. </p> <p> <ul id="CD003772-list-0023"> <li> <p>No child had persistent bacteriuria at 48 hours (<a href="./references#CD003772-fig-0041" title="">Analysis 7.1</a>). </p> </li> <li> <p>There were no significant differences between groups for bacteriuria at the end of treatment (<a href="./references#CD003772-fig-0042" title="">Analysis 7.2</a>.1: RR 0.87, 95% CI 0.37 to 2.03), for recurrent infection at one month after therapy (<a href="./references#CD003772-fig-0043" title="">Analysis 7.3</a>.1: RR 0.68, 95% CI 0.30 to 1.50), or for total adverse events (<a href="./references#CD003772-fig-0044" title="">Analysis 7.4</a>.1: RR 0.67, 95% CI 0.12 to 3.82). </p> </li> <li> <p>Post hoc subgroup analysis (<a href="./references#CD003772-fig-0042" title="">Analysis 7.2</a>.2 and <a href="./references#CD003772-fig-0042" title="">Analysis 7.2</a>.3) revealed no differences in outcomes for bacteriuria at the end of treatment or recurrent UTI at one month after therapy between children with and without abnormalities on imaging studies of the urinary tract. </p> </li> </ul> </p> </section> <section id="CD003772-sec-0086"> <h5 class="title">Aminoglycosides</h5> <p><a href="./references#CD003772-bbs2-0015" title="KafetzisDA , MaltezouHC , MavrikouM , SiafasC , ParaskakisI , DelisD , et al. Isepamicin versus amikacin for the treatment of acute pyelonephritis in children. International Journal of Antimicrobial Agents2000;14(1):51‐5. [MEDLINE: 10717501] ">Kafetzis 2000</a> compared the aminoglycosides isepamicin and amikacin in 16 children. </p> <p> <ul id="CD003772-list-0024"> <li> <p>No child in either group had persistent bacteriuria after 48 hours of treatment, or seven days or 30 days after treatment (<a href="./references#CD003772-fig-0045" title="">Analysis 8.1</a>). </p> </li> <li> <p>Mean time to resolution of fever in each group was identical (24 hours).</p> </li> <li> <p>No child in either treatment group developed hearing impairment on testing.</p> </li> </ul> </p> </section> </section> <section id="CD003772-sec-0087"> <h4 class="title">Duration of antibiotic administration</h4> <p>Four studies compared different durations of antibiotic administration (<a href="./references#CD003772-bbs2-0008" title="ChengCH , TsauYK , ChangCJ , ChangYC , KuoCY , TsaiIJ , et al. Acute lobar nephronia is associated with a high incidence of renal scarring in childhood urinary tract infections. Pediatric Infectious Disease Journal2010;29(7):624‐8. [MEDLINE: 20234330] ChengCH , TsauYK , LinTY . Effective duration of antimicrobial therapy for the treatment of acute lobar nephronia. Pediatrics2006;117(1):e84‐9. [MEDLINE: 16326693] ">Cheng 2006</a>; <a href="./references#CD003772-bbs2-0013" title="GrimwoodK , AbbottGD , FergussonDM . Single dose gentamicin treatment of urinary infections in children. New Zealand Medical Journal1988;101(852):539‐41. [MEDLINE: 3045718] ">Grimwood 1988</a>; <a href="./references#CD003772-bbs2-0022" title="PylkkänenJ , VilskaJ , KoskimiesO . The length of antimicrobial therapy in upper vs. lower urinary tract infection of childhood. Acta Paediatrica Scandinavica1981;70(6):885‐8. [MEDLINE: 7324942] PylkkänenJ , VilskaJ , KoskimiesO . The value of level diagnosis of childhood urinary tract infection in predicting renal injury. Acta Paediatrica Scandinavica1981;70(6):879‐83. [MEDLINE: 7324941] ">Pylkkänen 1981</a>; <a href="./references#CD003772-bbs2-0023" title="RepettoHA , MacLoughlinGJ . Single‐dose cefotaxime in the treatment of urinary tract infections in children: a randomized clinical trial. Journal of Antimicrobial Chemotherapy1984;14(Suppl B):307‐10. [MEDLINE: 6094457] ">Repetto 1984</a>). </p> <section id="CD003772-sec-0088"> <h5 class="title">Ten days versus 42 days of oral sulphafurazole</h5> <p>The study by <a href="./references#CD003772-bbs2-0022" title="PylkkänenJ , VilskaJ , KoskimiesO . The length of antimicrobial therapy in upper vs. lower urinary tract infection of childhood. Acta Paediatrica Scandinavica1981;70(6):885‐8. [MEDLINE: 7324942] PylkkänenJ , VilskaJ , KoskimiesO . The value of level diagnosis of childhood urinary tract infection in predicting renal injury. Acta Paediatrica Scandinavica1981;70(6):879‐83. [MEDLINE: 7324941] ">Pylkkänen 1981</a> involved 149 children and compared 10 days with 42 days of oral sulphafurazole. </p> <p> <ul id="CD003772-list-0025"> <li> <p>Recurrence of UTI within one month of ceasing therapy was significantly higher in children treated for 10 days compared with children treated for 42 days (<a href="./references#CD003772-fig-0046" title="">Analysis 9.1</a><i>:</i> RR 17.70, 95% CI 2.42 to 129.61). </p> </li> <li> <p>The number of children with recurrent UTI from one to 12 months after ceasing therapy did not differ between groups (<a href="./references#CD003772-fig-0047" title="">Analysis 9.2</a>: RR 0.87, 95% CI 0.40 to 1.88). </p> </li> </ul> </p> </section> <section id="CD003772-sec-0089"> <h5 class="title">Single dose parenteral antibiotic therapy versus seven to 10 days of oral therapy</h5> <p><a href="./references#CD003772-bbs2-0013" title="GrimwoodK , AbbottGD , FergussonDM . Single dose gentamicin treatment of urinary infections in children. New Zealand Medical Journal1988;101(852):539‐41. [MEDLINE: 3045718] ">Grimwood 1988</a> and <a href="./references#CD003772-bbs2-0023" title="RepettoHA , MacLoughlinGJ . Single‐dose cefotaxime in the treatment of urinary tract infections in children: a randomized clinical trial. Journal of Antimicrobial Chemotherapy1984;14(Suppl B):307‐10. [MEDLINE: 6094457] ">Repetto 1984</a> (involving a total of 61 children) compared single dose parenteral antibiotic therapy with seven to 10 days of oral therapy. </p> <p> <ul id="CD003772-list-0026"> <li> <p>There were no significant differences in the number of children with persistent bacteriuria after treatment (<a href="./references#CD003772-fig-0048" title="">Analysis 10.1</a> (2 studies, 35 children): RR 1.73, 95% CI 0.18 to 16.30; I² = 15%) or with recurrent UTI within six weeks (<a href="./references#CD003772-fig-0049" title="">Analysis 10.2</a> (2 studies, 35 children): RR 0.24, 95% CI 0.03 to 1.97). </p> </li> </ul> </p> </section> <section id="CD003772-sec-0090"> <h5 class="title">Three weeks with two weeks of antibiotics</h5> <p><a href="./references#CD003772-bbs2-0008" title="ChengCH , TsauYK , ChangCJ , ChangYC , KuoCY , TsaiIJ , et al. Acute lobar nephronia is associated with a high incidence of renal scarring in childhood urinary tract infections. Pediatric Infectious Disease Journal2010;29(7):624‐8. [MEDLINE: 20234330] ChengCH , TsauYK , LinTY . Effective duration of antimicrobial therapy for the treatment of acute lobar nephronia. Pediatrics2006;117(1):e84‐9. [MEDLINE: 16326693] ">Cheng 2006</a>, which involved 80 children, compared three weeks with two weeks of antibiotics for children with acute lobar nephronia. Antibiotics were chosen according to sensitivities. </p> <p> <ul id="CD003772-list-0027"> <li> <p>Seven children treated for two weeks had persistent or recurrent bacteriuria; this was not significantly different (<a href="./references#CD003772-fig-0050" title="">Analysis 11.1</a>: RR 0.07, 95% CI 0.00 to 1.19). </p> </li> <li> <p>Two children had recurrence of clinical symptoms with bacteriuria; this was not significantly different (<a href="./references#CD003772-fig-0051" title="">Analysis 11.2</a>: RR 0.21, 95% CI 0.01 to 4.24). </p> </li> </ul> </p> </section> <section id="CD003772-sec-0091"> <h5 class="title">Three days with 10 days of antibiotics</h5> <p><a href="./references#CD003772-bbs2-0016" title="KahnAJ , KumarK , EvansHE . Three‐day antimicrobial therapy of urinary tract infection. Journal of Pediatrics1981;99(6):992‐4. [MEDLINE: 7031217] ">Khan 1981</a> (54 children) compared three and 10 days of oral antibiotics. Data were reported as episodes of UTI (asymptomatic, lower tract, APN) and could not be included in a meta‐analysis. Of 31 episodes of UTI, 23 were cured in 27 children in the three day treatment group and 25 of 31 episodes were cured in 27 children in the 10 day treatment group. Of episodes of acute pyelonephritis, four were cured in five episodes in the three day treatment group and five were cured in six episodes in the 10 day treatment group. </p> </section> </section> <section id="CD003772-sec-0092"> <h4 class="title">Different routes of antibiotic administration</h4> <p><a href="./references#CD003772-bbs2-0012" title="FujiiR , ShinozakiT , MeguroH , ArimasuO , IzumiK , OsanoM , et al. Comparative, controlled study on an ampicillin suppository (KS‐R 1) with an oral form of ampicillin in urinary tract infections. Japanese Journal of Antibiotics1987;40(3):476‐92. [MEDLINE: 3302342] ">Fujii 1987</a>, which reported on 105 children, compared ampicillin administered by suppository with oral administration. </p> <p> <ul id="CD003772-list-0028"> <li> <p>There was no significant difference between treatments in the risk of persistent clinical symptoms (<a href="./references#CD003772-fig-0052" title="">Analysis 12.1</a>: RR 0.89, 95% CI 0.51 to 1.56) or bacteriuria (<a href="./references#CD003772-fig-0053" title="">Analysis 12.2</a>: RR 0.89, 95% CI 0.53 to 1.50). </p> </li> </ul> </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD003772-sec-0093" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD003772-sec-0093"></div> <section id="CD003772-sec-0094"> <h3 class="title" id="CD003772-sec-0094">Summary of main results</h3> <p>This review was designed to include all RCTs addressing all aspects of antibiotic treatment for children with acute pyelonephritis. Identified studies formed a heterogeneous group with few studies addressing the same or similar comparisons to enable assessment in meta‐analyses. The 27 included studies addressed a variety of different questions related to the therapy of children with acute pyelonephritis. </p> <section id="CD003772-sec-0095"> <h4 class="title">Oral therapy versus IV therapy</h4> <p>Four studies compared an oral antibiotic (ceftibuten, cefixime or amoxicillin/clavulanic acid) alone with IV therapy (cefotaxime or ceftriaxone) followed by oral therapy. These studies found: </p> <p> <ul id="CD003772-list-0029"> <li> <p>No significant difference in bacteriological outcomes between groups.</p> </li> <li> <p>The number of children with kidney parenchymal damage on DMSA scan at follow‐up whether expressed as a proportion of the total number considered to have acute pyelonephritis or as a proportion of those with DMSA changes at entry did not differ significantly between groups. </p> </li> </ul> </p> <p>Thus, there were no significant differences in efficacy between treatment with oral ceftibuten, cefixime and amoxicillin/clavulanic acid and IV therapy followed by oral therapy. Studies that support these findings enrolled children older than one month of age and hence the finding cannot be extrapolated to children aged less than one month. </p> </section> <section id="CD003772-sec-0096"> <h4 class="title">Short duration versus long duration IV therapy</h4> <p>A meta‐analysis of six studies showed:</p> <p> <ul id="CD003772-list-0030"> <li> <p>No significant differences in clinical or bacteriological outcomes between IV antibiotic therapy given for three to four days followed by oral therapy and IV therapy for seven to 14 days. </p> </li> <li> <p>That the prevalence of kidney parenchymal injury on DMSA scan at three to six months after UTI therapy did not differ significantly between treatment groups. </p> </li> </ul> </p> <p>These data show that short duration IV therapy (three to four days) can be used instead of longer courses of IV therapy to treat childhood acute pyelonephritis. The findings cannot be extrapolated to children less than one month of age as such children were excluded from the studies. </p> </section> <section id="CD003772-sec-0097"> <h4 class="title">Single daily dosing with aminoglycosides</h4> <p>If IV therapy is required, three studies provide data to support the safety and efficacy of daily dosing with aminoglycosides (gentamicin and netilmicin) compared with eight‐hourly dosing in children with acute pyelonephritis. Once daily dosing has been studied extensively in adults and is preferred due to improved efficacy, similar or reduced toxicity, convenience and lower costs. These findings have also been supported in children justifying the use of single daily dosing of aminoglycosides (<a href="./references#CD003772-bbs2-0076" title="Contopoulos‐IoannidisDG , GiotisND , BaliatsaDV , IoannidisJP . Extended‐interval aminoglycoside administration for children: a meta‐analysis. Pediatrics2004;114(1):e111‐8. [MEDLINE: 15231982] ">Contopoulos‐Ioannidis 2004</a>; <a href="./references#CD003772-bbs2-0080" title="JenhAM , TammaPD , MilstoneAM . Extended‐interval aminoglycoside dosing in pediatrics. Pediatric Infectious Disease Journal2011;30(4):338‐9. [MEDLINE: 21407038] ">Jenh 2011</a>), although aminoglycoside pharmacokinetics and toxicity differ in children from adults. </p> </section> <section id="CD003772-sec-0098"> <h4 class="title">Efficacy of different antibiotics</h4> <p>The seven studies that compared different antibiotics did not demonstrate any advantage of one agent over another. Four studies compared a cephalosporin with amoxicillin/clavulanic acid or TMP/SMX. A meta‐analysis of three studies demonstrated that children treated with oral ceftibuten had a higher clinical cure rate than TMP/SMX. However one large study (<a href="./references#CD003772-bbs2-0018" title="MarildS , EsbjornerE , JakobssonB , LinneT , LubeckP , SjogrenI , et al. Randomised study of ceftibuten vs trimethoprim‐sulfamethoxazole in pyelonephritis in children [abstract no: P466]. Pediatric Nephrology2004;19(9):C208. MarildS , JodalU , SandbergT . Ceftibuten versus trimethoprim‐sulfamethoxazole for oral treatment of febrile urinary tract infection in children. Pediatric Nephrology2009;24(3):521‐6. [MEDLINE: 18818954] ">Marild 2009</a>) contributed most of the weight of the analysis. The study defined clinical cure as the resolution of all symptoms related to the infection within 10 days. It is possible that there was some cross‐over of symptoms related to the infection and those due to adverse effects of medication such as vomiting. Furthermore, the study did not demonstrate any difference in bacteriological elimination rates despite 15% of the pathogens responsible for the infection being resistant to TMP/SMX compared to 2% that were resistant to ceftibuten. </p> <p>One study demonstrated that a single dose of parenteral medication added to oral therapy did not improve efficacy compared with oral therapy alone. </p> </section> <section id="CD003772-sec-0099"> <h4 class="title">Adverse events</h4> <p>Adverse events resulting from antibiotics were reported in 16 studies. Events were uncommon and rarely resulted in treatment discontinuation or significant alteration. </p> </section> </section> <section id="CD003772-sec-0100"> <h3 class="title" id="CD003772-sec-0100">Overall completeness and applicability of evidence</h3> <p>In this review a comprehensive and extensive literature review was performed to identify studies that assessed the benefits and harms of antibiotics to treat children with acute pyelonephritis. We found that oral antibiotic therapy alone is as effective as IV therapy followed by oral therapy, and similarly short IV therapy is as effective as longer courses of IV therapy to treat childhood acute pyelonephritis. It is unknown whether these findings apply to children less than one month of age since children aged below one month of age were excluded from studies. The exclusion criteria for participation in the included studies mean that our findings may not be generalizable to all children with acute pyelonephritis. There were 10 studies that excluded children who were severely ill or clinically unstable. Four studies did not specify any exclusion criteria. The applicability of the findings in children with uropathy may also be limited since 10 studies excluded children with known uropathy. <a href="./references#CD003772-bbs2-0014" title="HobermanA , WaldER . Intravenous versus oral antibiotics for urinary tract infections. Pediatrics2000;106(4):865. [MEDLINE: 11183178] HobermanA , WaldER , HickeyRW , BaskinM , CharronM , MajdM , et al. Oral versus initial intravenous therapy for urinary tract infections in young febrile children. Pediatrics1999;104(1 Pt 1):79‐86. [MEDLINE: 10390264] ">Hoberman 1999</a> performed a post hoc subgroup analysis to analyse differences in efficacy between children with or without VUR but the study was not designed and had no power to detect differences between small subgroups. Further data are required to determine whether treatment efficacy differs in children with non‐dilating VUR (grades I‐II) and dilating VUR (grades III‐V). </p> <p>Most of the studies examined the bacteriological efficacy of antibiotic therapy. Few studies compared the efficacy of antibiotic therapies on the resolution of clinical symptoms other than fever. </p> <p>None of the 27 included studies analysed the optimal duration of antibiotic therapy for childhood acute pyelonephritis. Our review evaluated oral antibiotic regimens in which oral antibiotics were used either alone or following IV antibiotics for a total duration of eight to 42 days of therapy. Inadequate data are available on the benefits and harms of shorter duration therapies (e.g. seven days or less). Three studies compared single dose parenteral antibiotic therapy or short course oral therapy with seven to 10 days of oral therapy and showed no significant differences but the studies were small. This is unlike the evidence supporting the use of short‐course therapies for the treatment of lower urinary tract infections in children (<a href="./references#CD003772-bbs2-0082" title="MichaelM , HodsonEM , CraigJC , MartinS , MoyerVA . Short compared with standard duration of antibiotic treatment for urinary tract infection: a systematic review of randomised controlled trials. Archives of Disease in Childhood2002;87(2):118‐23. [MEDLINE: 12138060] ">Michael 2002</a>; <a href="./references#CD003772-bbs2-0083" title="MichaelM , HodsonEM , CraigJC , MartinS , MoyerVA . Short versus standard duration oral antibiotic therapy for acute urinary tract infection in children. Cochrane Database of Systematic Reviews2003, Issue 1. [DOI: 10.1002/14651858.CD003966] ">Michael 2003</a>). </p> <p>From the low reported incidence of adverse events, we were only able to detect common adverse effects e.g. gastrointestinal upsets. Generally, RCTs are not powered to detect rare but serious side effects e.g. Stevens–Johnson syndrome, so our findings of adverse effects may not be generalizable to larger groups of children. </p> <p>Most of the included studies reported on short‐term outcomes. Nine studies analysed kidney parenchymal damage on DSMA scan at three to 12 months following an episode of acute pyelonephritis. Five of the nine studies had a high loss to follow up because of refusal to do a DMSA scan among well children and one study (not included) was terminated without any results for this reason (<a href="./references#CD003772-bbs2-0071" title="NCT00724256 . Randomised controlled trial on efficacy and safety of short term versus long term antibiotic therapy for pyelonephritis in childhood. ClinicalTrials.gov http://www.clinicaltrials.gov/ct2/results?term=NCT00724256; Vol. (accessed 4 July 2014). ">NCT00724256</a>). The loss to follow up of well children may lead to an underestimate of the effect of treatment. As the longest follow up of children was 12 months, this review cannot provide data on the likelihood of long term kidney scarring following antibiotic therapy. </p> <p>Although several studies potentially included adolescents aged to 16 years, none of the studies reported results for different age groups. Thus we could not determine whether there was any difference in results according to the patients' ages. </p> </section> <section id="CD003772-sec-0101"> <h3 class="title" id="CD003772-sec-0101">Quality of the evidence</h3> <p>The quality of the included studies was quite variable. The main limitations in the quality of the studies were concealment of allocation, blinding of participants and personnel and sponsorship from pharmaceutical companies. Of the 27 included studies, 12 reported adequate sequence generation and six demonstrated adequate allocation concealment. The lack of adequate sequence generation and allocation concealment can lead to biased estimates of treatment effects in the original study and therefore the results of a systematic review (<a href="./references#CD003772-bbs2-0079" title="HollisS , CampbellF . What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ1999;319(7221):670‐4. [MEDLINE: 10480822] ">Hollis 1999</a>; <a href="./references#CD003772-bbs2-0081" title="JuniP , WitschiA , BlochR , EggerM . The hazards of scoring the quality of clinical trials for meta‐analysis. JAMA1999;282(11):1054‐60. [MEDLINE: 10493204] ">Juni 1999</a>; <a href="./references#CD003772-bbs2-0084" title="MoherD , PhamB , JonesA , CookDJ , JadadAR , MoherM , et al. Does the quality of reports of randomised trials affect estimates of intervention efficacy reported in meta‐analyses?. Lancet1998;352(9128):609‐13. [MEDLINE: 9746022] ">Moher 1998</a>; <a href="./references#CD003772-bbs2-0087" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273(5):408‐12. [MEDLINE: 7823387] ">Schulz 1995</a>). All of the studies were unblinded to participants and personnel primarily because antibiotics were delivered by the parenteral route compared with oral or used different dosing regimens. This was considered a high risk of bias because clinicians’ management could be influenced by knowledge of the treatment group. For blinding of outcome assessors, blinding was adequate in 17 studies where the primary outcome was bacteriological or radiological and considered unlikely to be influenced by lack of blinding. We found that 19 studies provided complete data reporting and 13 reported on all reasonably expected outcomes (bacteriological eradication, clinical cure and adverse effects). The authors of 11 studies reported receiving sponsorship from pharmaceutical companies. </p> <p>The quality of the evidence was assessed according to the GRADE approach and is displayed in summary of findings tables. </p> <p>The evidence that oral therapy alone is as effective as IV therapy followed by oral therapy in children with acute pyelonephritis is considered to be of moderate quality. The quality of evidence was downgraded because of imprecision regarding the time to resolution of fever and the loss to follow‐up for DMSA scans (<a href="./full#CD003772-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>The evidence that short duration IV therapy followed by oral therapy is as effective as long duration IV therapy is considered to be of moderate quality. The quality of evidence was downgraded because of unclear or inadequate allocation concealment in the included studies which may increase the risk of selection bias, the studies being too small and the loss to follow‐up for DMSA scans (<a href="./full#CD003772-tbl-0002">summary of findings Table 2</a>). </p> <p>The evidence that daily dosing of aminoglycosides is as safe and effective as thrice daily dosing of aminoglycosides is considered to be of low quality. The quality of evidence was downgraded because of unclear allocation concealment in two of three studies and the small number of participants combined with the low frequency of events that made the analysis significantly underpowered to detect a difference (<a href="./full#CD003772-tbl-0003">summary of findings Table 3</a>). </p> <p>The evidence that third generation cephalosporins are no more effective than other antibiotics (amoxicillin/clavulanic acid and TMP/SMX) is low. The quality of evidence was downgraded because of unclear allocation, imprecision from sparse data, and inconsistent bacteriologic results from one study that provided most of the weight of the meta‐analysis (<a href="./full#CD003772-tbl-0004">summary of findings Table 4</a>). </p> </section> <section id="CD003772-sec-0102"> <h3 class="title" id="CD003772-sec-0102">Potential biases in the review process</h3> <p>We attempted to reduce publication bias by searching multiple databases and the grey literature without language restriction. Although the Cochrane Renal Group's Specialised Register contains the handsearched reports of studies, it is possible that we missed unpublished data presented at smaller conferences or studies published in foreign language journals and low impact journals. Studies may have been added since our last search of the register. No data were available from the terminated study (<a href="./references#CD003772-bbs2-0071" title="NCT00724256 . Randomised controlled trial on efficacy and safety of short term versus long term antibiotic therapy for pyelonephritis in childhood. ClinicalTrials.gov http://www.clinicaltrials.gov/ct2/results?term=NCT00724256; Vol. (accessed 4 July 2014). ">NCT00724256</a>) after personal communication with the lead author. Not all included studies reported all outcomes. Some outcomes that would be expected to be known (e.g. resolution of clinical symptoms) were not reported which may have affected the results of meta‐analyses. </p> </section> <section id="CD003772-sec-0103"> <h3 class="title" id="CD003772-sec-0103">Agreements and disagreements with other studies or reviews</h3> <p>A systematic review published in 2008 evaluated an early switch to oral antibiotics after at least one day of initial IV antibiotics with IV therapy alone for hospitalised patients with acute pyelonephritis (<a href="./references#CD003772-bbs2-0092" title="VouloumanouEK , RafailidisPI , KazantziMS , AthanasiouS , FalagasME . Early switch to oral versus intravenous antimicrobial treatment for hospitalized patients with acute pyelonephritis: a systematic review of randomized controlled trials. Current Medical Research &amp; Opinion2008;24(12):3423‐34. [MEDLINE: 19032124] ">Vouloumanou 2008</a>). The meta‐analysis included both children and adults with acute pyelonephritis but the data from the two populations could be separated. It identified all six RCTs in children that we included in our review for this comparison. The authors found there was no difference in the incidence of kidney scars, microbiological eradication, clinical cure, reinfection, persistence of acute pyelonephritis, or adverse events between the two treatment regimens. This is consistent with our finding that short duration IV therapy followed by oral therapy is as effective as longer courses of IV therapy for the treatment of acute pyelonephritis in children. </p> <p>No other systematic reviews were found for the 11 other comparisons in our review.</p> <p>This review agrees with recently published guidelines (<a href="./references#CD003772-bbs2-0072" title="American Academy of Pediatrics. Subcommittee On Urinary Tract Infection, Steering Committee On Quality Improvement and Management. Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months. Pediatrics2011;128(3):595‐610. [MEDLINE: 21873693] ">AAP 2011</a>; <a href="./references#CD003772-bbs2-0073" title="AmmentiA , CataldiL , ChimenzR , FanosV , LaMannaA , MarraG , et al. Febrile urinary tract infections in young children: recommendations for the diagnosis, treatment and follow‐up. Acta Paediatrica2012; Vol. 101, issue 5:451‐7. [MEDLINE: 22122295] ">Ammenti 2012</a>; <a href="./references#CD003772-bbs2-0085" title="National Institute for Health and Clinical Excellence. Urinary tract infection in children: diagnosis, treatment and long‐term management CG54. 2007. http://www.nice.org.uk/guidance/CG54. London: RCOG Press, (accessed 4 July 2014). ">NICE 2007</a>) for the treatment of childhood UTI, which recommend oral antibiotics for the initial treatment of children with acute pyelonephritis unless the child is seriously ill and/or unable to tolerate oral antibiotics. Our findings can be applied to children aged over one month. The <a href="./references#CD003772-bbs2-0085" title="National Institute for Health and Clinical Excellence. Urinary tract infection in children: diagnosis, treatment and long‐term management CG54. 2007. http://www.nice.org.uk/guidance/CG54. London: RCOG Press, (accessed 4 July 2014). ">NICE 2007</a> guidelines apply to children aged three months or older, the <a href="./references#CD003772-bbs2-0072" title="American Academy of Pediatrics. Subcommittee On Urinary Tract Infection, Steering Committee On Quality Improvement and Management. Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months. Pediatrics2011;128(3):595‐610. [MEDLINE: 21873693] ">AAP 2011</a> guidelines apply to children aged 2 to 24 months and the <a href="./references#CD003772-bbs2-0073" title="AmmentiA , CataldiL , ChimenzR , FanosV , LaMannaA , MarraG , et al. Febrile urinary tract infections in young children: recommendations for the diagnosis, treatment and follow‐up. Acta Paediatrica2012; Vol. 101, issue 5:451‐7. [MEDLINE: 22122295] ">Ammenti 2012</a> recommendations apply to children aged two months to three years. The guidelines also suggest seven or more days of antibiotic treatment but recognise that this is not based on best evidence because there are no data on the optimal duration of antibiotic therapy, particularly shorter courses. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD003772-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/urn:x-wiley:14651858:media:CD003772:CD003772-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_t/tCD003772-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD003772-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/full#CD003772-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003772-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/urn:x-wiley:14651858:media:CD003772:CD003772-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_t/tCD003772-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD003772-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/full#CD003772-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003772-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/urn:x-wiley:14651858:media:CD003772:CD003772-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_t/tCD003772-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003772-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/full#CD003772-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003772-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/urn:x-wiley:14651858:media:CD003772:CD003772-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_t/tCD003772-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral versus IV followed by oral (11 days) therapy, Outcome 1 Time to fever resolution." data-id="CD003772-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Oral versus IV followed by oral (11 days) therapy, Outcome 1 Time to fever resolution. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003772-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/urn:x-wiley:14651858:media:CD003772:CD003772-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_t/tCD003772-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral versus IV followed by oral (11 days) therapy, Outcome 2 Fever on Day 3." data-id="CD003772-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Oral versus IV followed by oral (11 days) therapy, Outcome 2 Fever on Day 3. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003772-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/urn:x-wiley:14651858:media:CD003772:CD003772-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_t/tCD003772-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral versus IV followed by oral (11 days) therapy, Outcome 3 Number with persistent UTI at 72 hours." data-id="CD003772-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Oral versus IV followed by oral (11 days) therapy, Outcome 3 Number with persistent UTI at 72 hours. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003772-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/urn:x-wiley:14651858:media:CD003772:CD003772-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_t/tCD003772-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral versus IV followed by oral (11 days) therapy, Outcome 4 Inflammatory markers at 72 hours." data-id="CD003772-fig-0007" src="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Oral versus IV followed by oral (11 days) therapy, Outcome 4 Inflammatory markers at 72 hours. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003772-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/urn:x-wiley:14651858:media:CD003772:CD003772-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_t/tCD003772-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral versus IV followed by oral (11 days) therapy, Outcome 5 Recurrent UTI within 6 months." data-id="CD003772-fig-0008" src="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Oral versus IV followed by oral (11 days) therapy, Outcome 5 Recurrent UTI within 6 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003772-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/urn:x-wiley:14651858:media:CD003772:CD003772-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_t/tCD003772-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral versus IV followed by oral (11 days) therapy, Outcome 6 Persistent kidney damage at 6‐12 months." data-id="CD003772-fig-0009" src="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Oral versus IV followed by oral (11 days) therapy, Outcome 6 Persistent kidney damage at 6‐12 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003772-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/urn:x-wiley:14651858:media:CD003772:CD003772-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_t/tCD003772-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral versus IV followed by oral (11 days) therapy, Outcome 7 Proportion of kidney parenchyma with damage at 6 months." data-id="CD003772-fig-0010" src="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Oral versus IV followed by oral (11 days) therapy, Outcome 7 Proportion of kidney parenchyma with damage at 6 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003772-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/urn:x-wiley:14651858:media:CD003772:CD003772-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_t/tCD003772-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral versus IV followed by oral (11 days) therapy, Outcome 8 Kidney damage at 6 months (post hoc subgroup analysis)." data-id="CD003772-fig-0011" src="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Oral versus IV followed by oral (11 days) therapy, Outcome 8 Kidney damage at 6 months (post hoc subgroup analysis). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003772-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/urn:x-wiley:14651858:media:CD003772:CD003772-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_t/tCD003772-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Short duration (3‐4 days) versus long duration (7‐14 days) IV therapy, Outcome 1 Persistent bacteriuria after treatment." data-id="CD003772-fig-0012" src="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Short duration (3‐4 days) versus long duration (7‐14 days) IV therapy, Outcome 1 Persistent bacteriuria after treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003772-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/urn:x-wiley:14651858:media:CD003772:CD003772-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_t/tCD003772-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Short duration (3‐4 days) versus long duration (7‐14 days) IV therapy, Outcome 2 Recurrent UTI within 6 months." data-id="CD003772-fig-0013" src="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Short duration (3‐4 days) versus long duration (7‐14 days) IV therapy, Outcome 2 Recurrent UTI within 6 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003772-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/urn:x-wiley:14651858:media:CD003772:CD003772-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_t/tCD003772-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Short duration (3‐4 days) versus long duration (7‐14 days) IV therapy, Outcome 3 Persistent kidney damage at 3‐6 months." data-id="CD003772-fig-0014" src="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Short duration (3‐4 days) versus long duration (7‐14 days) IV therapy, Outcome 3 Persistent kidney damage at 3‐6 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003772-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/urn:x-wiley:14651858:media:CD003772:CD003772-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_t/tCD003772-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Short duration (3‐4 days) versus long duration (7‐14 days) IV therapy, Outcome 4 Persistent kidney damage at 3‐6 months (post hoc subgroup analysis)." data-id="CD003772-fig-0015" src="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Short duration (3‐4 days) versus long duration (7‐14 days) IV therapy, Outcome 4 Persistent kidney damage at 3‐6 months (post hoc subgroup analysis). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003772-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/urn:x-wiley:14651858:media:CD003772:CD003772-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_t/tCD003772-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Short duration (3‐4 days) versus long duration (7‐14 days) IV therapy, Outcome 5 Adverse effects." data-id="CD003772-fig-0016" src="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Short duration (3‐4 days) versus long duration (7‐14 days) IV therapy, Outcome 5 Adverse effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003772-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/urn:x-wiley:14651858:media:CD003772:CD003772-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_t/tCD003772-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Single dose parenteral therapy and oral therapy versus oral therapy alone, Outcome 1 Persistent bacteriuria at 48 hours." data-id="CD003772-fig-0017" src="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Single dose parenteral therapy and oral therapy versus oral therapy alone, Outcome 1 Persistent bacteriuria at 48 hours. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003772-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/urn:x-wiley:14651858:media:CD003772:CD003772-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_t/tCD003772-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Single dose parenteral therapy and oral therapy versus oral therapy alone, Outcome 2 Treatment failure after 48 hours of therapy." data-id="CD003772-fig-0018" src="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Single dose parenteral therapy and oral therapy versus oral therapy alone, Outcome 2 Treatment failure after 48 hours of therapy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003772-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/urn:x-wiley:14651858:media:CD003772:CD003772-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_t/tCD003772-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Single dose parenteral therapy and oral therapy versus oral therapy alone, Outcome 3 Recurrent UTI within 1 month." data-id="CD003772-fig-0019" src="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Single dose parenteral therapy and oral therapy versus oral therapy alone, Outcome 3 Recurrent UTI within 1 month. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003772-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/urn:x-wiley:14651858:media:CD003772:CD003772-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_t/tCD003772-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Single dose parenteral therapy and oral therapy versus oral therapy alone, Outcome 4 Adverse events." data-id="CD003772-fig-0020" src="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Single dose parenteral therapy and oral therapy versus oral therapy alone, Outcome 4 Adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003772-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/urn:x-wiley:14651858:media:CD003772:CD003772-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_t/tCD003772-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Different dosing regimens of aminoglycosides (daily versus 8 hourly), Outcome 1 Persistent bacteriuria after 1‐3 days of treatment." data-id="CD003772-fig-0021" src="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Different dosing regimens of aminoglycosides (daily versus 8 hourly), Outcome 1 Persistent bacteriuria after 1‐3 days of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003772-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/urn:x-wiley:14651858:media:CD003772:CD003772-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_t/tCD003772-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Different dosing regimens of aminoglycosides (daily versus 8 hourly), Outcome 2 Persistent symptoms at end of 3 days of IV therapy." data-id="CD003772-fig-0022" src="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Different dosing regimens of aminoglycosides (daily versus 8 hourly), Outcome 2 Persistent symptoms at end of 3 days of IV therapy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003772-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/urn:x-wiley:14651858:media:CD003772:CD003772-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_t/tCD003772-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Different dosing regimens of aminoglycosides (daily versus 8 hourly), Outcome 3 Persistent bacteriuria at 1 week after treatment." data-id="CD003772-fig-0023" src="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Different dosing regimens of aminoglycosides (daily versus 8 hourly), Outcome 3 Persistent bacteriuria at 1 week after treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003772-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/urn:x-wiley:14651858:media:CD003772:CD003772-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_t/tCD003772-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Different dosing regimens of aminoglycosides (daily versus 8 hourly), Outcome 4 Reinfection at 1 month after completing treatment." data-id="CD003772-fig-0024" src="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Different dosing regimens of aminoglycosides (daily versus 8 hourly), Outcome 4 Reinfection at 1 month after completing treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003772-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/urn:x-wiley:14651858:media:CD003772:CD003772-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_t/tCD003772-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Different dosing regimens of aminoglycosides (daily versus 8 hourly), Outcome 5 Hearing impairment following treatment." data-id="CD003772-fig-0025" src="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Different dosing regimens of aminoglycosides (daily versus 8 hourly), Outcome 5 Hearing impairment following treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003772-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/urn:x-wiley:14651858:media:CD003772:CD003772-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_t/tCD003772-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Different dosing regimens of aminoglycosides (daily versus 8 hourly), Outcome 6 Increase in serum creatinine during treatment." data-id="CD003772-fig-0026" src="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Different dosing regimens of aminoglycosides (daily versus 8 hourly), Outcome 6 Increase in serum creatinine during treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003772-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/urn:x-wiley:14651858:media:CD003772:CD003772-CMP-004-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_t/tCD003772-CMP-004-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Different dosing regimens of aminoglycosides (daily versus 8 hourly), Outcome 7 Time to resolution of fever." data-id="CD003772-fig-0027" src="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-004-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 Different dosing regimens of aminoglycosides (daily versus 8 hourly), Outcome 7 Time to resolution of fever. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-004-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003772-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/urn:x-wiley:14651858:media:CD003772:CD003772-CMP-004-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_t/tCD003772-CMP-004-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Different dosing regimens of aminoglycosides (daily versus 8 hourly), Outcome 8 Kidney parenchymal damage at 3 months." data-id="CD003772-fig-0028" src="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-004-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4 Different dosing regimens of aminoglycosides (daily versus 8 hourly), Outcome 8 Kidney parenchymal damage at 3 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-004-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003772-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/urn:x-wiley:14651858:media:CD003772:CD003772-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_t/tCD003772-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Third generation cephalosporin versus other antibiotic, Outcome 1 Persistent bacteriuria." data-id="CD003772-fig-0029" src="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Third generation cephalosporin versus other antibiotic, Outcome 1 Persistent bacteriuria. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003772-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/urn:x-wiley:14651858:media:CD003772:CD003772-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_t/tCD003772-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Third generation cephalosporin versus other antibiotic, Outcome 2 Recurrent UTI after end of therapy." data-id="CD003772-fig-0030" src="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Third generation cephalosporin versus other antibiotic, Outcome 2 Recurrent UTI after end of therapy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003772-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/urn:x-wiley:14651858:media:CD003772:CD003772-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_t/tCD003772-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Third generation cephalosporin versus other antibiotic, Outcome 3 Persistent symptoms after end of treatment." data-id="CD003772-fig-0031" src="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Third generation cephalosporin versus other antibiotic, Outcome 3 Persistent symptoms after end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003772-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/urn:x-wiley:14651858:media:CD003772:CD003772-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_t/tCD003772-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Third generation cephalosporin versus other antibiotic, Outcome 4 Number with fever for more than 48 hours." data-id="CD003772-fig-0032" src="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 Third generation cephalosporin versus other antibiotic, Outcome 4 Number with fever for more than 48 hours. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003772-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/urn:x-wiley:14651858:media:CD003772:CD003772-CMP-005-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_t/tCD003772-CMP-005-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Third generation cephalosporin versus other antibiotic, Outcome 5 Recurrent bacteriuria at 4‐6 weeks." data-id="CD003772-fig-0033" src="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-005-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5 Third generation cephalosporin versus other antibiotic, Outcome 5 Recurrent bacteriuria at 4‐6 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-005-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003772-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/urn:x-wiley:14651858:media:CD003772:CD003772-CMP-005-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_t/tCD003772-CMP-005-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Third generation cephalosporin versus other antibiotic, Outcome 6 Recurrent symptomatic UTI at 4‐6 weeks." data-id="CD003772-fig-0034" src="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-005-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5 Third generation cephalosporin versus other antibiotic, Outcome 6 Recurrent symptomatic UTI at 4‐6 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-005-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003772-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/urn:x-wiley:14651858:media:CD003772:CD003772-CMP-005-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_t/tCD003772-CMP-005-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Third generation cephalosporin versus other antibiotic, Outcome 7 Gastrointestinal adverse events." data-id="CD003772-fig-0035" src="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-005-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5 Third generation cephalosporin versus other antibiotic, Outcome 7 Gastrointestinal adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-005-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003772-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/urn:x-wiley:14651858:media:CD003772:CD003772-CMP-005-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_t/tCD003772-CMP-005-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Third generation cephalosporin versus other antibiotic, Outcome 8 Number discontinuing treatment for adverse effect." data-id="CD003772-fig-0036" src="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-005-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.8</div> <div class="figure-caption"> <p>Comparison 5 Third generation cephalosporin versus other antibiotic, Outcome 8 Number discontinuing treatment for adverse effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-005-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003772-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/urn:x-wiley:14651858:media:CD003772:CD003772-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_t/tCD003772-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Cefepime versus ceftazidime, Outcome 1 Persistence or recurrence of initial pathogen." data-id="CD003772-fig-0037" src="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Cefepime versus ceftazidime, Outcome 1 Persistence or recurrence of initial pathogen. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003772-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/urn:x-wiley:14651858:media:CD003772:CD003772-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_t/tCD003772-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Cefepime versus ceftazidime, Outcome 2 Infection with new pathogen at 4‐6 weeks." data-id="CD003772-fig-0038" src="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Cefepime versus ceftazidime, Outcome 2 Infection with new pathogen at 4‐6 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003772-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/urn:x-wiley:14651858:media:CD003772:CD003772-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_t/tCD003772-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Cefepime versus ceftazidime, Outcome 3 Unsatisfactory clinical response." data-id="CD003772-fig-0039" src="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 Cefepime versus ceftazidime, Outcome 3 Unsatisfactory clinical response.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003772-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/urn:x-wiley:14651858:media:CD003772:CD003772-CMP-006-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_t/tCD003772-CMP-006-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Cefepime versus ceftazidime, Outcome 4 Adverse effects." data-id="CD003772-fig-0040" src="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-006-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 Cefepime versus ceftazidime, Outcome 4 Adverse effects.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-006-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003772-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/urn:x-wiley:14651858:media:CD003772:CD003772-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_t/tCD003772-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Ceftriaxone versus cefotaxime, Outcome 1 Persistent bacteriuria at 48 hours." data-id="CD003772-fig-0041" src="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Ceftriaxone versus cefotaxime, Outcome 1 Persistent bacteriuria at 48 hours. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003772-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/urn:x-wiley:14651858:media:CD003772:CD003772-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_t/tCD003772-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Ceftriaxone versus cefotaxime, Outcome 2 Bacteriuria 10 days after end of treatment." data-id="CD003772-fig-0042" src="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 Ceftriaxone versus cefotaxime, Outcome 2 Bacteriuria 10 days after end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003772-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/urn:x-wiley:14651858:media:CD003772:CD003772-CMP-007-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_t/tCD003772-CMP-007-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Ceftriaxone versus cefotaxime, Outcome 3 UTI at 1 month after therapy." data-id="CD003772-fig-0043" src="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-007-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7 Ceftriaxone versus cefotaxime, Outcome 3 UTI at 1 month after therapy.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-007-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003772-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/urn:x-wiley:14651858:media:CD003772:CD003772-CMP-007-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_t/tCD003772-CMP-007-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Ceftriaxone versus cefotaxime, Outcome 4 Adverse events." data-id="CD003772-fig-0044" src="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-007-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7 Ceftriaxone versus cefotaxime, Outcome 4 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-007-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003772-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/urn:x-wiley:14651858:media:CD003772:CD003772-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_t/tCD003772-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Isepamicin versus amikacin, Outcome 1 Persistent bacteriuria." data-id="CD003772-fig-0045" src="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 Isepamicin versus amikacin, Outcome 1 Persistent bacteriuria.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003772-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/urn:x-wiley:14651858:media:CD003772:CD003772-CMP-009-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_t/tCD003772-CMP-009-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 10 days versus 42 days of oral sulfafurazole, Outcome 1 Recurrent UTI within 1 month after ceasing therapy." data-id="CD003772-fig-0046" src="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-009-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9 10 days versus 42 days of oral sulfafurazole, Outcome 1 Recurrent UTI within 1 month after ceasing therapy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-009-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003772-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/urn:x-wiley:14651858:media:CD003772:CD003772-CMP-009-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_t/tCD003772-CMP-009-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 10 days versus 42 days of oral sulfafurazole, Outcome 2 Recurrent UTI at 1‐12 months after completing therapy." data-id="CD003772-fig-0047" src="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-009-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9 10 days versus 42 days of oral sulfafurazole, Outcome 2 Recurrent UTI at 1‐12 months after completing therapy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-009-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003772-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/urn:x-wiley:14651858:media:CD003772:CD003772-CMP-010-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_t/tCD003772-CMP-010-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Single dose of parenteral antibiotic versus 7‐10 days oral therapy, Outcome 1 Persistent bacteriuria 1‐2 days after treatment." data-id="CD003772-fig-0048" src="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-010-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10 Single dose of parenteral antibiotic versus 7‐10 days oral therapy, Outcome 1 Persistent bacteriuria 1‐2 days after treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-010-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003772-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/urn:x-wiley:14651858:media:CD003772:CD003772-CMP-010-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_t/tCD003772-CMP-010-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Single dose of parenteral antibiotic versus 7‐10 days oral therapy, Outcome 2 UTI relapse or reinfection within 6 weeks." data-id="CD003772-fig-0049" src="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-010-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10 Single dose of parenteral antibiotic versus 7‐10 days oral therapy, Outcome 2 UTI relapse or reinfection within 6 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-010-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003772-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/urn:x-wiley:14651858:media:CD003772:CD003772-CMP-011-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_t/tCD003772-CMP-011-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 3 weeks versus 2 weeks, Outcome 1 Persistence/recurrence of bacteriuria." data-id="CD003772-fig-0050" src="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-011-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11 3 weeks versus 2 weeks, Outcome 1 Persistence/recurrence of bacteriuria.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-011-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003772-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/urn:x-wiley:14651858:media:CD003772:CD003772-CMP-011-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_t/tCD003772-CMP-011-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 3 weeks versus 2 weeks, Outcome 2 Recurrence of clinical UTI." data-id="CD003772-fig-0051" src="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-011-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.2</div> <div class="figure-caption"> <p>Comparison 11 3 weeks versus 2 weeks, Outcome 2 Recurrence of clinical UTI.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-011-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003772-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/urn:x-wiley:14651858:media:CD003772:CD003772-CMP-012-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_t/tCD003772-CMP-012-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Suppositories versus oral ampicillin, Outcome 1 Persistence of clinical symptoms." data-id="CD003772-fig-0052" src="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-012-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12 Suppositories versus oral ampicillin, Outcome 1 Persistence of clinical symptoms. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-012-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003772-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/urn:x-wiley:14651858:media:CD003772:CD003772-CMP-012-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_t/tCD003772-CMP-012-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Suppositories versus oral ampicillin, Outcome 2 Persistence of bacteriuria." data-id="CD003772-fig-0053" src="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-012-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.2</div> <div class="figure-caption"> <p>Comparison 12 Suppositories versus oral ampicillin, Outcome 2 Persistence of bacteriuria.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/media/CDSR/CD003772/image_n/nCD003772-CMP-012-02.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD003772-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Oral versus IV followed by oral (11 days) therapy for acute pyelonephritis in children</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Oral versus IV followed by oral (11 days) therapy for acute pyelonephritis in children</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children with acute pyelonephritis<br/> <b>Intervention:</b> oral versus IV followed by oral (11 days) therapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Oral</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> IV followed by oral (11 days) therapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to fever resolution (hours)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean time to fever resolution (hours) in the intervention groups was <b>2.05 higher</b> (0.84 lower to 4.94 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>808 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Renal parenchymal damage at 6 to 12 months: all included children with acute pyelonephritis</b> <br/> DMSA scans<br/> Follow‐up: 6 to 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.82</b> <br/> (0.59 to 1.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>943 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>224 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>184 per 1000</b> <br/> (132 to 251) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>313 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>257 per 1000</b> <br/> (185 to 351) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Renal parenchymal damage at 6 to 12 months: children with renal parenchymal damage on initial DMSA</b> <br/> Follow‐up: 6 to 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.79</b> <br/> (0.61 to 1.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>681 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>320 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>253 per 1000</b> <br/> (195 to 330) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>382 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>302 per 1000</b> <br/> (233 to 393) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Wide confidence intervals due to large standard deviations around the mean durations of fever<br/> <sup>2</sup> Large number of patients excluded because of lack of follow‐up DMSA scans<br/> <sup>3</sup> No explanation was provided </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Oral versus IV followed by oral (11 days) therapy for acute pyelonephritis in children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/full#CD003772-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003772-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Short duration (3 to 4 days) versus long duration (7 to 14 days) IV therapy for acute pyelonephritis in children</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Short duration (3 to 4 days) versus long duration (7 to 14 days) IV therapy for acute pyelonephritis in children</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children with acute pyelonephritis<br/> <b>Intervention:</b> short duration (3 to 4 days) versus long duration (7 to 14 days) IV therapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Short duration (3 to 4 days)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Long duration (7 to 14 days) IV therapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Persistent bacteriuria after treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.78</b> <br/> (0.24 to 2.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>305 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>38 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>30 per 1000</b> <br/> (9 to 98) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Recurrent UTI within 6 months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.97</b> <br/> (0.58 to 1.62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>993 (5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>59 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>57 per 1000</b> <br/> (34 to 95) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>56 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>54 per 1000</b> <br/> (32 to 91) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Persistent renal damage at 3 to 6 months: all included children with acute pyelonephritis</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.01</b> <br/> (0.8 to 1.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>726 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>246 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>249 per 1000</b> <br/> (197 to 318) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>257 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>260 per 1000</b> <br/> (206 to 332) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Persistent renal damage at 3 to 6 months: children with initial renal parenchymal damage on initial DMSA scan</b> <br/> Follow‐up: 6‐12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.1</b> <br/> (0.84 to 1.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>315 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>357 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>393 per 1000</b> <br/> (300 to 518) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>327 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>360 per 1000</b> <br/> (275 to 474) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Unclear or inadequate allocation concealment<br/> <sup>2</sup> Small number of patients and events leading to wide confidence intervals<br/> <sup>3</sup> In several studies, more than 10% patients lost to follow‐up or did not have follow‐up DMSA scans </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Short duration (3 to 4 days) versus long duration (7 to 14 days) IV therapy for acute pyelonephritis in children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/full#CD003772-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003772-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Different dosing regimens of aminoglycosides (daily versus 8 hourly) for acute pyelonephritis in children</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Different dosing regimens of aminoglycosides (daily versus 8 hourly) for acute pyelonephritis in children</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children with acute pyelonephritis<br/> <b>Intervention:</b> different dosing regimens of aminoglycosides (daily versus 8 hourly) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Daily dose</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 hourly dose</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Persistent bacteriuria after 1 to 3 days of treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.05</b> <br/> (0.15 to 7.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>435 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>9 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per 1000</b> <br/> (1 to 67) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Hearing impairment following treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 2.83</b> <br/> (0.33 to 24.56) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>271 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Increase in serum creatinine during treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.75</b> <br/> (0.2 to 2.82) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>419 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>25 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>19 per 1000</b> <br/> (5 to 70) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>25 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>19 per 1000</b> <br/> (5 to 70) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Unclear allocation concealment in two of three studies<br/> <sup>2</sup> Few events resulting in wide confidence intervals </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Different dosing regimens of aminoglycosides (daily versus 8 hourly) for acute pyelonephritis in children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/full#CD003772-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003772-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Agent: Third generation cephalosporin versus other antibiotic for acute pyelonephritis in children</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Agent: Third generation cephalosporin versus other antibiotic for acute pyelonephritis in children</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children with acute pyelonephritis<br/> <b>Intervention:</b> third generation cephalosporin versus other antibiotic </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Antibiotic</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Third generation cephalosporin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Persistent bacteriuria</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 2.41</b> <br/> (0.98 to 5.93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>439 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>34 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>81 per 1000</b> <br/> (33 to 199) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Recurrent UTI after end of therapy</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.23</b> <br/> (0.32 to 4.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>491 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>22 per 1000</b> <br/> (6 to 87) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per 1000</b> <br/> (3 to 38) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Persistent symptoms after end of treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.28</b> <br/> (0.13 to 0.62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>471 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>104 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>29 per 1000</b> <br/> (14 to 64) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Unclear allocation in several studies<br/> <sup>2</sup> Few events leading to imprecision<br/> <sup>3</sup> Meta‐analysis dominated by single trial and results inconsistent with bacteriologic results </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Agent: Third generation cephalosporin versus other antibiotic for acute pyelonephritis in children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/full#CD003772-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003772-tbl-0005"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Reported outcomes of included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Study/ comparisons</b> </p> <p><b> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b> Reported outcomes</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Persistent bacteriuria at 48 to 72 hours</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Bacteriuria at the end or ≥ 5 days of treatment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>UTI at follow‐up</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Resolution of clinical symptoms</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Symptomatic recurrence of UTI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Parenchymal renal damage on DSMA scan</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Oral therapy versus sequential short duration IV therapy and oral therapy</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003772-bbs2-0005" title="BocquetN , Sergent AlaouiA , JaisJP , GajdosV , GuigonisV , LacourB , et al. Randomized trial of oral versus sequential IV/oral antibiotic for acute pyelonephritis in children. Pediatrics2012;129(2):e269‐75. [MEDLINE: 22291112] ">Bocquet 2012</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003772-bbs2-0014" title="HobermanA , WaldER . Intravenous versus oral antibiotics for urinary tract infections. Pediatrics2000;106(4):865. [MEDLINE: 11183178] HobermanA , WaldER , HickeyRW , BaskinM , CharronM , MajdM , et al. Oral versus initial intravenous therapy for urinary tract infections in young febrile children. Pediatrics1999;104(1 Pt 1):79‐86. [MEDLINE: 10390264] ">Hoberman 1999</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003772-bbs2-0019" title="HewittIK , TomasiL , PavanelloL , MaschioF , MolinariPP , ToffoloA , et al. Early treatment of acute pyelonephritis in children fails to reduce renal scarring [abstract no: SA‐PO1100]. Journal of the American Society of Nephrology2006;17(Abstracts):804A. [CENTRAL: CN‐00653791] HewittIK , ZucchettaP , RigonL , MaschioF , MolinariPP , TomasiL , et al. Early treatment of acute pyelonephritis in children fails to reduce renal scarring: data from the Italian Renal Infection Study Trials. Pediatrics2008;122(3):486‐90. [MEDLINE: 18762516] LaScolaC , DeMutiisC , HewittIK , PuccioG , ToffoloA , ZucchettaP , et al. Different guidelines for imaging after first UTI in febrile infants: yield, cost, and radiation. Pediatrics2013;131(3):e665‐71. [MEDLINE: 23439905] MontiniG , MurerL , GobberD , CommacchioS , ToffoloA , Dall'AmicoR , et al. Oral vs initial intravenous antibiotic treatment of urinary tract infections in children: a multicentre study [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):816. [CENTRAL: CN‐00446817] MontiniG , ToffoloA , ZucchettaP , Dall'AmicoR , GobberD , CalderonA , et al. Antibiotic treatment for pyelonephritis in children: multicentre randomised controlled non‐inferiority trial. BMJ2007;335(7616):386‐92. [MEDLINE: 17611232] MontiniG , ZucchettaP , GobberD , MurerL , RigonL , ToffoloA , et al. Usefulness of renal radiology and scintigraphy in children with a first episode of upper urinary tract infection [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):813. [CENTRAL: CN‐00446818] MontiniG , ZucchettaP , TomasiL , TalentiE , RigamontiW , PiccoG , et al. Value of imaging studies after a first febrile urinary tract infection in young children: data from Italian renal infection study 1. Pediatrics2009;123(2):e239‐46. [MEDLINE: 19139086] ">Montini 2007</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003772-bbs2-0020" title="BuechnerK , GirardinF , BergerC , WilliU , NadafD , Neuhaus T for the Swiss Pyelonephritis Study Group. Randomised controlled trial of oral versus sequential intravenous/oral cephalosporins in DMSA scintigraphy‐documented acute pyelonephritis [abstract no: COD. OP 18]. Pediatric Nephrology2006;21(10):1511. [CENTRAL: CN‐00601934] NeuhausTJ , BergerC , BuechnerK , ParvexP , BischoffG , GoetschelP , et al. Randomised trial of oral versus sequential intravenous/oral cephalosporins in children with pyelonephritis. European Journal of Pediatrics2008;167(9):1037‐47. [MEDLINE: 18074149] NeuhausTJ , BüchnerK , GirardinE , WilliU , BergerC , NadalD . Oral versus sequential intravenous/oral cephalosporin‐therapy in DMSA‐scintigraphy documented acute pyelonephritis: randomized Swiss pyelonephritis‐study [abstract] [Orale versus sequentiell intravenös/orale Cephalosporin‐Therapie bei DMSA‐Szintigraphie dokumentierter akuter Pyelonephritis: Randomisierte Schweizer Pyelonephritis‐Studie]. Nieren‐ und Hochdruckkrankheiten2007;36(2):43. [CENTRAL: CN‐00615897] ">Neuhaus 2008</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Sequential short duration (3 to 4 days) IV therapy and oral therapy versus long duration (7to 14 days) IV therapy</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003772-bbs2-0004" title="BenadorD , NeuhausTJ , PapazyanJ‐P , WilliUV , Engel‐BicikI , NadalD , et al. Randomised controlled trial of three day versus 10 day intravenous antibiotics in acute pyelonephritis: effect on renal scarring. Archives of Disease in Childhood2001;84(3):241‐6. [MEDLINE: 11207174] GirardinE , NeuhausT , PapazyanJ , WilliUV , BicikI , NadalD , et al. Acute pyelonephritis: comparison of 3 vs 10 days IV antibiotic treatment [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):592A. [CENTRAL: CN‐00583905] ">Benador 2001</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003772-bbs2-0006" title="BouissouF , MunzerC , DecramerS , RousselB , NovoR , MorinD , et al. Prospective, randomized trial comparing short and long intravenous antibiotic treatment of acute pyelonephritis in children: dimercaptosuccinic acid scintigraphic evaluation at 9 months. Pediatrics2008;121(3):e553‐60. [MEDLINE: 18267977] ">Bouissou 2008</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003772-bbs2-0011" title="FrancoisP , BensmanA , BegueP , ArtazM‐A , CoudevilleL , LebrunT , et al. Assessment of the efficacy and cost efficiency of two strategies in the treatment of acute pyelonephritis in children: oral cefixime or parenteral ceftriaxone after an initial IV combination therapy [Evaluation de l'efficacité et du coût de deux stratégies thérapeutiques dans les pyélonéphrites de l'enfant: céfixime per os versus ceftriaxone parentérale en relais d'une bithérapie intraveineuse]. Medecine et Maladies Infectieuses1997;27(Spec Iss June):667‐73. [EMBASE: 1997230388] ">Francois 1997</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003772-bbs2-0017" title="LevtchenkoE , LahyC , LevyJ , HamH , PiepszA . Treatment of children with acute pyelonephritis: a prospective randomized study. Pediatric Nephrology2001;16(11):878‐84. [MEDLINE: 11685593] ">Levtchenko 2001</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003772-bbs2-0021" title="NoorbakhshS , LariAR , MasjedianF , MostafaviH , AlaghehbandanR . Comparison of intravenous aminoglycoside therapy with switch therapy to cefixime in urinary tract infections. Saudi Medical Journal2004;25(10):1513‐5. [MEDLINE: 15494842] ">Noorbakhsh 2004</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003772-bbs2-0027" title="VilaichoneA , WatanaD , ChaiwatanaratT . Oral ceftibuten switch therapy for acute pyelonephritis in children. Journal of the Medical Association of Thailand2001;84 Suppl(1):61‐7. [MEDLINE: 11529382] ">Vilaichone 2001</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Single dose parenteral therapy and oral therapy versus oral therapy alone</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003772-bbs2-0001" title="BakerPC , NelsonDS , SchunkJE . The addition of ceftriaxone to oral therapy does not improve outcome in febrile children with urinary tract infections. Archives of Pediatrics &amp; Adolescent Medicine2001;155(2):135‐9. [MEDLINE: 11177086] ">Baker 2001</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Different dosing regimens of aminoglycoside therapy</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003772-bbs2-0007" title="CarapetisJ , JaquieryA , ButteryJ , StarrM . A randomised controlled trial of once‐daily gentamicin in children with urinary tract infections [abstract]. Australian &amp; New Zealand Journal of Medicine1999;29:608. [CENTRAL: CN‐00583423] CarapetisJ , JaquieryA , ButteryJ , StarrM , CranswickN , KohnS , et al. Randomized, controlled trial comparing once daily and three times daily gentamicin in children with urinary tract infections. Pediatric Infectious Disease Journal2001;20(3):240‐6. [MEDLINE: 11303823] ">Carapetis 2001</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003772-bbs2-0009" title="ChaoSM , ChongCY , Tan‐HendrickA , TanAS , NgWY . Efficacy and safety of once‐a‐day gentamicin in the treatment of childhood acute pyelonephritis [abstract]. Pediatric Nephrology2001;16(8):C105. [CENTRAL: CN‐00444755] ChongCY , TanAS , NgW , Tan‐KendrickA , BalakrishnanA , ChaoSM . Treatment of urinary tract infection with gentamicin once or three times daily. Acta Paediatrica2003;92(3):291‐6. [MEDLINE: 12725542] ">Chong 2003</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003772-bbs2-0026" title="ViganoA , PrincipiN , BrivioL , TommasiP , StasiP , VillaAD . Comparison of 5 milligrams of netilmicin per kilogram of body weight once daily versus 2 milligrams per kilogram thrice daily for treatment of gram‐negative pyelonephritis in children. Antimicrobial Agents &amp; Chemotherapy1992;36(7):1499‐503. [MEDLINE: 92378248] ">Vigano 1992</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Third generation cephalosporins versus other antibiotics</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003772-bbs2-0003" title="BanfiAG , Hill‐JuarezJM , KaufmanA , MoensE . Multinational comparative trial of ceftibuten and trimethoprim‐sulfamethoxazole in the treatment of children with complicated or recurrent urinary tract infections. Members of the ceftibuten urinary tract infection international study group. Pediatric Infectious Disease Journal1993;12(6 Suppl):S84‐S91. [CENTRAL: CN‐00334829] ">Banfi 1993</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003772-bbs2-0010" title="FischbachM , SimeoniU , MengusL , JehlF , MonteilH , GeisertJ , et al. Urinary tract infections with tissue penetration in children: cefotaxime compared with amoxycillin/clavulanate. Journal of Antimicrobial Chemotherapy1989;24(Suppl B):177‐83. [MEDLINE: 2691478] ">Fischbach 1989</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003772-bbs2-0018" title="MarildS , EsbjornerE , JakobssonB , LinneT , LubeckP , SjogrenI , et al. Randomised study of ceftibuten vs trimethoprim‐sulfamethoxazole in pyelonephritis in children [abstract no: P466]. Pediatric Nephrology2004;19(9):C208. MarildS , JodalU , SandbergT . Ceftibuten versus trimethoprim‐sulfamethoxazole for oral treatment of febrile urinary tract infection in children. Pediatric Nephrology2009;24(3):521‐6. [MEDLINE: 18818954] ">Marild 2009</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003772-bbs2-0025" title="ToporovskiJ , SteffensL , NoackM , KranzA , BurdeskaA , KisslingM . Effectiveness of cefetamet pivoxil in the treatment of pyelonephritis in children. Journal of International Medical Research1992;20(1):87‐93. [MEDLINE: 1568523] ">Toporovski 1992</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Third generation cephalosporins versus fourth generation cephalosporins</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003772-bbs2-0024" title="SchaadUB , EskolaJ , KafetzisD , FischbachM , AshekenaziS , SyriopoulouV , et al. Cefepine vs. ceftazidime treatment of pyelonephritis: a European, randomized, controlled study of 300 pediatric cases. European Society for Paediatric Infectious Diseases (ESPID) Pyelonephritis Study Group. Pediatric Infectious Disease Journal1998;17(7):639‐44. [MEDLINE: 9686732] ">Schaad 1998</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Ceftriaxone versus cefotaxime</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003772-bbs2-0002" title="BakkalogluA , SaatciU , SoylemezogluO , OzenS , TopalogluR , BesbasN , et al. Comparison of ceftriaxone versus cefotaxime for childhood upper urinary tract infections. Journal of Chemotherapy1996;8(1):59‐62. [MEDLINE: 8835111] ">Bakkaloglu 1996</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Aminoglycosides versus aminoglycosides</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003772-bbs2-0015" title="KafetzisDA , MaltezouHC , MavrikouM , SiafasC , ParaskakisI , DelisD , et al. Isepamicin versus amikacin for the treatment of acute pyelonephritis in children. International Journal of Antimicrobial Agents2000;14(1):51‐5. [MEDLINE: 10717501] ">Kafetzis 2000</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Different durations of the same oral antibiotic</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003772-bbs2-0022" title="PylkkänenJ , VilskaJ , KoskimiesO . The length of antimicrobial therapy in upper vs. lower urinary tract infection of childhood. Acta Paediatrica Scandinavica1981;70(6):885‐8. [MEDLINE: 7324942] PylkkänenJ , VilskaJ , KoskimiesO . The value of level diagnosis of childhood urinary tract infection in predicting renal injury. Acta Paediatrica Scandinavica1981;70(6):879‐83. [MEDLINE: 7324941] ">Pylkkänen 1981</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Single dose parenteral therapy versus oral therapy alone</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003772-bbs2-0013" title="GrimwoodK , AbbottGD , FergussonDM . Single dose gentamicin treatment of urinary infections in children. New Zealand Medical Journal1988;101(852):539‐41. [MEDLINE: 3045718] ">Grimwood 1988</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003772-bbs2-0023" title="RepettoHA , MacLoughlinGJ . Single‐dose cefotaxime in the treatment of urinary tract infections in children: a randomized clinical trial. Journal of Antimicrobial Chemotherapy1984;14(Suppl B):307‐10. [MEDLINE: 6094457] ">Repetto 1984</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Different durations of different antibiotics</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003772-bbs2-0008" title="ChengCH , TsauYK , ChangCJ , ChangYC , KuoCY , TsaiIJ , et al. Acute lobar nephronia is associated with a high incidence of renal scarring in childhood urinary tract infections. Pediatric Infectious Disease Journal2010;29(7):624‐8. [MEDLINE: 20234330] ChengCH , TsauYK , LinTY . Effective duration of antimicrobial therapy for the treatment of acute lobar nephronia. Pediatrics2006;117(1):e84‐9. [MEDLINE: 16326693] ">Cheng 2006</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Different routes of antibiotic administration</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003772-bbs2-0012" title="FujiiR , ShinozakiT , MeguroH , ArimasuO , IzumiK , OsanoM , et al. Comparative, controlled study on an ampicillin suppository (KS‐R 1) with an oral form of ampicillin in urinary tract infections. Japanese Journal of Antibiotics1987;40(3):476‐92. [MEDLINE: 3302342] ">Fujii 1987</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Three days versus 10 days of oral therapy</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003772-bbs2-0016" title="KahnAJ , KumarK , EvansHE . Three‐day antimicrobial therapy of urinary tract infection. Journal of Pediatrics1981;99(6):992‐4. [MEDLINE: 7031217] ">Khan 1981</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>•</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>DMSA ‐ Tc99m‐dimercaptosuccinic acid nuclear scan; UTI ‐ urinary tract infection</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Reported outcomes of included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/full#CD003772-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003772-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Oral versus IV followed by oral (11 days) therapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Time to fever resolution <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>808</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.05 [‐0.84, 4.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Fever on Day 3 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Number with persistent UTI at 72 hours <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>542</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.07, 17.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Inflammatory markers at 72 hours <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 WCC [×10⁹/L]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 ESR [mm/60 min]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 CRP [mg/L]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Recurrent UTI within 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Total UTIs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Symptomatic UTIs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Persistent kidney damage at 6‐12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 All included patients with acute pyelonephritis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>943</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.59, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Patients with kidney parenchymal damage on initial DMSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>681</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.61, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Proportion of kidney parenchyma with damage at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Kidney damage at 6 months (post hoc subgroup analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Persistent damage in children with VUR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Persistent damage in children without VUR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Persistent kidney damage with VUR grades 1‐2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 Persistent damage with VUR grades 3‐5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Oral versus IV followed by oral (11 days) therapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003772-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Short duration (3‐4 days) versus long duration (7‐14 days) IV therapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Persistent bacteriuria after treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>305</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.24, 2.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Recurrent UTI within 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>993</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.58, 1.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Persistent kidney damage at 3‐6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 All included patients with acute pyelonephritis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>726</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.80, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Patients with renal parenchymal damage on initial DMSA scan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>315</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.84, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Persistent kidney damage at 3‐6 months (post hoc subgroup analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 VUR present</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.69, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 No VUR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>173</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.81, 1.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Age less than 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [0.71, 3.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Age 1 year or over</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.59, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 Delay in treatment less than 7 days in individual kidneys</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.52 [0.59, 3.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6 Delay in treatment of 7 days or more in individual kidneys</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.10 [0.92, 4.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Gastrointestinal effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.55, 3.05]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Short duration (3‐4 days) versus long duration (7‐14 days) IV therapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003772-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Single dose parenteral therapy and oral therapy versus oral therapy alone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Persistent bacteriuria at 48 hours <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Treatment failure after 48 hours of therapy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Recurrent UTI within 1 month <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Total adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Gastrointestinal adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Single dose parenteral therapy and oral therapy versus oral therapy alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003772-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Different dosing regimens of aminoglycosides (daily versus 8 hourly)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Persistent bacteriuria after 1‐3 days of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>435</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.15, 7.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Persistent symptoms at end of 3 days of IV therapy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Persistent bacteriuria at 1 week after treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Reinfection at 1 month after completing treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Hearing impairment following treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>271</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.83 [0.33, 24.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Increase in serum creatinine during treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>419</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.20, 2.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Time to resolution of fever <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Kidney parenchymal damage at 3 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Different dosing regimens of aminoglycosides (daily versus 8 hourly)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003772-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Third generation cephalosporin versus other antibiotic</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Persistent bacteriuria <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>439</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.41 [0.98, 5.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Recurrent UTI after end of therapy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>491</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.32, 4.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Persistent symptoms after end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>471</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.13, 0.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Number with fever for more than 48 hours <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Recurrent bacteriuria at 4‐6 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Recurrent symptomatic UTI at 4‐6 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Gastrointestinal adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>591</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.34, 2.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Number discontinuing treatment for adverse effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Third generation cephalosporin versus other antibiotic</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003772-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Cefepime versus ceftazidime</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Persistence or recurrence of initial pathogen <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 At end of IV therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 At the end of IV and oral therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 At 5‐9 days after treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 At 4‐6 weeks after treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Infection with new pathogen at 4‐6 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Unsatisfactory clinical response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 At end of IV therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 At end of IV and oral therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 At 5‐9 days after treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 At 4‐6 weeks after treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Total adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Drug‐related adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Gastrointestinal adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Cutaneous adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 Discontinuation due to drug related adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Cefepime versus ceftazidime</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003772-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Ceftriaxone versus cefotaxime</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Persistent bacteriuria at 48 hours <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Bacteriuria 10 days after end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 All patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Normal renal tract imaging (post hoc analysis)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Abnormal renal tract imaging (post hoc analysis)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 UTI at 1 month after therapy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 All patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Normal renal tract imaging</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Abnormal renal tract imaging</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 All adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Skin eruptions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Gastrointestinal adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Ceftriaxone versus cefotaxime</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003772-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Isepamicin versus amikacin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Persistent bacteriuria <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 After 2‐3 days of therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 At 7 days after completing therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 At 30 days after completing therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Isepamicin versus amikacin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003772-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">10 days versus 42 days of oral sulfafurazole</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Recurrent UTI within 1 month after ceasing therapy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Recurrent UTI at 1‐12 months after completing therapy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">10 days versus 42 days of oral sulfafurazole</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003772-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Single dose of parenteral antibiotic versus 7‐10 days oral therapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Persistent bacteriuria 1‐2 days after treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [0.18, 16.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 UTI relapse or reinfection within 6 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.03, 1.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Single dose of parenteral antibiotic versus 7‐10 days oral therapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003772-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">3 weeks versus 2 weeks</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Persistence/recurrence of bacteriuria <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Recurrence of clinical UTI <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">3 weeks versus 2 weeks</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003772-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Suppositories versus oral ampicillin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Persistence of clinical symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Persistence of bacteriuria <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Suppositories versus oral ampicillin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003772.pub4/references#CD003772-tbl-0017">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD003772.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD003772-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD003772-note-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD003772-note-0003">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD003772-note-0002">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD003772-note-0001">Bahasa Malaysia</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003772\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003772\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003772\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003772\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003772\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003772\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003772\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003772\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003772\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003772\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003772\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003772\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003772\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003772\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003772\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003772\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003772\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003772\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=KUoIaN9D&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003772.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003772.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD003772.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD003772.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003772.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717122723"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003772.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717122727"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003772.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918db038ed55936e',t:'MTc0MDcxNzEyMy4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 